

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by DrugPatentWatch.com

**CUMULATIVE
SUPPLEMENT 4
APRIL 2018**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2018

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

38th EDITION

**Cumulative Supplement 4
April 2018**

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content	vi
1.3 Applicant Name Changes	vii
1.4 Levothyroxine Sodium.....	viii
1.5 Availability of the Edition	ix
1.6 Report of Counts for the Prescription Drug Product List.....	x
1.7 Cumulative Supplement Legend.....	xi
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

38th EDITION

CUMULATIVE SUPPLEMENT 4
April 2018

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 38th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
 Office of Generic Drugs
 7620 Standish Place
 Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
IDT AUSTRALIA LTD (IDT AUSTRALIA LTD)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
KREMERS URBAN PHARMACEUTICALS INC (KREMERS URBAN PHARMS)	LANNETT CO INC (LANNETT CO INC)
LANNETT HOLDINGS INC (LANNETT)	LANNETT CO INC (LANNETT CO INC)
LANNETT HOLDINGS INC (LANNETT HOLDINGS INC)	LANNETT CO INC (LANNETT CO INC)
SILARX PHARMACEUTICALS INC (SILARX)	LANNETT CO INC (LANNETT CO INC)

SILARX PHARMACEUTICALS INC
(SILARX PHARMS INC)

LANNETT CO INC
(LANNETT CO INC)

SAGENT AGILA LLIC
(SAGENT AGILA)

MYLAN ASI LLC
(MYLAN ASI)

SAGENT AGILA LLC
(SAGENT AGILA LLC)

MYLAN ASI LLC
(MYLAN ASI)

SAGENT STRIDES LLC
(SAGENT STRIDESC)

MYLAN ASI LLC
(MYLAN ASI)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharmas NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Cediprof Inc NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharmas NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001

LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVEXOYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2017</u>	<u>MAR 2018</u>	<u>JUN 2018</u>	<u>SEP 2018</u>	<u>DEC 2018</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	19294	19359			
	2758	2763			
	(14.3%)	(14.3%)			
MULTISOURCE	16536	16596			
	(85.7%)	(85.7%)			
THERAPEUTICALLY EQUIVALENT	16431	16501			
	(85.2%)	(85.2%)			
NOT THERAPEUTICALLY EQUIVALENT	105	95			
	(0.5%)	(0.5%)			
EXCEPTIONS ¹	73	72			
	(0.4%)	(0.4%)			
NEW MOLECULAR ENTITIES APPROVED	25	6			
NUMBER OF APPLICANTS	1075	1084			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**Note:

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full

applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE

SOLUTION;ORAL
 ABACAVIR SULFATE
 AA AUROBINDO PHARMA LTD EQ 20MG BASE/ML A 077950 001 Mar 14, 2018 Feb NEWA

ABIRATERONE ACETATE

TABLET;ORAL
 ZYTIGA
 + JANSSEN BIOTECH 250MG N202379 001 Apr 28, 2011 Feb CHRS
 +! 500MG N202379 002 Apr 14, 2017 Feb CHRS

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL
 APADAZ
 + KEMPARM 325MG;EQ 6.12MG BASE N208653 001 Feb 23, 2018 Feb NEWA

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL
 BUTALBITAL AND ACETAMINOPHEN
 MAYNE PHARMA INC 300MG;50MG A207313 001 Dec 27, 2017 Mar CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 >D> AB NUVO PHARM INC 300MG;50MG;40MG A207118 001 Oct 28, 2016 Apr CTEC
 >A> AA 300MG;50MG;40MG A207118 001 Oct 28, 2016 Apr CTEC
 >D> AB TEDOR PHARMA INC 300MG;50MG;40MG A206615 001 Aug 04, 2017 Apr CTEC
 >A> AA 300MG;50MG;40MG A206615 001 Aug 04, 2017 Apr CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL
 ACETAMINOPHEN AND CODEINE PHOSPHATE
 @ FOSUN PHARMA 300MG;30MG A081250 001 Jul 16, 1992 Jan CAHN
 @ 300MG;60MG A081249 001 Jul 16, 1992 Jan CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN
 AA EPIC PHARMA LLC 325MG;5MG A203863 001 Mar 30, 2018 Mar NEWA
 AA 325MG;7.5MG A203863 002 Mar 30, 2018 Mar NEWA
 AA 325MG;10MG A203863 003 Mar 30, 2018 Mar NEWA
 AA RHODES PHARMS 300MG;5MG A207808 001 Mar 30, 2018 Mar NEWA
 AA 300MG;7.5MG A207808 002 Mar 30, 2018 Mar NEWA
 AA 300MG;10MG A207808 003 Mar 30, 2018 Mar NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL
 OXYCODONE AND ACETAMINOPHEN
 @ SPECGX LLC 325MG/5ML;5MG/5ML A040680 001 Sep 29, 2006 Jan DISC
 OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN
 @ VINTAGE PHARMS 325MG/5ML;5MG/5ML A203573 001 Dec 18, 2014 Jan DISC
 TABLET;ORAL
 OXYCODONE AND ACETAMINOPHEN
 AA ABHAI LLC 325MG;2.5MG A210644 001 Feb 09, 2018 Jan NEWA
 AA 325MG;5MG A210644 002 Feb 09, 2018 Jan NEWA
 AA 325MG;7.5MG A210644 003 Feb 09, 2018 Jan NEWA
 AA 325MG;10MG A210644 004 Feb 09, 2018 Jan NEWA
 AA WES PHARMA INC 325MG;5MG A207510 001 Mar 21, 2018 Mar NEWA
 AA 325MG;7.5MG A207510 002 Mar 21, 2018 Mar NEWA
 AA 325MG;10MG A207510 003 Mar 21, 2018 Mar NEWA

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL
 ACETIC ACID 0.25% IN PLASTIC CONTAINER
 AT +! ICU MEDICAL INC 250MG/100ML N017656 001 Mar CRLD
 SOLUTION/DROPS;OTIC
 ACETIC ACID
 AT RISING PHARMS INC 2% A207280 001 Mar 09, 2018 Feb NEWA

ACYCLOVIR

		CAPSULE;ORAL							
		ACYCLOVIR							
AB		HERITAGE PHARMS INC	200MG		A074889	001	Oct 31, 1997	Mar	CMFD
		OINTMENT;TOPICAL							
		ACYCLOVIR							
AB		ALEMBIC PHARMS LTD	5%		A209000	001	Apr 06, 2018	Mar	NEWA
		TABLET;ORAL							
		ACYCLOVIR							
AB		YILING PHARM LTD	400MG		A210401	001	Mar 07, 2018	Feb	NEWA
AB			800MG		A210401	002	Mar 07, 2018	Feb	NEWA

ADAPALENE; BENZOYL PEROXIDE

		GEL;TOPICAL							
		ADAPALENE AND BENZOYL PEROXIDE							
AB		PERRIGO ISRAEL	0.1%;2.5%		A205033	001	Jan 23, 2018	Jan	NEWA
AB		TARO	0.1%;2.5%		A206959	001	Jan 24, 2018	Jan	NEWA

ADENOSINE

		INJECTABLE;INJECTION							
		ADENOSINE							
>A>	AP	FRESENIUS KABI USA	3MG/ML		A205568	001	Apr 16, 2018	Apr	NEWA
	AP	GLAND PHARMA LTD	3MG/ML		A206778	001	Feb 16, 2018	Feb	NEWA

ALBUTEROL SULFATE

		TABLET;ORAL							
		ALBUTEROL SULFATE							
		@ YAOPHARMA CO LTD	EQ 2MG BASE		A072151	001	Dec 05, 1989	Jan	CAHN
		@	EQ 4MG BASE		A072152	001	Dec 05, 1989	Jan	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

		SOLUTION;INHALATION							
		ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE							
		@ FOSUN PHARMA	EQ 0.083% BASE;0.017%		A076867	001	Dec 21, 2006	Jan	CAHN

ALENDRONATE SODIUM

		TABLET;ORAL							
		ALENDRONATE SODIUM							
AB		HANGZHOU BINJIANG	EQ 5MG BASE		A090258	001	Sep 24, 2009	Jan	CAHN
AB			EQ 10MG BASE		A090258	002	Sep 24, 2009	Jan	CAHN
AB			EQ 35MG BASE		A090258	003	Sep 24, 2009	Jan	CAHN
AB			EQ 70MG BASE		A090258	004	Sep 24, 2009	Jan	CAHN
>D>	AB	MYLAN	EQ 35MG BASE		A076584	003	Aug 04, 2008	Apr	DISC
>A>		@	EQ 35MG BASE		A076584	003	Aug 04, 2008	Apr	DISC
>D>	AB		EQ 70MG BASE		A076584	004	Aug 04, 2008	Apr	DISC
>A>		@	EQ 70MG BASE		A076584	004	Aug 04, 2008	Apr	DISC

ALLOPURINOL

		TABLET;ORAL							
		ALLOPURINOL							
		@ FOSUN PHARMA	100MG		A070268	001	Dec 31, 1985	Jan	CAHN

ALOSETRON HYDROCHLORIDE

		TABLET;ORAL							
		ALOSETRON HYDROCHLORIDE							
AB		PAR PHARM INC	EQ 0.5MG BASE		A206113	001	Feb 23, 2018	Feb	NEWA
AB			EQ 1MG BASE		A206113	002	Feb 23, 2018	Feb	NEWA

AMANTADINE HYDROCHLORIDE

		TABLET;ORAL							
		AMANTADINE HYDROCHLORIDE							
AB		JUBILANT GENERICS	100MG		A210403	001	Feb 07, 2018	Jan	NEWA
		TABLET, EXTENDED RELEASE;ORAL							
		OSMOLEX ER							
	+	OSMOTICA PHARM	EQ 129MG BASE		N209410	001	Feb 16, 2018	Feb	NEWA
	+		EQ 193MG BASE		N209410	002	Feb 16, 2018	Feb	NEWA
	+		EQ 258MG BASE		N209410	003	Feb 16, 2018	Feb	NEWA

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ YAOPHARMA CO LTD	EQ 5MG ANHYDROUS;50MG	A073357	001	Nov 27, 1991	Jan CAHN
--------------------	-----------------------	---------	-----	--------------	----------

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN-HF 8%

@ ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996	Mar DISC
-------------------	----------------	---------	-----	--------------	----------

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	10MG	A089399	002	Jul 14, 1987	Jan CMFD
AB		25MG	A089399	001	Jul 14, 1987	Jan CMFD
AB		50MG	A089399	003	Jul 14, 1987	Jan CMFD
AB		75MG	A089399	004	Jul 14, 1987	Jan CMFD
AB		100MG	A089399	005	Jul 14, 1987	Jan CMFD
AB		150MG	A089399	006	Jul 14, 1987	Jan CMFD

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

@ FOSUN PHARMA	10MG;2MG	A071062	001	Nov 27, 1987	Jan CAHN
@	10MG;4MG	A071862	001	Dec 21, 1987	Jan CAHN
@	25MG;2MG	A071063	001	Nov 27, 1987	Jan CAHN
@	25MG;4MG	A071064	001	Nov 27, 1987	Jan CAHN
@	50MG;4MG	A071863	001	Dec 21, 1987	Jan CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>A>	AB	SUNSHINE LAKE	EQ 2.5MG BASE	A206524	001	May 04, 2018	Apr NEWA
>A>	AB		EQ 5MG BASE	A206524	002	May 04, 2018	Apr NEWA
>A>	AB		EQ 10MG BASE	A206524	003	May 04, 2018	Apr NEWA
		@ YAOPHARMA CO LTD	EQ 2.5MG BASE	A076859	001	Sep 10, 2007	Jan CAHN
		@	EQ 5MG BASE	A076859	002	Sep 10, 2007	Jan CAHN
		@	EQ 10MG BASE	A076859	003	Sep 10, 2007	Jan CAHN

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	SOFIE	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Feb CAHN
----	-------	--------------------------------------	---------	-----	--------------	----------

AMMONIUM LACTATE

CREAM; TOPICAL

LAC-HYDRIN

@ SUN PHARM INDS INC	EQ 12% BASE	N020508	001	Aug 29, 1996	Feb CAHN
----------------------	-------------	---------	-----	--------------	----------

LOTION; TOPICAL

LAC-HYDRIN

+ @ SUN PHARM INDS INC	EQ 12% BASE	N019155	001	Apr 24, 1985	Feb CAHN
------------------------	-------------	---------	-----	--------------	----------

AMOXPAPINE

TABLET; ORAL

AMOXPAPINE

WATSON LABS	25MG	A072691	002	Aug 28, 1992	Mar CMS1
	50MG	A072691	003	Aug 28, 1992	Mar CMS1
	100MG	A072691	004	Aug 28, 1992	Mar CMS1

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

@ ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993	Mar DISC
------------------------	--------------------	---------	-----	--------------	----------

ANASTROZOLE

TABLET; ORAL

ARIMIDEX

AB	+!	ANI PHARMS INC	1MG	N020541	001	Dec 27, 1995	Jan CAHN
----	----	----------------	-----	---------	-----	--------------	----------

ANGIOTENSIN II ACETATESOLUTION; IV (INFUSION)
GIAPREZA

+!	LA JOLLA PHARM CO	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	N209360	001	Dec 21, 2017	Jan	CAIN
+!		EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	N209360	002	Dec 21, 2017	Jan	CAIN

APALUTAMIDETABLET; ORAL
ERLEADA

+!	JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Feb	NEWA
----	-----------------	------	---------	-----	--------------	-----	------

APREPITANTCAPSULE; ORAL
APREPITANT

AB	GLENMARK PHARMS SA	40MG	A207777	001	Oct 12, 2017	Jan	CAHN
AB		80MG	A207777	002	Oct 12, 2017	Jan	CAHN
AB		125MG	A207777	003	Oct 12, 2017	Jan	CAHN

ARGATROBANINJECTABLE; INJECTION
ARGATROBAN

AP	AMNEAL PHARMS CO	250MG/2.5ML (100MG/ML)	A206698	001	Jan 26, 2018	Jan	NEWA
----	------------------	------------------------	---------	-----	--------------	-----	------

ARIPIPIRAZOLETABLET, ORALLY DISINTEGRATING; ORAL
ARIPIPIRAZOLE

>A>	AB	SCIEGEN PHARMS INC	10MG	A207240	001	Apr 18, 2018	Apr	NEWA
>A>	AB		15MG	A207240	002	Apr 18, 2018	Apr	NEWA

ARMODAFINILTABLET; ORAL
ARMODAFINIL

AB	AUROBINDO PHARMA LTD	50MG	A206069	001	Mar 06, 2018	Feb	NEWA
AB		150MG	A206069	002	Mar 06, 2018	Feb	NEWA
AB		250MG	A206069	003	Mar 06, 2018	Feb	NEWA

ASPIRIN; BUTALBITAL; CAFFEINETABLET; ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

@	FOSUN PHARMA	325MG; 50MG; 40MG	A086398	002	Apr 06, 1984	Jan	CAHN
---	--------------	-------------------	---------	-----	--------------	-----	------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATETABLET; ORAL
ORPHENGESIC

@	GALT PHARMS	385MG; 30MG; 25MG	A075141	001	May 29, 1998	Feb	CAHN
---	-------------	-------------------	---------	-----	--------------	-----	------

@	GALT PHARMS	770MG; 60MG; 50MG	A075141	002	May 29, 1998	Feb	CAHN
---	-------------	-------------------	---------	-----	--------------	-----	------

>D> ASPIRIN; OMEPRAZOLE>D> TABLET, DELAYED RELEASE; ORAL
>D> YOSPRALA

>D>	+	ARALEZ PHARMS	81MG; 40MG	N205103	001	Sep 14, 2016	Apr	DISC
>A>	+	@	81MG; 40MG	N205103	001	Sep 14, 2016	Apr	DISC
>D>	+	!	325MG; 40MG	N205103	002	Sep 14, 2016	Apr	DISC
>A>	+	@	325MG; 40MG	N205103	002	Sep 14, 2016	Apr	DISC

ATOMOXETINE HYDROCHLORIDECAPSULE; ORAL
ATOMOXETINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	10MG	A090609	001	Feb 23, 2018	Feb	NEWA
AB		18MG	A090609	002	Feb 23, 2018	Feb	NEWA
AB		25MG	A090609	003	Feb 23, 2018	Feb	NEWA
AB		40MG	A090609	004	Feb 23, 2018	Feb	NEWA
AB		60MG	A090609	005	Feb 23, 2018	Feb	NEWA
AB		80MG	A090609	006	Feb 23, 2018	Feb	NEWA
AB		100MG	A090609	007	Feb 23, 2018	Feb	NEWA

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	ACCORD HLTHCARE	EQ 10MG BASE	A207687	001	Mar 30, 2018	Mar	NEWA
AB		EQ 20MG BASE	A207687	002	Mar 30, 2018	Mar	NEWA
AB		EQ 40MG BASE	A207687	003	Mar 30, 2018	Mar	NEWA
AB		EQ 80MG BASE	A207687	004	Mar 30, 2018	Mar	NEWA

ATROPINE SULFATE

SOLUTION; IV (INFUSION), INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

+!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	Jan	NEWA
----	--------------------	---------------------	---------	-----	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

>D>	ISOPTO ATROPINE						
>D>	ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Apr	DISC
>A>	@	1%	N208151	001	Dec 01, 2016	Apr	DISC
		1%	N208151	001	Dec 01, 2016	Feb	CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@	FOSUN PHARMA	0.025MG; 2.5MG	A086173	001		Jan	CAHN
	LONOX						
@	FOSUN PHARMA	0.025MG; 2.5MG	A085311	002		Jan	CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+!	ALLERGAN SALES LLC	EQ 0.5GM BASE; 2GM/VIAL	N206494	001	Feb 25, 2015	Jan	CAHN
----	--------------------	-------------------------	---------	-----	--------------	-----	------

AZACITIDINE

POWDER; IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

>A>	AP	CIPLA LTD	100MG/VIAL	A209540	001	May 04, 2018	Apr	NEWA
-----	----	-----------	------------	---------	-----	--------------	-----	------

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

AB	EPIC PHARMA LLC	EQ 100MG BASE/5ML	A207531	001	Apr 09, 2018	Mar	NEWA
AB		EQ 200MG BASE/5ML	A207531	002	Apr 09, 2018	Mar	NEWA

TABLET; ORAL

AZITHROMYCIN

@	APOTEX CORP	EQ 250MG BASE	A065507	001	Jul 13, 2011	Mar	DISC
@		EQ 500MG BASE	A065509	001	Jul 13, 2011	Mar	DISC
@		EQ 600MG BASE	A065508	001	Jul 13, 2011	Mar	DISC

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

@	MYLAN ASI	50,000 UNITS/VIAL	A090211	001	May 11, 2010	Jan	DISC
---	-----------	-------------------	---------	-----	--------------	-----	------

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

AP	MYLAN LABS LTD	0.5MG/ML	A209592	001	Mar 21, 2018	Mar	NEWA
AP		1MG/ML	A209594	001	Mar 06, 2018	Feb	NEWA
AP		2MG/ML	A209592	002	Mar 21, 2018	Mar	NEWA
AP	+!	GABLOFEN					
	PIRAMAL CRITICAL	1MG/ML	N022462	004	Jun 22, 2012	Feb	CFTG

BARIUM SULFATE

FOR SUSPENSION; ORAL

E-Z-HD

>D>	+!	BRACCO	98% (334GM/BOTTLE)	N208036	001	Jan 11, 2016	Apr	CPOT
>A>	+!		98% (334GM/BOT)	N208036	001	Jan 11, 2016	Apr	CPOT
		E-Z-PAQUE						
>D>	+!	BRACCO	96% (169GM/BOTTLE)	N208036	002	Apr 07, 2017	Apr	CPOT
>A>	+!		96% (169GM/BOT)	N208036	002	Apr 07, 2017	Apr	CPOT

SUSPENSION; ORAL									
LIQUID E-Z-PAQUE									
>D>	+	BRACCO	60% (213GM/355ML)	N208143	003	Mar 01, 2017	Apr	CPOT	
>A>	+		60% (213GM/BOT)	N208143	003	Mar 01, 2017	Apr	CPOT	
READI-CAT 2									
>D>	+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Apr	CPOT	
>A>	+		2% (9GM/BOT)	N208143	001	Jan 15, 2016	Apr	CPOT	
READI-CAT 2 SMOOTHIES									
>D>	+	BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016	Apr	CPOT	
>A>	+		2% (9GM/BOT)	N208143	002	Jan 15, 2016	Apr	CPOT	
TAGITOL V									
>D>	+	BRACCO	40% (8GM/20ML)	N208143	005	Aug 04, 2017	Apr	CPOT	
>A>	+		40% (8GM/BOT)	N208143	005	Aug 04, 2017	Apr	CPOT	
VARIBAR HONEY									
	+	BRACCO	40% (100GM/250ML)	N208143	007	Mar 26, 2018	Mar	NEWA	
VARIBAR THIN HONEY									
	+	BRACCO	40% (100GM/250ML)	N208143	006	Jan 23, 2018	Jan	NEWA	
<u>BECLOMETHASONE DIPROPIONATE</u>									
AEROSOL, METERED; INHALATION									
QVAR REDIHALER									
	+	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017	Jan	CHRS	
<u>BENZAEPRIIL HYDROCHLORIDE</u>									
TABLET; ORAL									
BENZAEPRIIL HYDROCHLORIDE									
AB		CASI PHARMS INC	5MG	A076402	001	Feb 11, 2004	Mar	CAHN	
AB			10MG	A076402	002	Feb 11, 2004	Mar	CAHN	
AB			20MG	A076402	003	Feb 11, 2004	Mar	CAHN	
AB			40MG	A076402	004	Feb 11, 2004	Mar	CAHN	
<u>BENZAEPRIIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE</u>									
TABLET; ORAL									
BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE									
		@ SUN PHARM INDS LTD	5MG; 6.25MG	A077483	001	Sep 08, 2005	Mar	DISC	
<u>BENDAMUSTINE HYDROCHLORIDE</u>									
POWDER; IV (INFUSION)									
BENDAMUSTINE HYDROCHLORIDE									
>A>	AP	MYLAN LABS LTD	25MG/VIAL	A204104	001	Apr 26, 2018	Apr	NEWA	
>A>	AP		100MG/VIAL	A204104	002	Apr 26, 2018	Apr	NEWA	
<u>BENZONATATE</u>									
CAPSULE; ORAL									
BENZONATATE									
AA		CSPC NBP PHARM CO	100MG	A202765	002	Aug 25, 2017	Mar	NEWA	
<u>BENZTROPINE MESYLATE</u>									
TABLET; ORAL									
BENZTROPINE MESYLATE									
		@ CHARTWELL RX	1MG	A081264	001	Jan 23, 1992	Jan	CAHN	
		@	2MG	A081265	001	Jan 23, 1992	Jan	CAHN	
<u>BETAMETHASONE DIPROPIONATE</u>									
LOTION; TOPICAL									
BETAMETHASONE DIPROPIONATE									
AB		HI-TECH PHARMACAL	EQ 0.05% BASE	A209896	001	Feb 06, 2018	Jan	NEWA	
LOTION, AUGMENTED; TOPICAL									
BETAMETHASONE DIPROPIONATE									
AB		TELIGENT PHARMA INC	EQ 0.05% BASE	A206389	001	Feb 13, 2018	Jan	NEWA	
<u>BETAMETHASONE VALERATE</u>									
LOTION; TOPICAL									
BETA-VAL									
		@ G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Jan	DISC	

BETAXOLOL HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
BETOPTIC

AT +! SANDOZ INC EQ 0.5% BASE N019270 001 Aug 30, 1985 Jan CAHN

BEXAROTENECAPSULE;ORAL
BEXAROTENE

>A> AB AMERIGEN PHARMS LTD 75MG A209861 001 May 08, 2018 Apr NEWA

BICALUTAMIDETABLET;ORAL
CASODEX

AB +! ANI PHARMS INC 50MG N020498 001 Oct 04, 1995 Jan CAHN

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATETABLET;ORAL
BIKTARVY

+! GILEAD SCIENCES INC EQ 50MG BASE;200MG;EQ 25MG BASE N210251 001 Feb 07, 2018 Feb NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINECAPSULE;ORAL
PYLERA

+! ALLERGAN SALES LLC 140MG;125MG;125MG N050786 001 Sep 28, 2006 Jan CAHN

BISOPROLOL FUMARATE

TABLET;ORAL

BISOPROLOL FUMARATE

AB CASI PHARMS INC 5MG A075643 001 Nov 16, 2000 Mar CAHN

AB 10MG A075643 002 Nov 16, 2000 Mar CAHN

BIVALIRUDIN

SOLUTION;IV (INFUSION)

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

+! BAXTER HLTHCARE CORP 250MG/50ML (5MG/ML) N208374 001 Dec 21, 2017 Jan CAHN

+! 500MG/100ML (5MG/ML) N208374 002 Dec 21, 2017 Jan CAHN

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

>A> AP HONG KONG EQ 15 UNITS BASE/VIAL A205030 001 Apr 20, 2018 Apr NEWA

>A> AP EQ 30 UNITS BASE/VIAL A205030 002 Apr 20, 2018 Apr NEWA

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

>D> AA ! WOCKHARDT 2MG/5ML;10MG/5ML;30MG/5ML A088811 001 Jun 07, 1985 Apr CAHN

>A> AA ! WOCKHARDT BIO AG 2MG/5ML;10MG/5ML;30MG/5ML A088811 001 Jun 07, 1985 Apr CAHN

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

>D> AP ! ATHENEX INC 0.25MG/ML A074441 001 Jan 27, 1995 Apr DISC

>A> @ 0.25MG/ML A074441 001 Jan 27, 1995 Apr DISC

>D> AP WEST-WARD PHARMS INT 0.25MG/ML A079196 001 Apr 30, 2008 Apr CHRS

>A> AP ! 0.25MG/ML A079196 001 Apr 30, 2008 Apr CHRS

TABLET;ORAL

BUMETANIDE

AB UPSHER-SMITH LABS 0.5MG A209916 001 Jan 23, 2018 Jan NEWA

AB 1MG A209916 002 Jan 23, 2018 Jan NEWA

AB 2MG A209916 003 Jan 23, 2018 Jan NEWA

>A> AB ZYDUS PHARMS USA INC 0.5MG A202900 001 Apr 30, 2018 Apr NEWA

>A> AB 1MG A202900 002 Apr 30, 2018 Apr NEWA

>A> AB 2MG A202900 003 Apr 30, 2018 Apr NEWA

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	CASI PHARMS INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	Mar	CAHN
AB		EQ 8MG BASE	A090279	002	Jun 10, 2015	Mar	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB2	SCIEGEN PHARMS INC	150MG	A206122	001	Aug 17, 2016	Jan	CAHN
-----	--------------------	-------	---------	-----	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	5MG	A078246	001	Feb 27, 2009	Feb	CAHN
AB		10MG	A078246	002	Feb 27, 2009	Feb	CAHN
AB		15MG	A078246	003	Feb 27, 2009	Feb	CAHN
AB		30MG	A078246	004	Feb 27, 2009	Feb	CAHN
	@ FOSUN PHARMA	5MG	A075413	001	Mar 19, 2002	Jan	CAHN
	@	10MG	A075413	002	Mar 19, 2002	Jan	CAHN
	@	15MG	A075413	003	Mar 19, 2002	Jan	CAHN
>A>	AB	INVENTIA HLTHCARE	A209696	001	May 03, 2018	Apr	NEWA
>A>	AB	7.5MG	A209696	002	May 03, 2018	Apr	NEWA
>A>	AB	10MG	A209696	003	May 03, 2018	Apr	NEWA
>A>	AB	15MG	A209696	004	May 03, 2018	Apr	NEWA
>A>	AB	30MG	A209696	005	May 03, 2018	Apr	NEWA

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	!	HOSPIRA	1MG/ML	A074626	001	Jan 23, 1997	Mar	CHRS
AP	!		2MG/ML	A074626	002	Jan 23, 1997	Mar	CHRS
		STADOL						
	+	@ APOTHECON	2MG/ML	N017857	004		Mar	CRLD
		STADOL PRESERVATIVE FREE						
	+	@ APOTHECON	1MG/ML	N017857	001		Mar	CRLD
	+	@	2MG/ML	N017857	002		Mar	CRLD

CABERGOLINE

TABLET;ORAL

CABERGOLINE

	@	APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013	Mar	DISC
--	---	-------------	-------	---------	-----	--------------	-----	------

CALCIUM ACETATE

TABLET;ORAL

ELIPHOS

>D>								
>D>	AB	CYPRESS PHARM	667MG	A078502	001	Nov 25, 2008	Apr	DISC
>A>		@	667MG	A078502	001	Nov 25, 2008	Apr	DISC

CALCIUM CHLORIDE

INJECTABLE;INJECTION

CALCIUM CHLORIDE 10%

>A>	AP	INTL MEDICATION SYS	100MG/ML	A203477	001	May 09, 2018	Apr	NEWA
-----	----	---------------------	----------	---------	-----	--------------	-----	------

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	+	@ ICU MEDICAL INC	20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML	N019685	005	Oct 17, 1988	Jan	CRLD
	+	@	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	006	Oct 17, 1988	Jan	CRLD
		POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	+	@ ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	007	Oct 17, 1988	Jan	CRLD
		POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
AP	+	ICU MEDICAL INC	20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML	N019685	002	Oct 17, 1988	Jan	CRLD
	+	@	20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML	N019685	008	Oct 17, 1988	Jan	DISC
		POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER						
	+	@ ICU MEDICAL INC	20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML	N019685	003	Oct 17, 1988	Jan	CRLD

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685	004	Oct 17, 1988	Jan	DISC
-----	-----------------	--	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ @	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685	001	Oct 17, 1988	Jan	CRLD
-----	-----------------	--	---------	-----	--------------	-----	------

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

AB	+	ANI PHARMS INC	4MG	N020838	001	Jun 04, 1998	Jan	CAHN
AB	+		8MG	N020838	002	Jun 04, 1998	Jan	CAHN
AB	+		16MG	N020838	003	Jun 04, 1998	Jan	CAHN
AB	+	!	32MG	N020838	004	Jun 04, 1998	Jan	CAHN

CANDESARTAN CILEXETIL

	@	APOTEX INC	4MG	A202079	001	Jan 10, 2014	Mar	DISC
	@		8MG	A202079	002	Jan 10, 2014	Mar	DISC
	@		16MG	A202079	003	Jan 10, 2014	Mar	DISC
	@		32MG	A202079	004	Jan 10, 2014	Mar	DISC
>A>	AB	MYLAN PHARMS INC	4MG	A078702	001	May 03, 2013	Apr	CAHN
>A>	AB		8MG	A078702	002	May 03, 2013	Apr	CAHN
>A>	AB		16MG	A078702	003	May 03, 2013	Apr	CAHN
>A>	AB		32MG	A078702	004	May 03, 2013	Apr	CAHN
>D>	AB	SANDOZ	4MG	A078702	001	May 03, 2013	Apr	CAHN
>D>	AB		8MG	A078702	002	May 03, 2013	Apr	CAHN
>D>	AB		16MG	A078702	003	May 03, 2013	Apr	CAHN
>D>	AB		32MG	A078702	004	May 03, 2013	Apr	CAHN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

AB	+	ANI PHARMS INC	16MG; 12.5MG	N021093	001	Sep 05, 2000	Feb	CAHN
AB	+		32MG; 12.5MG	N021093	002	Sep 05, 2000	Feb	CAHN
AB	+	!	32MG; 25MG	N021093	003	May 16, 2008	Feb	CAHN

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

	@	APOTEX INC	16MG; 12.5MG	A202884	001	Dec 04, 2012	Mar	DISC
	@		32MG; 12.5MG	A202884	002	Dec 04, 2012	Mar	DISC
	@		32MG; 25MG	A202884	003	Jun 03, 2013	Mar	DISC
AB		PRINSTON INC	16MG; 12.5MG	A207455	001	Apr 11, 2018	Mar	NEWA
AB			32MG; 12.5MG	A207455	002	Apr 11, 2018	Mar	NEWA
AB			32MG; 25MG	A207455	003	Apr 11, 2018	Mar	NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

>A>	AB	EUGIA PHARMA	150MG	A210604	001	Apr 17, 2018	Apr	NEWA
>A>	AB		500MG	A210604	002	Apr 17, 2018	Apr	NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@ YAOPHARMA CO LTD

12.5MG

@ 12.5MG

@ 25MG

@ 25MG

@ 50MG

@ 50MG

@ 100MG

@ 100MG

A074363	001	Nov 09, 1995	Jan	CAHN
A074519	001	Feb 13, 1996	Jan	CAHN
A074363	002	Nov 09, 1995	Jan	CAHN
A074519	002	Feb 13, 1996	Jan	CAHN
A074363	003	Nov 09, 1995	Jan	CAHN
A074519	003	Feb 13, 1996	Jan	CAHN
A074363	004	Nov 09, 1995	Jan	CAHN
A074519	004	Feb 13, 1996	Jan	CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

@ G AND W LABS INC

25MG; 15MG

@ 25MG; 25MG

@ 50MG; 15MG

@ 50MG; 25MG

MYLAN

25MG; 15MG

!

25MG; 25MG

!

50MG; 15MG

50MG; 25MG

A074827	001	Dec 29, 1997	Jan	DISC
A074827	002	Dec 29, 1997	Jan	DISC
A074827	004	Dec 29, 1997	Jan	DISC
A074827	003	Dec 29, 1997	Jan	DISC
A074896	001	Dec 29, 1997	Jan	CTEC
A074896	002	Dec 29, 1997	Jan	CTEC
A074896	004	Dec 29, 1997	Jan	CTEC
A074896	003	Dec 29, 1997	Jan	CTEC

CARBIDOPATABLET; ORAL
CARBIDOPA

>A>	AB	ZYDUS PHARMS USA INC	25MG	A209910	001	May 07, 2018	Apr	NEWA
-----	----	----------------------	------	---------	-----	--------------	-----	------

CARBINOXAMINE MALEATESOLUTION; ORAL
CARBINOXAMINE MALEATE

>D>	AA	CYPRESS PHARM	4MG/5ML	A090418	001	May 04, 2010	Apr	DISC
>A>		@	4MG/5ML	A090418	001	May 04, 2010	Apr	DISC

TABLET; ORAL
CARBINOXAMINE MALEATE

>D>	AA	CYPRESS PHARM	4MG	A090417	001	Aug 23, 2010	Apr	DISC
>A>		@	4MG	A090417	001	Aug 23, 2010	Apr	DISC

CARBOPLATININJECTABLE; IV (INFUSION)
CARBOPLATIN

>A>	AP	EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Apr	CAHN
>A>	AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Apr	CAHN
>A>	AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Apr	CAHN
>D>	AP	SANJA PHARMS CO	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Apr	CAHN
>D>	AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Apr	CAHN
>D>	AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Apr	CAHN

CARIPRAZINE HYDROCHLORIDECAPSULE; ORAL
VRAYLAR

+	ALLERGAN SALES LLC	EQ 1.5MG BASE
+		EQ 3MG BASE
+		EQ 4.5MG BASE
+	!	EQ 6MG BASE

N204370	001	Sep 17, 2015	Jan	CAHN
N204370	002	Sep 17, 2015	Jan	CAHN
N204370	003	Sep 17, 2015	Jan	CAHN
N204370	004	Sep 17, 2015	Jan	CAHN

CARISOPRODOLTABLET; ORAL
CARISOPRODOL

@ FOSUN PHARMA 350MG

A081025 001 Apr 13, 1989 Jan CAHN

CARVEDILOLTABLET; ORAL
CARVEDILOL

AB	CHARTWELL MOLECULAR	3.125MG
AB		6.25MG
AB		12.5MG
AB		25MG

A077474	001	Sep 05, 2007	Mar	CAHN
A077474	002	Sep 05, 2007	Mar	CAHN
A077474	003	Sep 05, 2007	Mar	CAHN
A077474	004	Sep 05, 2007	Mar	CAHN

CARVEDILOL PHOSPHATECAPSULE, EXTENDED RELEASE; ORAL
CARVEDILOL PHOSPHATE

>A>	AB	IMPAX LABS INC	10MG
>A>	AB		20MG
>A>	AB		40MG
>A>	AB		80MG

A204717	001	May 07, 2018	Apr	NEWA
A204717	002	May 07, 2018	Apr	NEWA
A204717	003	May 07, 2018	Apr	NEWA
A204717	004	May 07, 2018	Apr	NEWA

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

@	FOSUN PHARMA	EQ 500MG BASE/VIAL
@		EQ 1GM BASE/VIAL
@		EQ 2GM BASE/VIAL

A090291	001	Dec 21, 2010	Jan	CAHN
A090291	002	Dec 21, 2010	Jan	CAHN
A090291	003	Dec 21, 2010	Jan	CAHN

CEFOTAXIME SODIUMINJECTABLE; INJECTION
CEFOTAXIME

>D>	AP	HIKMA	EQ 500MG BASE/VIAL
>A>	AP	!	EQ 500MG BASE/VIAL
>D>	AP		EQ 1GM BASE/VIAL
>A>	AP	!	EQ 1GM BASE/VIAL
>D>	AP		EQ 2GM BASE/VIAL
>A>	AP	!	EQ 2GM BASE/VIAL
>D>	AP		EQ 10GM BASE/VIAL

A065072	001	Nov 20, 2002	Apr	CHRS
A065072	001	Nov 20, 2002	Apr	CHRS
A065072	002	Nov 20, 2002	Apr	CHRS
A065072	002	Nov 20, 2002	Apr	CHRS
A065072	003	Nov 20, 2002	Apr	CHRS
A065072	003	Nov 20, 2002	Apr	CHRS
A065071	001	Nov 20, 2002	Apr	CHRS

INJECTABLE; INJECTION
CEFOTAXIME

>A>	AP	!	EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002	Apr	CHRS
>D>		CLAFORAN						
>D>	AP	+!	US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Apr DISC
>A>		+ @		EQ 500MG BASE/VIAL	N050547	001		Apr DISC
>D>	AP	+!		EQ 1GM BASE/VIAL	N050547	002		Apr DISC
>A>		+ @		EQ 1GM BASE/VIAL	N050547	002		Apr DISC
>D>	AP	+!		EQ 2GM BASE/VIAL	N050547	003		Apr DISC
>A>		+ @		EQ 2GM BASE/VIAL	N050547	003		Apr DISC
>D>	AP	+!		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Apr DISC
>A>		+ @		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Apr DISC

CEFPROZILTABLET; ORAL
CEFPROZIL

AB		CASI PHARMS INC	250MG	A065235	001	Nov 14, 2005	Mar	CAHN
AB			500MG	A065235	002	Nov 14, 2005	Mar	CAHN

CEFTAROLINE FOSAMILPOWDER; IV (INFUSION)
TEFLARO

+		ALLERGAN SALES LLC	400MG/VIAL	N200327	001	Oct 29, 2010	Jan	CAHN
+	!		600MG/VIAL	N200327	002	Oct 29, 2010	Jan	CAHN

CEFTIBUTEN DIHYDRATECAPSULE; ORAL
CEDAX

@		SI PHARMS	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jan	CAHN
		FOR SUSPENSION; ORAL						
		CEDAX						
+	@	SI PHARMS	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jan	CAHN
+	@		EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jan	CAHN

CEFUROXIME AXETILTABLET; ORAL
CEFUROXIME AXETIL

@		FOSUN PHARMA	EQ 250MG BASE	A065126	001	Oct 28, 2003	Jan	CAHN
@			EQ 500MG BASE	A065126	002	Oct 28, 2003	Jan	CAHN

CELECOXIBCAPSULE; ORAL
CELECOXIB

AB		CSPC OUYI PHARM CO	50MG	A210071	001	Jan 23, 2018	Jan	NEWA
AB			100MG	A210071	002	Jan 23, 2018	Jan	NEWA
AB			200MG	A210071	003	Jan 23, 2018	Jan	NEWA
>A>	AB	MICRO LABS	50MG	A204776	001	Apr 30, 2018	Apr	NEWA
>A>	AB		100MG	A204776	002	Apr 30, 2018	Apr	NEWA
>A>	AB		200MG	A204776	003	Apr 30, 2018	Apr	NEWA
>A>	AB		400MG	A204776	004	Apr 30, 2018	Apr	NEWA

CEVIMELINE HYDROCHLORIDECAPSULE; ORAL
CEVIMELINE HYDROCHLORIDE
@ APOTEX INC

		30MG	A091260	001	Aug 25, 2011	Mar	DISC
--	--	------	---------	-----	--------------	-----	------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREXSUSPENSION, EXTENDED RELEASE; ORAL
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

>D>	AB		NEOS THERAP INC	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	A091671	001	Jun 29, 2012	Apr	CHRS
>A>	AB	!		EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	A091671	001	Jun 29, 2012	Apr	CHRS
>D>			TUSSIONEX PENNKINETIC						
>D>	AB	+!	UCB INC	EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	N019111	001	Dec 31, 1987	Apr	DISC
>A>		+ @		EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML	N019111	001	Dec 31, 1987	Apr	DISC

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

SONAZINE

@ FOSUN PHARMA	30MG/ML	A 080983	004		Jan	CAHN
@	100MG/ML	A 080983	005		Jan	CAHN

SYRUP; ORAL

SONAZINE

@ FOSUN PHARMA	10MG/5ML	A 083040	001		Jan	CAHN
----------------	----------	----------	-----	--	-----	------

CHLORTHALIDONE

TABLET; ORAL

THALITONE

>D>	@ CASPER PHARMA LLC	15MG	N019574	001	Dec 20, 1988	Apr	CRLD
>A>	+ @	15MG	N019574	001	Dec 20, 1988	Apr	CRLD

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLOPRES

@ MYLAN	15MG;0.1MG	A 071325	003	Feb 09, 1987	Mar	DISC
@	15MG;0.2MG	A 071325	002	Feb 09, 1987	Mar	DISC
@	15MG;0.3MG	A 071325	001	Feb 09, 1987	Mar	DISC

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT	TELIGENT PHARMA INC	1%	A 209975	001	Apr 05, 2018	Mar	NEWA
----	---------------------	----	----------	-----	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

AT	INGENUS PHARMS LLC	8%	A 078124	001	Sep 18, 2007	Jan	CAHN
----	--------------------	----	----------	-----	--------------	-----	------

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

>D>	AP	ACS DOBFAR	EQ 250MG BASE/VIAL; 250MG/VIAL	A 090577	001	Dec 21, 2011	Apr	CHRS
>A>		!	EQ 250MG BASE/VIAL; 250MG/VIAL	A 090577	001	Dec 21, 2011	Apr	CHRS
>D>	AP	HOSPIRA INC	EQ 250MG BASE/VIAL; 250MG/VIAL	A 090825	001	Nov 16, 2011	Apr	DISC
>A>		@	EQ 250MG BASE/VIAL; 250MG/VIAL	A 090825	001	Nov 16, 2011	Apr	DISC
		PRIMAXIN						
>D>	AP	+! MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	N 050587	001	Nov 26, 1985	Apr	DISC
>A>		+ @	EQ 250MG BASE/VIAL; 250MG/VIAL	N 050587	001	Nov 26, 1985	Apr	DISC

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB	CASI PHARMS INC	50MG	A 077310	001	Nov 08, 2005	Mar	CAHN
AB		100MG	A 077021	001	Nov 23, 2004	Mar	CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

@ CHARTWELL MOLECULES	200MG	A 074329	002	May 17, 1994	Jan	CMS1
@	300MG	A 074329	003	May 17, 1994	Jan	CMS1
@	400MG	A 074329	004	May 17, 1994	Jan	CMS1
@ YAOPHARMA CO LTD	200MG	A 074100	001	Jan 31, 1995	Jan	CAHN
@	300MG	A 074100	002	Jan 31, 1995	Jan	CAHN
@	400MG	A 074100	003	Jan 31, 1995	Jan	CAHN
@	800MG	A 074100	004	Jan 31, 1995	Jan	CAHN

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 30MG BASE	A 206125	001	Mar 08, 2018	Feb	NEWA	
AB		EQ 60MG BASE	A 206125	002	Mar 08, 2018	Feb	NEWA	
AB		EQ 90MG BASE	A 206125	003	Mar 08, 2018	Feb	NEWA	
AB	CIPLA LTD	EQ 30MG BASE	A 208915	001	Mar 08, 2018	Feb	NEWA	
AB		EQ 60MG BASE	A 208915	002	Mar 08, 2018	Feb	NEWA	
AB		EQ 90MG BASE	A 208915	003	Mar 08, 2018	Feb	NEWA	
>A>	AB	STRIDES PHARMA	EQ 30MG BASE	A 209226	001	Apr 30, 2018	Apr	NEWA
>A>	AB		EQ 60MG BASE	A 209226	002	Apr 30, 2018	Apr	NEWA
>A>	AB		EQ 90MG BASE	A 209226	003	Apr 30, 2018	Apr	NEWA
>A>	AB	ZYDUS PHARMS USA INC	EQ 30MG BASE	A 208971	001	Apr 23, 2018	Apr	NEWA

TABLET;ORAL

CINACALCET HYDROCHLORIDE

>A>	AB		EQ 60MG BASE	A208971	002	Apr 23, 2018	Apr NEWA	
>A>	AB		EQ 90MG BASE	A208971	003	Apr 23, 2018	Apr NEWA	
		SENSIPAR						
	AB	+	AMGEN	EQ 30MG BASE	N021688	001	Mar 08, 2004	Feb CFTG
	AB	+		EQ 60MG BASE	N021688	002	Mar 08, 2004	Feb CFTG
	AB	+	!	EQ 90MG BASE	N021688	003	Mar 08, 2004	Feb CFTG

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		INFORLIFE	200MG/100ML	A078252	001	Mar 18, 2008	Jan CAHN
AP			400MG/200ML	A078252	002	Mar 18, 2008	Jan CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

>A>	AT		ALTAIRE PHARMS INC	EQ 0.3% BASE	A204613	001	May 03, 2018	Apr NEWA
		TABLET;ORAL						
		CIPRO						
		+	@ BAYER HLTHCARE	EQ 100MG BASE	N019537	001	Apr 08, 1996	Mar DISC
		+	@	EQ 750MG BASE	N019537	004	Oct 22, 1987	Mar DISC
		CIPROFLOXACIN HYDROCHLORIDE						
		@	FOSUN PHARMA	EQ 250MG BASE	A076593	002	Jun 09, 2004	Jan CAHN
		@		EQ 500MG BASE	A076593	003	Jun 09, 2004	Jan CAHN
		@		EQ 750MG BASE	A076593	004	Jun 09, 2004	Jan CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

		@	FOSUN PHARMA	212.6MG;EQ 287.5MG BASE	A078712	001	Dec 11, 2007	Jan CAHN
--	--	---	--------------	-------------------------	---------	-----	--------------	----------

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		HOSPIRA INC	EQ 2MG BASE/ML	A203236	001	Mar 30, 2018	Mar NEWA
AP			EQ 2MG BASE/ML	A203236	001	Mar 30, 2018	Mar NEWA
AP			EQ 10MG BASE/ML	A203236	002	Mar 30, 2018	Mar NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CELEXA

AB	+	ALLERGAN SALES LLC	EQ 10MG BASE	N020822	001	Apr 27, 2000	Jan CAHN	
AB	+		EQ 20MG BASE	N020822	002	Jul 17, 1998	Jan CAHN	
AB	+	!	EQ 40MG BASE	N020822	003	Jul 17, 1998	Jan CAHN	
		@	EQ 60MG BASE	N020822	004	Jul 17, 1998	Jan CAHN	
		CITALOPRAM HYDROBROMIDE						
AB		CHARTWELL MOLECULAR	EQ 10MG BASE	A077044	001	Nov 05, 2004	Mar CAHN	
AB			EQ 20MG BASE	A077044	002	Nov 05, 2004	Mar CAHN	
AB			EQ 40MG BASE	A077044	003	Nov 05, 2004	Mar CAHN	
		@	FOSUN PHARMA	EQ 10MG BASE	A077035	001	Oct 28, 2004	Jan CAHN
		@		EQ 10MG BASE	A077040	001	Aug 17, 2005	Jan CAHN
		@		EQ 20MG BASE	A077035	002	Oct 28, 2004	Jan CAHN
		@		EQ 20MG BASE	A077040	002	Aug 17, 2005	Jan CAHN
		@		EQ 40MG BASE	A077035	003	Oct 28, 2004	Jan CAHN
		@		EQ 40MG BASE	A077040	003	Aug 17, 2005	Jan CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

SOLUTION;ORAL

CLENPIQ

>D>		+	FERRING PHARMS INC	12GM/160ML;3.5GM/160ML;10MG/160ML	N209589	001	Nov 28, 2017	Apr CPOT
>A>		+	!	12GM/BOT;3.5GM/BOT;10MG/BOT	N209589	001	Nov 28, 2017	Apr CPOT

CLARITHROMYCIN

FOR SUSPENSION;ORAL

>D>		BIAXIN						
>D>	AB	+	ABBVIE	125MG/5ML	N050698	001	Dec 23, 1993	Apr DISC
>A>		+	@	125MG/5ML	N050698	001	Dec 23, 1993	Apr DISC
>D>	AB	+	!	250MG/5ML	N050698	002	Dec 23, 1993	Apr DISC
>A>		+	@	250MG/5ML	N050698	002	Dec 23, 1993	Apr DISC

	FOR SUSPENSION;ORAL							
	CLARITHROMYCIN							
>D>	AB	SANDOZ	250MG/5ML	A065283	003	Sep 04, 2007	Apr	CHRS
>A>	AB	!	250MG/5ML	A065283	003	Sep 04, 2007	Apr	CHRS
	<u>CLINDAMYCIN PALMITATE HYDROCHLORIDE</u>							
	FOR SOLUTION;ORAL							
	CLINDAMYCIN PALMITATE HYDROCHLORIDE							
>A>	AA	APPCO PHARMA LLC	EQ 75MG BASE/5ML	A207047	001	May 11, 2018	Apr	NEWA
	<u>CLINDAMYCIN PHOSPHATE</u>							
	INJECTABLE;INJECTION							
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
		@ ABBOTT LABS	EQ 6MG BASE/ML	A065027	001	Jun 29, 2001	Mar	CAHN
		@	EQ 12MG BASE/ML	A065027	002	Jun 29, 2001	Mar	CAHN
		@	EQ 18MG BASE/ML	A065027	003	Jun 29, 2001	Mar	CAHN
	SOLUTION;TOPICAL							
	CLINDAMYCIN PHOSPHATE							
AT		GLASSHOUSE PHARMS	EQ 1% BASE	A209846	001	Feb 08, 2018	Jan	NEWA
	<u>CLOBETASOL PROPIONATE</u>							
	CREAM;TOPICAL							
	CLOBETASOL PROPIONATE							
>A>	AB1	GLENMARK PHARMS	0.05%	A209095	001	May 10, 2018	Apr	NEWA
	AB1	LUPIN LTD	0.05%	A210208	001	Jan 30, 2018	Jan	NEWA
>A>	AB1	TELLIGENT PHARMA INC	0.05%	A209974	001	Apr 17, 2018	Apr	NEWA
	IMPOYZ							
	+	ENCORE DERMAT	0.025%	N209483	001	Nov 28, 2017	Jan	CAHN
	OINTMENT;TOPICAL							
	CLOBETASOL PROPIONATE							
>A>	AB	CHEMO RESEARCH SL	0.05%	A209701	001	Apr 17, 2018	Apr	NEWA
>A>	AB	NOVEL LABS INC	0.05%	A208841	001	May 04, 2018	Apr	NEWA
	SOLUTION;TOPICAL							
	CLOBETASOL PROPIONATE							
>A>	AT	GLENMARK PHARMS LTD	0.05%	A210190	001	Apr 18, 2018	Apr	NEWA
	SPRAY;TOPICAL							
	CLOBETASOL PROPIONATE							
>A>	AT	APOTEX INC	0.05%	A210446	001	Apr 17, 2018	Apr	NEWA
	AT	GLENMARK PHARMS	0.05%	A209004	001	Mar 26, 2018	Mar	NEWA
	AT	LUPIN LTD	0.05%	A208125	001	Mar 26, 2018	Mar	NEWA
	AT	TARO	0.05%	A208842	001	Mar 26, 2018	Mar	NEWA
	<u>CLONIDINE HYDROCHLORIDE</u>							
	TABLET;ORAL							
	CLONIDINE HYDROCHLORIDE							
		@ AUROLIFE PHARMA LLC	0.1MG	A070886	002	Aug 31, 1988	Jan	CMS1
		@	0.3MG	A070886	003	Aug 31, 1988	Jan	CMS1
>D>		CHARTWELL MOLECULES	0.1MG	A071785	002	Apr 05, 1988	Apr	CMS1
>A>		@	0.1MG	A071785	002	Apr 05, 1988	Apr	CMS1
>D>			0.2MG	A071785	003	Apr 05, 1988	Apr	CMS1
>A>		@	0.2MG	A071785	003	Apr 05, 1988	Apr	CMS1
	TABLET, EXTENDED RELEASE;ORAL							
	CLONIDINE HYDROCHLORIDE							
	AB1	JUBILANT GENERICS	0.1MG	A210338	001	Jan 29, 2018	Jan	NEWA
>A>	AB1	MAYNE PHARMA INC	0.1MG	A210680	001	Apr 30, 2018	Apr	NEWA
	<u>CLOPIDOGREL BISULFATE</u>							
	TABLET;ORAL							
	CLOPIDOGREL BISULFATE							
>A>	AB	PRINSTON INC	EQ 75MG BASE	A206376	001	May 07, 2018	Apr	NEWA
>A>	AB		EQ 300MG BASE	A206376	002	May 07, 2018	Apr	NEWA
	<u>CLOZAPINE</u>							
	TABLET, ORALLY DISINTEGRATING;ORAL							
	CLOZAPINE							
	AB	BARR LABS INC	12.5MG	A090308	003	Apr 09, 2018	Mar	NEWA
		FAZACLO ODT						
	AB	+ JAZZ PHARMS III	12.5MG	N021590	004	May 30, 2007	Mar	CTEC

COLESEVELAM HYDROCHLORIDE

TABLET; ORAL

>A>	COLESEVELAM HYDROCHLORIDE						
>A> AB	IMPAX LABS INC	625MG	A091600	001	May 16, 2018	Apr	NEWA
	WELCHOL						
>D>	+! DAIICHI SANKYO	625MG	N021176	001	May 26, 2000	Apr	CFTG
>A> AB	+!	625MG	N021176	001	May 26, 2000	Apr	CFTG

CROFELEMER

TABLET, DELAYED RELEASE; ORAL

MYTESI

+!	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012	Mar	CTNA
----	-----------------	-------	---------	-----	--------------	-----	------

CROMOLYN SODIUM

SOLUTION; INHALATION

CROMOLYN SODIUM

@ FERA PHARMS LLC 10MG/ML

A075437	001	Apr 21, 2000	Mar	CAHN
---------	-----	--------------	-----	------

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

AT	SANDOZ INC	4%	A075282	001	Jun 16, 1999	Jan	CAHN
----	------------	----	---------	-----	--------------	-----	------

CROTAMITON

CREAM; TOPICAL

EURAX

+!	SUN PHARM INDS INC	10%	N006927	001		Feb	CAHN
----	--------------------	-----	---------	-----	--	-----	------

LOTION; TOPICAL

EURAX

AT	+!	SUN PHARM INDS INC	10%	N009112	003	Feb	CAHN
----	----	--------------------	-----	---------	-----	-----	------

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOGYL

AT	!	ALCON LABS INC	0.5%	A084109	001	Feb	CAHN
AT	!		1%	A084110	001	Feb	CAHN
	!		2%	A084108	001	Feb	CAHN

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

!	ALCON LABS INC	0.2%;1%	A084300	001		Feb	CAHN
---	----------------	---------	---------	-----	--	-----	------

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

AB	AMERIGEN PHARMS LTD	25MG	A207014	001	Mar 19, 2018	Mar	NEWA
AB		50MG	A207014	002	Mar 19, 2018	Mar	NEWA
>A> AB	STI PHARMA LLC	25MG	A209872	001	May 07, 2018	Apr	NEWA
>A> AB		50MG	A209872	002	May 07, 2018	Apr	NEWA
AB	+ WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Mar	CFTG
AB	+!	50MG	N203856	002	Sep 16, 2013	Mar	CFTG

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

>D> AA	AILEX PHARMS LLC	4MG	A207555	001	Jan 31, 2017	Apr	CAHN
>A> AA	APNAR PHARMA LP	4MG	A207555	001	Jan 31, 2017	Apr	CAHN
	@ FOSUN PHARMA	4MG	A086808	001		Jan	CAHN
AA	MOUNTAIN	4MG	A040537	001	Sep 30, 2003	Jan	CAHN
AA	STRIDES PHARMA	4MG	A209172	001	Apr 11, 2018	Mar	NEWA

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	MYLAN LABS LTD	20MG/ML	A200916	001	Dec 13, 2011	Jan	CAHN
----	----------------	---------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN

TABLET; ORAL

FARXIGA

+	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Mar	CAIN
+	!	10MG	N202293	002	Jan 08, 2014	Mar	CAIN

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

XIGDUO XR

+	ASTRAZENECA AB	2.5MG;1GM	N205649	005	Jul 28, 2017	Mar	CAIN
+		5MG;500MG	N205649	001	Oct 29, 2014	Mar	CAIN
+		5MG;1GM	N205649	002	Oct 29, 2014	Mar	CAIN
+		10MG;500MG	N205649	003	Oct 29, 2014	Mar	CAIN
+	!	10MG;1GM	N205649	004	Oct 29, 2014	Mar	CAIN

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

QTERN

+	!	ASTRAZENECA AB	10MG;EQ 5MG BASE	N209091	001	Feb 27, 2017	Mar	CAIN
---	---	----------------	------------------	---------	-----	--------------	-----	------

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPTOMYCIN

AP	FRESENIUS KABI USA	500MG/VIAL	A206077	001	Apr 11, 2018	Mar	NEWA
AP	TEVA PHARMS USA	500MG/VIAL	A091039	001	Mar 25, 2016	Feb	CAHN

DECITABINE

INJECTABLE; INTRAVENOUS

DECITABINE

AP	SAGENT PHARMS	50MG/VIAL	A207100	001	Mar 16, 2018	Mar	NEWA
----	---------------	-----------	---------	-----	--------------	-----	------

DEFERIPRONE

SOLUTION; ORAL

FERRIPROX

>A>	+	AOPHARMA INC	80MG/ML	N208030	002	Apr 20, 2018	Apr	NEWA
-----	---	--------------	---------	---------	-----	--------------	-----	------

DESFLURANE

LIQUID; INHALATION

DESFLURANE

AN	SHANGHAI HENGRUI	100%	A208234	001	Feb 26, 2018	Feb	NEWA		
AN	+	!	BAXTER HLTHCARE	100%	N020118	001	Sep 18, 1992	Feb	CFTG

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

>D>		ANI PHARMS INC	25MG	A071803	002	Dec 08, 1987	Apr	CMS1
>A>		@	25MG	A071803	002	Dec 08, 1987	Apr	CMS1
>D>			50MG	A071803	003	Dec 08, 1987	Apr	CMS1
>A>		@	50MG	A071803	003	Dec 08, 1987	Apr	CMS1
>D>			75MG	A071803	004	Dec 08, 1987	Apr	CMS1
>A>		@	75MG	A071803	004	Dec 08, 1987	Apr	CMS1
>D>			150MG	A071803	005	May 29, 1997	Apr	CMS1
>A>		@	150MG	A071803	005	May 29, 1997	Apr	CMS1

DESOXIMETASONE

SPRAY; TOPICAL

DESOXIMETASONE

AT	LUPIN ATLANTIS	0.25%	A208124	001	Mar 16, 2018	Mar	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB	CASI PHARMS INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Mar	CAHN
AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Mar	CAHN

DEXAMETHASONE

ELIXIR; ORAL

HEXADROL

@ ASPEN GLOBAL INC

0.5MG/5ML

N012674 001

Feb CAHN

SUSPENSION; INTRAOCULAR

DEXYCU KIT

>A>	+	EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018	Apr CAHN
>D>	+	ICON BIOSCIENCE	9%	N208912	001	Feb 09, 2018	Apr CAHN
	+		9%	N208912	001	Feb 09, 2018	Feb NEWA

TABLET; ORAL

DEXAMETHASONE

BP FERA PHARMS LLC

0.5MG

A088148 001 Apr 28, 1983

Jan CAHN

BP 0.75MG

A088160 001 Apr 28, 1983

Jan CAHN

BP 4MG

A088238 001 Apr 28, 1983

Jan CAHN

BP 6MG

A088481 001 Nov 28, 1983

Jan CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

>A>	AP	SOMERSET THERAPS LLC	EQ 10MG PHOSPHATE/ML	A207442	001	Apr 19, 2018	Apr NEWA
		HEXADROL					
		+ @ ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML	N014694	002		Feb CAHN
		+ @	EQ 10MG PHOSPHATE/ML	N014694	003		Feb CAHN
		@	EQ 20MG PHOSPHATE/ML	N014694	004		Feb CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ZYDUS PHARMS USA INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A206798	001	Feb 27, 2018	Feb NEWA
----	--	----------------------	--	---------	-----	--------------	----------

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

>A>		ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	Apr CAHN
>A>	AA		5MG	A090533	002	Oct 25, 2011	Apr CAHN
>A>			7.5MG	A090533	003	Oct 25, 2011	Apr CAHN
>A>	AA		10MG	A090533	004	Oct 25, 2011	Apr CAHN
>A>			15MG	A090533	005	Oct 25, 2011	Apr CAHN
>A>			20MG	A090533	006	Oct 25, 2011	Apr CAHN
>A>			30MG	A090533	007	Oct 25, 2011	Apr CAHN
>D>		MIKART	2.5MG	A090533	001	Oct 25, 2011	Apr CAHN
>D>	AA		5MG	A090533	002	Oct 25, 2011	Apr CAHN
>D>			7.5MG	A090533	003	Oct 25, 2011	Apr CAHN
>D>	AA		10MG	A090533	004	Oct 25, 2011	Apr CAHN
>D>			15MG	A090533	005	Oct 25, 2011	Apr CAHN
>D>			20MG	A090533	006	Oct 25, 2011	Apr CAHN
>D>			30MG	A090533	007	Oct 25, 2011	Apr CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

@ G AND W LABS INC

15MG/5ML; 6.25MG/5ML

A088762 001 Oct 31, 1984

Jan DISC

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 5% IN PLASTIC CONTAINER

		+ @ ICU MEDICAL INC	50MG/ML	N019222	001	Jul 13, 1984	Mar DISC
AP		+	50MG/ML	N019222	001	Jul 13, 1984	Feb CAHN
		DEXTROSE 70% IN PLASTIC CONTAINER					
AP		+	B BRAUN	N019626	005	Feb 18, 2015	Feb NEWA

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP		+	ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362	009	Jul 05, 1983	Mar CHRS
AP		+		5GM/100ML; 149MG/100ML; 450MG/100ML	N018362	005	Mar 28, 1988	Mar CPOT
		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
		BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 900MG/100ML	N019308	004	Apr 05, 1985	Mar CTEC	
			5GM/100ML; 150MG/100ML; 900MG/100ML	N019308	002	Apr 05, 1985	Mar CTEC	
		+ @ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	002	Mar 24, 1988	Mar DISC	

INJECTABLE; INJECTION		POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	+ @	5GM/100ML;149MG/100ML;900MG/100ML	N019691	004	Mar 24, 1988	Mar	DISC
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
	+ @	ICU MEDICAL INC 5GM/100ML;224MG/100ML;450MG/100ML	N018362	006	Mar 28, 1988	Mar	DISC
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
	+ @	ICU MEDICAL INC 5GM/100ML;224MG/100ML;900MG/100ML	N019691	006	Mar 24, 1988	Mar	DISC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	+!	ICU MEDICAL INC 5GM/100ML;149MG/100ML;450MG/100ML	N018362	010	Jul 05, 1983	Mar	CHRS
	+ @	5GM/100ML;298MG/100ML;450MG/100ML	N018362	007	Mar 28, 1988	Mar	DISC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
		BAXTER HLTHCARE 5GM/100ML;300MG/100ML;900MG/100ML	N019308	003	Apr 05, 1985	Mar	CTEC
AP	+!	ICU MEDICAL INC 5GM/100ML;149MG/100ML;900MG/100ML	N019691	005	Mar 24, 1988	Mar	CRLD
	+ @	5GM/100ML;298MG/100ML;900MG/100ML	N019691	008	Mar 24, 1988	Mar	DISC
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	+!	ICU MEDICAL INC 5GM/100ML;224MG/100ML;450MG/100ML	N018362	002		Mar	CHRS
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
		BAXTER HLTHCARE 5GM/100ML;224MG/100ML;900MG/100ML	N019308	006	Apr 05, 1985	Mar	CTEC
	+ @	ICU MEDICAL INC 5GM/100ML;224MG/100ML;900MG/100ML	N019691	007	Mar 24, 1988	Mar	DISC
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
AP	+!	ICU MEDICAL INC 5GM/100ML;298MG/100ML;450MG/100ML	N018362	003		Mar	CHRS
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	+!	ICU MEDICAL INC 5GM/100ML;298MG/100ML;900MG/100ML	N019691	009	Mar 24, 1988	Mar	CRLD
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER							
		BAXTER HLTHCARE 5GM/100ML;150MG/100ML;450MG/100ML	N018008	004		Mar	CTEC
	+ @	ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;450MG/100ML	N018362	008	Mar 28, 1988	Mar	DISC
	+ @	5GM/100ML;149MG/100ML;450MG/100ML	N018362	004	Mar 28, 1988	Mar	DISC
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
		BAXTER HLTHCARE 5GM/100ML;150MG/100ML;900MG/100ML	N019308	001	Apr 05, 1985	Mar	CTEC
	+ @	ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;900MG/100ML	N019691	001	Mar 24, 1988	Mar	DISC
	+ @	5GM/100ML;149MG/100ML;900MG/100ML	N019691	003	Mar 24, 1988	Mar	DISC

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION		DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP	+	ICU MEDICAL INC 5GM/100ML;450MG/100ML	N017607	001		Jan	CRLD

DIAZEPAM

TABLET; ORAL		DIAZEPAM					
>D>		DAVA PHARMS INC 2MG	A070228	002	Sep 26, 1985	Apr	CMS1
>A>	@	2MG	A070228	002	Sep 26, 1985	Apr	CMS1
>D>		5MG	A070228	003	Sep 26, 1985	Apr	CMS1
>A>	@	5MG	A070228	003	Sep 26, 1985	Apr	CMS1

DICLOFENAC POTASSIUM

TABLET; ORAL		DICLOFENAC POTASSIUM					
AB		CASI PHARMS INC 50MG	A075229	001	Nov 20, 1998	Mar	CAHN

DICLOFENAC SODIUM

SOLUTION; TOPICAL		DICLOFENAC SODIUM					
>A>	AT	ZYDUS PHARMS USA INC 1.5%	A206411	001	Apr 17, 2018	Apr	NEWA
TABLET, DELAYED RELEASE; ORAL		DICLOFENAC SODIUM					
AB	!	CASI PHARMS INC 25MG	A074376	001	Sep 28, 1995	Mar	CAHN
AB	!	50MG	A074376	002	Sep 28, 1995	Mar	CAHN
AB	!	75MG	A074394	001	Nov 30, 1995	Mar	CAHN

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL		BENTYL					
AB	+!	ALLERGAN SALES LLC 10MG	N007409	003	Oct 15, 1984	Jan	CAHN
INJECTABLE; INJECTION		BENTYL					
AP	+!	ALLERGAN SALES LLC 10MG/ML	N008370	001	Oct 15, 1984	Jan	CAHN
		BENTYL PRESERVATIVE FREE					
AP	+!	ALLERGAN SALES LLC 10MG/ML	N008370	002	Oct 15, 1984	Jan	CAHN
DICYCLOMINE HYDROCHLORIDE							
>A>	AP	AKORN INC 10MG/ML	A207084	001	May 04, 2018	Apr	NEWA

TABLET;ORAL

BENTYL
 AB +! ALLERGAN SALES LLC 20MG N007409 001 Oct 15, 1984 Jan CAHN

DIRIDANOSINECAPSULE, DELAYED REL PELLETS;ORAL
 DIDANOSINE

@ BARR 200MG A077167 001 Dec 03, 2004 Mar DISC
 @ 250MG A077167 002 Dec 03, 2004 Mar DISC
 @ 400MG A077167 003 Dec 03, 2004 Mar DISC

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

@ FOSUN PHARMA 25MG A080832 001 Jan CAHN
 @ 25MG A080845 002 Jan CAHN
 @ 50MG A080832 002 Jan CAHN
 @ 50MG A080845 001 Jan CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

>A> AB APOTEX INC EQ 125MG VALPROIC ACID A077615 003 Jul 29, 2008 Apr CAHN
 >A> AB EQ 250MG VALPROIC ACID A077615 002 Jul 29, 2008 Apr CAHN
 >A> AB EQ 500MG VALPROIC ACID A077615 001 Jul 29, 2008 Apr CAHN
 >D> AB NU PHARM EQ 125MG VALPROIC ACID A077615 003 Jul 29, 2008 Apr CAHN
 >D> AB EQ 250MG VALPROIC ACID A077615 002 Jul 29, 2008 Apr CAHN
 >D> AB EQ 500MG VALPROIC ACID A077615 001 Jul 29, 2008 Apr CAHN

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP AMNEAL PHARMS CO 20MG/ML (20MG/ML) A209640 001 Jan 19, 2018 Jan NEWA
 AP 80MG/4ML (20MG/ML) A209640 002 Jan 19, 2018 Jan NEWA
 AP 160MG/8ML (20MG/ML) A209640 003 Jan 19, 2018 Jan NEWA

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

>A> AP MYLAN LABS LTD 160MG/16ML (10MG/ML) A208859 001 Apr 30, 2018 Apr NEWA

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

AB SIGMAPHARM LABS LLC 0.125MG A207746 001 Mar 26, 2018 Mar NEWA
 AB 0.25MG A207746 002 Mar 26, 2018 Mar NEWA
 AB 0.5MG A207746 003 Mar 26, 2018 Mar NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

@ APOTEX 5MG A078841 001 Jun 02, 2011 Mar DISC
 @ 10MG A078841 002 Jun 02, 2011 Mar DISC
 >D> AB SUN PHARM INDS LTD 5MG A076786 001 Nov 26, 2010 Apr DISC
 >A> @ 5MG A076786 001 Nov 26, 2010 Apr DISC
 >D> AB 10MG A076786 002 Nov 26, 2010 Apr DISC
 >A> @ 10MG A076786 002 Nov 26, 2010 Apr DISC

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

AP HIKMA INTL PHARMS 40MG/ML A207707 001 Apr 11, 2018 Mar NEWA
 AP 80MG/ML A207707 002 Apr 11, 2018 Mar NEWA

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

>A> AB APPCO PHARMA LLC EQ 1MG BASE A209013 001 Apr 17, 2018 Apr NEWA
 >A> AB EQ 2MG BASE A209013 002 Apr 17, 2018 Apr NEWA
 >A> AB EQ 4MG BASE A209013 003 Apr 17, 2018 Apr NEWA
 >A> AB EQ 8MG BASE A209013 004 Apr 17, 2018 Apr NEWA
 AB HERITAGE PHARMA EQ 1MG BASE A205210 001 Feb 13, 2018 Jan NEWA

TABLET;ORAL

DOXAZOSIN MESYLATE							
AB		EQ 2MG BASE	A205210	002	Feb 13, 2018	Jan	NEWA
AB		EQ 4MG BASE	A205210	003	Feb 13, 2018	Jan	NEWA
AB		EQ 8MG BASE	A205210	004	Feb 13, 2018	Jan	NEWA
	@ YAOPHARMA CO LTD	EQ 1MG BASE	A075646	001	Oct 18, 2000	Jan	CAHN
	@	EQ 2MG BASE	A075646	002	Oct 18, 2000	Jan	CAHN
	@	EQ 4MG BASE	A075646	003	Oct 18, 2000	Jan	CAHN
	@	EQ 8MG BASE	A075646	004	Oct 18, 2000	Jan	CAHN

DOXEPIN HYDROCHLORIDE

TABLET;ORAL

DOXEPIN HYDROCHLORIDE							
	@ ACTAVIS ELIZABETH	EQ 3MG BASE	A201951	001	Jul 26, 2013	Jan	DISC
	@	EQ 6MG BASE	A201951	002	Jul 26, 2013	Jan	DISC
	SILENOR						
+	PERNIX THERAPS LLC	EQ 3MG BASE	N022036	001	Mar 17, 2010	Jan	CTEC
+	!	EQ 6MG BASE	N022036	002	Mar 17, 2010	Jan	CTEC

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE;ORAL

DORYX								
>D>	AB +	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	DISC
>A>	AB + @		EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	DISC
		DOXYCYCLINE HYCLATE						
>D>	AB	MYLAN	EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr	DISC
>A>	AB @		EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr	DISC

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL								
AB		JUBILANT CADISTA	3MG;0.02MG	A209423	001	Dec 22, 2017	Mar	CAHN
		LO-ZUMANDIMINE						
AB		AUROBINDO PHARMA LTD	3MG;0.02MG	A209632	001	Feb 27, 2018	Feb	NEWA
		TABLET;ORAL-28						
		ZUMANDIMINE						
AB		AUROBINDO PHARMA LTD	3MG;0.03MG	A209407	001	Mar 26, 2018	Mar	NEWA

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE								
AB		CASI PHARMS INC	1%	A076075	001	Nov 26, 2002	Mar	CAHN
>A>	AB	MYLAN PHARMS INC	1%	A210364	001	Apr 18, 2018	Apr	NEWA

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ								
>A>	AB	HETERO LABS LTD III	600MG	A078886	001	Apr 27, 2018	Apr	NEWA
	AB	STRIDES PHARMA	600MG	A204869	001	Mar 12, 2018	Feb	NEWA

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

ATRIPLA								
+	!	GILEAD SCIENCES	600MG;200MG;300MG	N021937	001	Jul 12, 2006	Mar	CAHN

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

SYMFI								
+	!	MYLAN LABS LTD	600MG;300MG;300MG	N022142	001	Mar 22, 2018	Mar	NEWA
		SYMFI LO						
+	!	MYLAN PHARMS INC	400MG;300MG;300MG	N208255	001	Feb 05, 2018	Feb	NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE								
AB		AUROBINDO PHARMA LTD	200MG;300MG	A090513	001	Jan 26, 2018	Jan	NEWA
AB		MYLAN PHARMS INC	200MG;300MG	A206436	001	Apr 09, 2018	Mar	NEWA

ENTECAVIR

TABLET; ORAL

ENTECAVIR

>A>	AB	BRECKENRIDGE PHARM	0.5MG	A208721	001	Mar 15, 2018	Apr	NEWA
>A>	AB		1MG	A208721	002	Mar 15, 2018	Apr	NEWA
	AB	CASI PHARMS INC	0.5MG	A206672	001	May 11, 2017	Mar	CAHN
	AB		1MG	A206672	002	May 11, 2017	Mar	CAHN

EPHEDRINE SULFATE

>A>		SOLUTION; INTRAVENOUS						
>A>		CORPHEDRA						
>A>	AP	PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Apr	CDFR
>D>		SOLUTION; IV (INFUSION)						
>D>		CORPHEDRA						
>D>		PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017	Apr	CDFR

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT		CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Mar	CAHN
----	--	-----------------	-------	---------	-----	--------------	-----	------

EPINEPHRINE

SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE

>D>		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Apr	CRLD
>A>		+	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Apr	CRLD

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

@ EASTMAN KODAK 0.01MG/ML; 2%

@ 0.02MG/ML; 2%

A040057	002	Feb 26, 1993	Mar	DISC
A040057	001	Feb 26, 1993	Mar	DISC

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

AB	!	MYLAN PHARMS INC	EQ 600MG BASE	A202012	002	Nov 16, 2011	Mar	CHRS
		TEVETEN						
	+	@ ABBVIE	EQ 400MG BASE	N020738	005	Dec 22, 1997	Mar	DISC
	+	@	EQ 600MG BASE	N020738	006	May 27, 1999	Mar	DISC

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

AP		SAGENT PHARMS	2MG/ML	A204693	001	Mar 07, 2018	Feb	NEWA
AP			75MG/100ML	A204693	002	Mar 07, 2018	Feb	NEWA

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, IV (INFUSION)

ERTAPENEM SODIUM

>A>									
>A>	AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A208790	001	Apr 16, 2018	Apr	NEWA	
		INVANZ							
>D>		+	MERCK SHARP DOHME	EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Apr	CFTG
>A>	AP	+		EQ 1GM BASE/VIAL	N021337	001	Nov 21, 2001	Apr	CFTG

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

STEGLUJAN

+		MERCK SHARP DOHME	5MG; EQ 100MG BASE	N209805	001	Dec 19, 2017	Jan	CMS1
+		!	15MG; EQ 100MG BASE	N209805	002	Dec 19, 2017	Jan	CMS1

ERYTHROMYCIN

TABLET; ORAL

ERYTHROMYCIN

AB		AMNEAL PHARMS CO	250MG	A209720	001	Mar 09, 2018	Feb	NEWA
AB			500MG	A209720	002	Mar 09, 2018	Feb	NEWA
AB		ARBOR PHARMS LLC	250MG	A061621	001		Feb	CTEC
AB	!		500MG	A061621	002		Feb	CTEC

ESCITALOPRAM OXALATE

SOLUTION;ORAL

LEXAPRO

AA	+	ALLERGAN SALES LLC	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Jan CAHN
TABLET;ORAL							
LEXAPRO							
AB	+	ALLERGAN SALES LLC	EQ 5MG BASE	N021323	001	Aug 14, 2002	Jan CAHN
AB	+		EQ 10MG BASE	N021323	002	Aug 14, 2002	Jan CAHN
AB	+		EQ 20MG BASE	N021323	003	Aug 14, 2002	Jan CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

>A>	AB	SUN PHARM INDS LTD	EQ 20MG BASE	A209735	001	Apr 30, 2018	Apr NEWA
>A>	AB		EQ 40MG BASE	A209735	002	Apr 30, 2018	Apr NEWA

ESTRADIOL

CREAM;VAGINAL

ESTRADIOL

AB		ALVOGEN PINE BROOK	0.01%	A209767	001	Mar 05, 2018	Feb NEWA
AB		PERRIGO UK FINCO	0.01%	A210194	001	Jan 22, 2018	Jan NEWA
AB		TEVA PHARMS USA	0.01%	A210488	001	Mar 30, 2018	Mar NEWA

ESTRADIOL VALERATE

INJECTABLE;INJECTION

ESTRADIOL VALERATE

@ FOSUN PHARMA

10MG/ML

A040628 001 Oct 04, 2007 Jan CAHN

@

20MG/ML

A040628 002 Oct 04, 2007 Jan CAHN

@

40MG/ML

A040628 003 Oct 04, 2007 Jan CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB		ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Feb NEWA
----	--	-----------------	-----------	---------	-----	--------------	----------

ETHACRYNIC ACID

TABLET;ORAL

ETHACRYNIC ACID

>A>	AB	AMNEAL PHARMS CO	25MG	A208805	001	May 08, 2018	Apr NEWA
-----	----	------------------	------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

BALCOLTRA

AVION PHARMS

0.02MG;0.1MG

N208612 001 Jan 09, 2018 Feb CAHN

NEUVOSYN LABS LLC

0.02MG;0.1MG

N208612 001 Jan 09, 2018 Jan NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL

>D>	AB	LUPIN LTD	0.02MG,0.01MG;0.1MG,N/A	A091674	001	Oct 26, 2011	Apr CPOT
>D>	AB	MAYNE PHARMA	0.02MG,0.01MG;0.1MG,N/A	A200407	001	Oct 25, 2011	Apr CPOT

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

>D>	AB	LABS LEON FARMA	0.02MG,0.01MG;0.1MG,N/A	A205131	001	Dec 14, 2017	Apr CPOT
-----	----	-----------------	-------------------------	---------	-----	--------------	----------

>A>	AB		0.02MG,0.1MG;0.01MG,N/A	A205131	001	Dec 14, 2017	Apr CPOT
-----	----	--	-------------------------	---------	-----	--------------	----------

>A>	AB	LUPIN LTD	0.02MG,0.1MG;0.01MG,N/A	A091674	001	Oct 26, 2011	Apr CPOT
-----	----	-----------	-------------------------	---------	-----	--------------	----------

>A>	AB	MAYNE PHARMA	0.02MG,0.1MG;0.01MG,N/A	A200407	001	Oct 25, 2011	Apr CPOT
-----	----	--------------	-------------------------	---------	-----	--------------	----------

>D>	AB	MYLAN LABS LTD	0.02MG,0.01MG;0.1MG,N/A	A200493	001	Jun 17, 2015	Apr CPOT
-----	----	----------------	-------------------------	---------	-----	--------------	----------

>A>	AB		0.02MG,0.1MG;0.01MG,N/A	A200493	001	Jun 17, 2015	Apr CPOT
-----	----	--	-------------------------	---------	-----	--------------	----------

LO SIMPESE

>D>	AB	AUROBINDO PHARMA LTD	0.02MG,0.01MG;0.01MG,N/A	A206852	001	Apr 28, 2017	Apr CPOT
-----	----	----------------------	--------------------------	---------	-----	--------------	----------

>A>	AB		0.02MG,0.1MG;0.01MG,N/A	A206852	001	Apr 28, 2017	Apr CPOT
-----	----	--	-------------------------	---------	-----	--------------	----------

LOSEASONIQUE

>D>	AB	TEVA BRANDED PHARM	0.01MG;0.02MG;0.1MG	N022262	001	Oct 24, 2008	Apr CPOT
-----	----	--------------------	---------------------	---------	-----	--------------	----------

>A>	AB		0.02MG,0.1MG;0.01MG,N/A	N022262	001	Oct 24, 2008	Apr CPOT
-----	----	--	-------------------------	---------	-----	--------------	----------

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB		MYLAN LABS LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202970	001	Mar 23, 2018	Mar NEWA
----	--	----------------	---	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE

	TABLET;ORAL-28							
	MODICON 28							
	+ @ JANSSEN PHARMS	0.035MG;0.5MG		N017735	001			Feb DISC
	WERA							
AB	! NOVAST LABS LTD	0.035MG;0.5MG		A091204	001	Mar 27, 2012		Feb CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

	TABLET;ORAL							
	LO LOESTRIN FE							
>D>	AB +!	APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010		Apr CTEC
>A>		+!	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010		Apr CTEC
>D>		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
>D>	AB	MYLAN LABS LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016		Apr DISC
>A>		@	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016		Apr DISC
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB		APOTEX INC	0.02MG;1MG	A208639	001	Mar 21, 2018		Mar NEWA
	TABLET, CHEWABLE, TABLET;ORAL							
	LO MINASTRIN FE							
	+ @ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A		N204654	001	Jul 24, 2013		Jan DISC

EVEROLIMUS

	TABLET;ORAL							
	EVEROLIMUS							
>A>	AB	WEST-WARD PHARMS INT	0.25MG	A206133	001	Apr 12, 2018		Apr NEWA
>A>	AB		0.5MG	A206133	002	Apr 12, 2018		Apr NEWA
>A>	AB		0.75MG	A206133	003	Apr 12, 2018		Apr NEWA
	ZORTRESS							
>D>		+ NOVARTIS	0.25MG	N021560	001	Apr 20, 2010		Apr CFTG
>A>	AB	+	0.25MG	N021560	001	Apr 20, 2010		Apr CFTG
>D>		+	0.5MG	N021560	002	Apr 20, 2010		Apr CFTG
>A>	AB	+	0.5MG	N021560	002	Apr 20, 2010		Apr CFTG
>D>		+!	0.75MG	N021560	003	Apr 20, 2010		Apr CFTG
>A>	AB	+!	0.75MG	N021560	003	Apr 20, 2010		Apr CFTG

EXEMESTANE

	TABLET;ORAL							
	EXEMESTANE							
>A>	AB	CIPLA LTD	25MG	A210323	001	Apr 27, 2018		Apr NEWA

FAMOTIDINE

	TABLET;ORAL							
	FAMOTIDINE							
	@ PLD ACQUISITIONS	20MG		A075302	001	Apr 16, 2001		Feb CAHN
	@	40MG		A075302	002	Apr 16, 2001		Feb CAHN

FENOFIBRATE

	CAPSULE;ORAL							
	FENOFIBRATE (MICRONIZED)							
>A>	AB	AMERIGEN PHARMS LTD	67MG	A209504	001	Apr 30, 2018		Apr NEWA
>A>	AB		134MG	A209504	002	Apr 30, 2018		Apr NEWA
>A>	AB		200MG	A209504	003	Apr 30, 2018		Apr NEWA
	TABLET;ORAL							
	FENOFIBRATE							
AB		AMNEAL PHARMS LLC	48MG	A209951	001	Feb 09, 2018		Jan NEWA
AB			54MG	A209950	001	Mar 19, 2018		Mar NEWA
AB			145MG	A209951	002	Feb 09, 2018		Jan NEWA
AB			160MG	A209950	002	Mar 19, 2018		Mar NEWA

FENTANYL

	FILM, EXTENDED RELEASE;TRANSDERMAL							
	DURAGESIC-37							
	+ JANSSEN PHARMS	37.5MCG/HR		N019813	006	Jan 24, 2018		Jan NEWA

FLUCONAZOLE

	INJECTABLE;INJECTION							
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER							
AP	!	INFORLIFE	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009		Jan CAHN
AP	!		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009		Jan CAHN

FLUOCINOLONE ACETONIDE

	CREAM;TOPICAL								
	FLUOCINOLONE ACETONIDE								
	@ G AND W LABS	0.025%		A089525	001	Jul 26, 1988	Jan	DISC	
	OIL/DROPS;OTIC								
	FLAC								
AT	PATRIN PHARMA INC	0.01%		A210736	001	Apr 11, 2018	Mar	NEWA	
	SOLUTION;TOPICAL								
	FLUOCINOLONE ACETONIDE								
	@ G AND W LABS INC	0.01%		A207441	001	Sep 28, 2016	Jan	DISC	

FLUOCINONIDE

	SOLUTION;TOPICAL								
	FLUOCINONIDE								
>A>	AT	GLASSHOUSE PHARMS	0.05%		A209118	001	Apr 23, 2018	Apr	NEWA
>A>	AT	MACLEODS PHARMS LTD	0.05%		A209283	001	Apr 23, 2018	Apr	NEWA

FLUORESCEIN SODIUM

	INJECTABLE;INTRAVENOUS								
	FLUORESCITE								
AP	+!	ALCON LABS INC	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)		N021980	001	Mar 28, 2006	Feb	CAHN

FLUOXETINE HYDROCHLORIDE

	TABLET;ORAL								
	FLUOXETINE HYDROCHLORIDE								
>D>	AB	DR REDDYS LABS INC	EQ 10MG BASE		A076006	001	Jan 30, 2002	Apr	CAHN
>A>	AB	DR REDDYS LABS LTD	EQ 10MG BASE		A076006	001	Jan 30, 2002	Apr	CAHN
>A>	AB		EQ 20MG BASE		A076006	002	Apr 23, 2018	Apr	NEWA
>A>	AB		EQ 20MG BASE		A076006	002	Apr 23, 2018	Apr	CAHN
		@ FOSUN PHARMA	EQ 10MG BASE		A076024	001	Jan 29, 2002	Jan	CAHN

FLUTAMIDE

	CAPSULE;ORAL								
	FLUTAMIDE								
	@ YAOPHARMA CO LTD	125MG			A075818	001	Sep 18, 2001	Jan	CAHN

FLUTICASONE PROPIONATE

	SPRAY, METERED;NASAL								
	XHANCE								
	+!	OPTINOSE US INC	0.093MG		N209022	001	Sep 18, 2017	Jan	CMS1

FONDAPARINUX SODIUM

	INJECTABLE;SUBCUTANEOUS								
	FONDAPARINUX SODIUM								
>A>	AP	JIANGSU HENGRUI MED	2.5MG/0.5ML		A206812	001	May 15, 2018	Apr	NEWA
>A>	AP		5MG/0.4ML		A206812	002	May 15, 2018	Apr	NEWA
>A>	AP		7.5MG/0.6ML		A206812	003	May 15, 2018	Apr	NEWA
>A>	AP		10MG/0.8ML		A206812	004	May 15, 2018	Apr	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

	TABLET;ORAL								
	FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE								
AB		EMCURE PHARMS LTD	10MG;12.5MG		A079025	001	Sep 17, 2010	Jan	CAHN
AB	!		20MG;12.5MG		A079025	002	Sep 17, 2010	Jan	CAHN

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

>A>		POWDER;INTRAVENOUS							
>A>		AKYNZEO							
>A>		+!	HELSSINN HLTHCARE	EQ 235MG BASE;EQ 0.25MG BASE	N210493	001	Apr 19, 2018	Apr	NEWA

FOSTAMATINIB DISODIUM

>A>		TABLET;ORAL							
>A>		TAVALISSE							
>A>		+ RIGEL PHARMS INC	EQ 100MG BASE		N209299	001	Apr 17, 2018	Apr	NEWA
>A>		+!	EQ 150MG BASE		N209299	002	Apr 17, 2018	Apr	NEWA

GABAPENTINCAPSULE;ORAL
GABAPENTIN

>A>	AB	ACI HEALTHCARE LTD	100MG	A206943	001	May 14, 2018	Apr	NEWA
>A>	AB		300MG	A206943	002	May 14, 2018	Apr	NEWA
>A>	AB		400MG	A206943	003	May 14, 2018	Apr	NEWA

GEMCITABINE HYDROCHLORIDEINJECTABLE;INJECTION
GEMCITABINE HYDROCHLORIDE

@	HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663	001	Sep 10, 2012	Mar	DISC
@		EQ 1GM BASE/VIAL	A090663	002	Sep 10, 2012	Mar	DISC

GEMFIBROZILTABLET;ORAL
GEMFIBROZIL

@	YAOPHARMA CO LTD	600MG	A074615	001	Sep 29, 1995	Jan	CAHN
---	------------------	-------	---------	-----	--------------	-----	------

GENTAMICIN SULFATEOINTMENT;TOPICAL
GENTAMICIN SULFATE

AT	G AND W LABS INC	EQ 0.1% BASE	A064054	001	Apr 29, 1994	Jan	CMFD
----	------------------	--------------	---------	-----	--------------	-----	------

GLATIRAMER ACETATEINJECTABLE;SUBCUTANEOUS
GLATOFA

AP	SANDOZ INC	40MG/ML	A206921	001	Feb 12, 2018	Jan	NEWA
----	------------	---------	---------	-----	--------------	-----	------

>A> GLUCAGON>A> INJECTABLE;INJECTION
>A> GLUCAGON

>A>	+	LILLY	1MG/VIAL	N020928	001	Sep 11, 1998	Apr	CAIN
-----	---	-------	----------	---------	-----	--------------	-----	------

>A> GLUCAGON HYDROCHLORIDE>A> INJECTABLE;INJECTION
>A> GLUCAGEN

>A>	+	NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998	Apr	CAIN
-----	---	--------------	------------------	---------	-----	--------------	-----	------

>D> GLUCAGON HYDROCHLORIDE RECOMBINANT>D> INJECTABLE;INJECTION
>D> GLUCAGEN

>D>	+	NOVO NORDISK	EQ 1MG BASE/VIAL	N020918	001	Jun 22, 1998	Apr	CAIN
-----	---	--------------	------------------	---------	-----	--------------	-----	------

>D> GLUCAGON RECOMBINANT>D> INJECTABLE;INJECTION
>D> GLUCAGON

>D>	+	LILLY	1MG/VIAL	N020928	001	Sep 11, 1998	Apr	CAIN
-----	---	-------	----------	---------	-----	--------------	-----	------

GLYBURIDETABLET;ORAL
GLYBURIDE (MICRONIZED)

@	YAOPHARMA CO LTD	1.5MG	A075174	001	Jun 22, 1998	Jan	CAHN
@		3MG	A075174	002	Jun 22, 1998	Jan	CAHN

GLYCINESOLUTION;IRRIGATION
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	1.5GM/100ML	N017865	001		Mar	CRLD
----	---	-----------------	-------------	---------	-----	--	-----	------

GLYCOPYRROLATETABLET;ORAL
GLYCOPYRROLATE

>D>	@	EPIC PHARMA LLC	1MG	A040568	001	Dec 22, 2004	Apr	CAHN
>D>	@		2MG	A040568	002	Dec 22, 2004	Apr	CAHN
>A>	@	RENATA	1MG	A040568	001	Dec 22, 2004	Apr	CAHN
>A>	@		2MG	A040568	002	Dec 22, 2004	Apr	CAHN

GRANISETRON HYDROCHLORIDE

	INJECTABLE; INJECTION								
	GRANISETRON HYDROCHLORIDE								
	@ TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963	001	Jan 03, 2008	Feb	DISC		
	TABLET; ORAL								
	GRANISETRON HYDROCHLORIDE								
AB	CHARTWELL MOLECULAR	EQ 1MG BASE	A078037	001	Feb 27, 2008	Mar	CAHN		

GRISEOFULVIN, ULTRAMICROSIZED

	TABLET; ORAL								
	GRISEOFULVIN, ULTRAMICROSIZED								
AB	MOUNTAIN	125MG	A204371	001	Jan 09, 2014	Jan	CAHN		
AB		250MG	A204371	002	Jan 09, 2014	Jan	CAHN		

GUAIFENESIN; HYDROCODONE BITARTRATE

>A>	TABLET; ORAL								
>A>	HYDROCODONE BITARTRATE AND GUAIFENESIN								
>A>	+! ECI PHARMS LLC	400MG; 5MG	N208085	001	Apr 25, 2018	Apr	NEWA		

GUANABENZ ACETATE

	TABLET; ORAL								
	GUANABENZ ACETATE								
	@ YAOPHARMA CO LTD	EQ 4MG BASE	A074517	001	Sep 30, 1998	Jan	CAHN		
	@	EQ 8MG BASE	A074517	002	Sep 30, 1998	Jan	CAHN		

HALCINONIDE

	CREAM; TOPICAL								
	HALOG								
+!	SUN PHARM INDS INC	0.1%	N017556	001		Feb	CAHN		

HALOBETASOL PROPIONATE

	CREAM; TOPICAL								
	ULTRAVATE								
AB	+ SUN PHARM INDS INC	0.05%	N019967	001	Dec 27, 1990	Feb	CAHN		
	OINTMENT; TOPICAL								
	HALOBETASOL PROPIONATE								
AB	TELLIGENT PHARMA INC	0.05%	A209978	001	Mar 20, 2018	Mar	NEWA		
	ULTRAVATE								
AB	+ SUN PHARM INDS INC	0.05%	N019968	001	Dec 17, 1990	Feb	CAHN		

HALOPERIDOL LACTATE

	INJECTABLE; INJECTION								
	HALOPERIDOL								
	@ FOSUN PHARMA	EQ 5MG BASE/ML	A076464	001	Sep 29, 2004	Jan	CAHN		

HEPARIN SODIUM

	INJECTABLE; INJECTION								
	HEPARIN SODIUM								
AP	CASI PHARMS INC	5,000 UNITS/ML	A091659	001	Jun 08, 2011	Mar	CAHN		

HYDRALAZINE HYDROCHLORIDE

	TABLET; ORAL								
	HYDRALAZINE HYDROCHLORIDE								
AA	SCIEGEN PHARMS INC	10MG	A205236	001	May 26, 2017	Feb	CAHN		
AA		25MG	A205236	002	May 26, 2017	Feb	CAHN		
AA		50MG	A205236	003	May 26, 2017	Feb	CAHN		
AA		100MG	A205236	004	May 26, 2017	Feb	CAHN		

HYDROCHLOROTHIAZIDE

	CAPSULE; ORAL								
	HYDROCHLOROTHIAZIDE								
	@ APOTEX	12.5MG	A078389	001	May 16, 2008	Mar	DISC		
	TABLET; ORAL								
	HYDROCHLOROTHIAZIDE								
	@ APOTEX	25MG	A040774	001	Oct 03, 2007	Mar	DISC		
	@	50MG	A040774	002	Oct 03, 2007	Mar	DISC		
AB	SCIEGEN PHARMS INC	25MG	A203018	001	Jul 23, 2014	Jan	CAHN		
AB		50MG	A203018	002	Jul 23, 2014	Jan	CAHN		
	@ YAOPHARMA CO LTD	25MG	A087565	001	Mar 09, 1982	Jan	CAHN		
	@	50MG	A084912	001		Jan	CAHN		

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

>D>	AB	APOTEX INC	12.5MG;10MG	A076674	001	Oct 05, 2004	Apr	DISC
>A>		@	12.5MG;10MG	A076674	001	Oct 05, 2004	Apr	DISC
>D>	AB		12.5MG;20MG	A076674	002	Oct 05, 2004	Apr	DISC
>A>		@	12.5MG;20MG	A076674	002	Oct 05, 2004	Apr	DISC
>D>	AB		25MG;20MG	A076674	003	Oct 05, 2004	Apr	DISC
>A>		@	25MG;20MG	A076674	003	Oct 05, 2004	Apr	DISC

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

>D>	AB	+ MERCK SHARP DOHME	12.5MG;50MG	N020387	001	Apr 28, 1995	Apr	DISC
>A>		+ @	12.5MG;50MG	N020387	001	Apr 28, 1995	Apr	DISC
>D>	AB	+!	25MG;100MG	N020387	002	Nov 10, 1998	Apr	DISC
>A>		+ @	25MG;100MG	N020387	002	Nov 10, 1998	Apr	DISC

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

		@ APOTEX	12.5MG;50MG	A090150	001	Oct 06, 2010	Mar	DISC
		@	12.5MG;100MG	A090150	002	Aug 11, 2010	Mar	DISC
		@	25MG;100MG	A090150	003	Oct 06, 2010	Mar	DISC
>D>	AB	AUROBINDO PHARMA	25MG;100MG	A091629	003	Jan 06, 2010	Apr	CHRS
>A>	AB	!	25MG;100MG	A091629	003	Jan 06, 2010	Apr	CHRS

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

@	YAOPHARMA CO LTD	15MG;250MG
@		25MG;250MG
@		30MG;500MG
@		50MG;500MG

A070182	001	Jan 15, 1986	Jan	CAHN
A070183	001	Jan 15, 1986	Jan	CAHN
A070543	001	Jan 15, 1986	Jan	CAHN
A070544	001	Jan 15, 1986	Jan	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	YAOPHARMA CO LTD	25MG;40MG
@		25MG;80MG

A071060	001	Aug 26, 1987	Jan	CAHN
A071061	001	Aug 26, 1987	Jan	CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

@	YAOPHARMA CO LTD	25MG;25MG
---	------------------	-----------

A086881	001		Jan	CAHN
---------	-----	--	-----	------

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	!	CASI PHARMS INC	25MG;50MG
----	---	-----------------	-----------

A073191	001	Jul 31, 1991	Mar	CAHN
---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

@	APOTEX INC	12.5MG;80MG
@		12.5MG;160MG
@		12.5MG;320MG
@		25MG;160MG
@		25MG;320MG

A203026	001	Mar 21, 2013	Mar	DISC
A203026	002	Mar 21, 2013	Mar	DISC
A203026	003	Mar 21, 2013	Mar	DISC
A203026	004	Mar 21, 2013	Mar	DISC
A203026	005	Mar 21, 2013	Mar	DISC

HYDROCORTISONE VALERATE

CREAM; TOPICAL

WESTCORT

+ @	SUN PHARM INDS INC	0.2%
-----	--------------------	------

N017950	001		Mar	CAHN
---------	-----	--	-----	------

OINTMENT; TOPICAL

WESTCORT

+ @	SUN PHARM INDS INC	0.2%
-----	--------------------	------

N018726	001	Aug 08, 1983	Feb	CAHN
---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROMORPHONE HYDROCHLORIDE

>A>	AP	EUROHLTH INTL SARL	2MG/ML
-----	----	--------------------	--------

A202159	001	Apr 27, 2018	Apr	NEWA
---------	-----	--------------	-----	------

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	ASCENT PHARMS INC	2MG	A210506	001	Jan 17, 2018	Jan NEWA
AB		4MG	A210506	002	Jan 17, 2018	Jan NEWA
AB		8MG	A210506	003	Jan 17, 2018	Jan NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

>A>	AB	ALKALOIDA ZRT	200MG	A201691	001	May 08, 2018	Apr NEWA
>A>	AB	AMNEAL PHARMS CO	200MG	A210577	001	May 15, 2018	Apr NEWA
>A>	AB	APPCO PHARMA LLC	200MG	A210441	001	May 01, 2018	Apr NEWA

HYDROXYPROGESTERONE CAPROATE

SOLUTION;SUBCUTANEOUS

MAKENA (AUTOINJECTOR)

+	!	AMAG PHARMA USA	275MG/1.1ML (250MG/ML)	N021945	004	Feb 14, 2018	Feb NEWA
---	---	-----------------	------------------------	---------	-----	--------------	----------

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

ATARAX

+	@	PFIZER	10MG	N010392	001		Feb CRLD
+	@		25MG	N010392	004		Feb CRLD
+	@		50MG	N010392	006		Feb CRLD
+	@		100MG	N010392	005		Feb CRLD

IBRUTINIB

TABLET;ORAL

IMBRUVICA

+		PHARMACYCLICS INC	140MG	N210563	001	Feb 16, 2018	Feb NEWA
+			280MG	N210563	002	Feb 16, 2018	Feb NEWA
+			420MG	N210563	003	Feb 16, 2018	Feb NEWA
+	!		560MG	N210563	004	Feb 16, 2018	Feb NEWA

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

		AUROBINDO PHARMA LTD	100MG/5ML	A209178	001	Feb 16, 2018	Feb NEWA
--	--	----------------------	-----------	---------	-----	--------------	----------

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

IBUTILIDE FUMARATE

	@	MYLAN INSTITUTIONAL	0.1MG/ML	A090924	001	Jan 11, 2010	Jan DISC
--	---	---------------------	----------	---------	-----	--------------	----------

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

	@	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Jan DISC
--	---	------------------	----	---------	-----	--------------	----------

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

	@	YAOPHARMA CO LTD	1.25MG	A074594	001	May 23, 1996	Jan CAHN
	@		2.5MG	A074594	002	May 23, 1996	Jan CAHN

INSULIN GLARGINE RECOMBINANT

SOLUTION;SUBCUTANEOUS

TOUJEO MAX SOLOSTAR

+	!	SANOFI US SERVICES	900 UNITS/3ML (300 UNITS/ML)	N206538	002	Mar 26, 2018	Mar NEWA
+	!	SANOFI US SERVICES	450 UNITS/1.5ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Mar CPOT

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL

ATROVENT

+	@	BOEHRINGER INGELHEIM	0.021MG/SPRAY	N020393	001	Oct 20, 1995	Jan DISC
+	@		0.042MG/SPRAY	N020394	001	Oct 20, 1995	Jan DISC

IPRATROPIUM BROMIDE

AB	!	WEST-WARD PHARMS INT	0.021MG/SPRAY	A076664	001	Nov 05, 2003	Jan CHRS
AB	!		0.042MG/SPRAY	A076598	001	Nov 05, 2003	Jan CHRS

IRBESARTANTABLET; ORAL
IRBESARTAN

>A>	AB	AMNEAL PHARMS	75MG	A204740	001	Apr 17, 2018	Apr	NEWA
>A>	AB		150MG	A204740	002	Apr 17, 2018	Apr	NEWA
>A>	AB		300MG	A204740	003	Apr 17, 2018	Apr	NEWA
		@ APOTEX INC	75MG	A200832	001	Oct 15, 2012	Mar	DISC
		@	150MG	A200832	002	Oct 15, 2012	Mar	DISC
		@	300MG	A200832	003	Oct 15, 2012	Mar	DISC
>A>	AB	CHARTWELL MOLECULAR	75MG	A077205	001	Nov 14, 2012	Apr	CAHN
>A>	AB		150MG	A077205	002	Nov 14, 2012	Apr	CAHN
>A>	AB		300MG	A077205	003	Nov 14, 2012	Apr	CAHN
>D>	AB	CIPLA LTD	75MG	A077205	001	Nov 14, 2012	Apr	CAHN
>D>	AB		150MG	A077205	002	Nov 14, 2012	Apr	CAHN
>D>	AB		300MG	A077205	003	Nov 14, 2012	Apr	CAHN

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

>D>	AP	SUN PHARMA GLOBAL	40MG/2ML (20MG/ML)	A078805	001	Apr 21, 2008	Apr	DISC
>A>		@	40MG/2ML (20MG/ML)	A078805	001	Apr 21, 2008	Apr	DISC
>D>	AP		100MG/5ML (20MG/ML)	A078805	002	Apr 21, 2008	Apr	DISC
>A>		@	100MG/5ML (20MG/ML)	A078805	002	Apr 21, 2008	Apr	DISC

ISOSORBIDE MONONITRATETABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

>D>	AB	ACCORD HLTHCARE	30MG	A209684	001	Oct 24, 2017	Apr	DISC
>A>		@	30MG	A209684	001	Oct 24, 2017	Apr	DISC
>D>	AB		60MG	A209684	002	Oct 24, 2017	Apr	DISC
>A>		@	60MG	A209684	002	Oct 24, 2017	Apr	DISC
>D>	AB		120MG	A209684	003	Oct 24, 2017	Apr	DISC
>A>		@	120MG	A209684	003	Oct 24, 2017	Apr	DISC

IVACAFTOR; IVACAFTOR, TEZACAFTORTABLET, TABLET; ORAL
SYMDEKO (COPACKAGED)

+	!	VERTEX PHARMS INC	150MG, N/A; 150MG, 100MG	N210491	001	Feb 12, 2018	Feb	NEWA
---	---	-------------------	--------------------------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINESOLUTION/DROPS; OPHTHALMIC
KETOROLAC TROMETHAMINE

AT		SANDOZ INC	0.4%	A078721	001	Nov 05, 2009	Jan	CAHN
----	--	------------	------	---------	-----	--------------	-----	------

LAMIVUDINETABLET; ORAL
LAMIVUDINE

>A>	AB	STRIDES PHARMA	150MG	A090457	001	Apr 19, 2018	Apr	NEWA
>A>	AB		300MG	A090457	002	Apr 19, 2018	Apr	NEWA

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
CIMDUO

+	!	MYLAN LABS LTD	300MG; 300MG	N022141	001	Feb 28, 2018	Feb	NEWA
---	---	----------------	--------------	---------	-----	--------------	-----	------

LAMIVUDINE; ZIDOVUDINETABLET; ORAL
LAMIVUDINE AND ZIDOVUDINE

AB		SHANGHAI DESANO	150MG; 300MG	A206375	001	Apr 10, 2018	Mar	NEWA
----	--	-----------------	--------------	---------	-----	--------------	-----	------

LEFLUNOMIDETABLET; ORAL
LEFLUNOMIDE

		@ FOSUN PHARMA	10MG	A077087	001	Sep 13, 2005	Jan	CAHN
		@	20MG	A077087	002	Sep 13, 2005	Jan	CAHN

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

FRESENIUS KABI USA EQ 10MG BASE/ML A207241 001 Mar 14, 2018 Mar NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION
LUPRON

+ @ ABBVIE ENDOCRINE INC 1MG/0.2ML N019010 001 Apr 09, 1985 Feb CRLD

LEVETIRACETAM

INJECTABLE; IV (INFUSION)
LEVETIRACETAM

>A> AP AKORN 500MG/5ML (100MG/ML) A209934 001 May 04, 2018 Apr NEWA
AP HAINAN POLY PHARM 500MG/5ML (100MG/ML) A209781 001 Mar 20, 2018 Mar NEWA

TABLET; ORAL

LEVETIRACETAM

@ FOSUN PHARMA 250MG A077324 001 Jan 15, 2009 Jan CAHN
@ 500MG A077324 002 Jan 15, 2009 Jan CAHN
@ 750MG A077324 003 Jan 15, 2009 Jan CAHN
@ 1GM A077324 004 Jan 15, 2009 Jan CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ FOSUN PHARMA 5MG A090486 001 Mar 26, 2013 Jan CAHN

LEVOFLOXACIN

INJECTABLE; INJECTION
LEVAQUIN

+ @ JANSSEN PHARMS EQ 500MG/20ML (EQ 25MG/ML) N020635 001 Dec 20, 1996 Feb DISC
+ @ EQ 750MG/30ML (EQ 25MG/ML) N020635 004 Dec 20, 1996 Feb DISC

LEVOFLOXACIN

AP ! AUROBINDO PHARMA LTD EQ 500MG/20ML (EQ 25MG/ML) A202328 001 Jan 24, 2013 Mar CHRS
AP ! EQ 750MG/30ML (EQ 25MG/ML) A202328 002 Jan 24, 2013 Mar CHRS
@ EMCURE PHARMS LTD EQ 500MG/20ML (EQ 25MG/ML) A202590 001 Jan 24, 2013 Mar DISC
@ EQ 750MG/30ML (EQ 25MG/ML) A202590 002 Jan 24, 2013 Mar DISC
@ ZYDUS PHARMS USA INC EQ 500MG/20ML (EQ 25MG/ML) A205968 001 Jun 01, 2017 Feb DISC
@ EQ 750MG/30ML (EQ 25MG/ML) A205968 002 Jun 01, 2017 Feb DISC
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
AP ! INFORLIFE EQ 250MG/50ML (EQ 5MG/ML) A090343 001 Jul 07, 2011 Jan CAHN
AP ! EQ 500MG/100ML (EQ 5MG/ML) A090343 002 Jul 07, 2011 Jan CAHN
AP ! EQ 750MG/150ML (EQ 5MG/ML) A090343 003 Jul 07, 2011 Jan CAHN

TABLET; ORAL

LEVAQUIN

+ @ JANSSEN PHARMS 250MG N020634 001 Dec 20, 1996 Feb DISC
+ @ 500MG N020634 002 Dec 20, 1996 Feb DISC
+ @ 750MG N020634 003 Sep 08, 2000 Feb DISC

LEVOFLOXACIN

AB ! AUROBINDO PHARMA LTD 750MG A201043 003 Jun 20, 2011 Feb CHRS

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)
LEVOLEUCOVORIN CALCIUM

>A> AP INGENUS PHARMS LLC EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) A210623 001 May 03, 2018 Apr NEWA
>A> AP EQ 250MG BASE/25ML (EQ 10MG BASE/ML) A210623 002 May 03, 2018 Apr NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
FETZIMA

+ ALLERGAN SALES LLC EQ 20MG BASE N204168 001 Jul 25, 2013 Jan CAHN
+ EQ 40MG BASE N204168 002 Jul 25, 2013 Jan CAHN
+ EQ 80MG BASE N204168 003 Jul 25, 2013 Jan CAHN
+! EQ 120MG BASE N204168 004 Jul 25, 2013 Jan CAHN

LEVOTHYROXINE SODIUMPOWDER; INTRAVENOUS
LEVOTHYROXINE SODIUM

AP	PIRAMAL CRITICAL	100MCG/VIAL	A206163	001	Jun 29, 2016	Jan CAHN
AP		500MCG/VIAL	A206163	002	Jun 29, 2016	Jan CAHN

LIDOCAINEOINTMENT; TOPICAL
LIDOCAINE

AT	TEVA PHARMS USA	5%	A210256	001	Jan 16, 2018	Jan NEWA
	PATCH; TOPICAL ZTLIDO					
	+! SCILEX PHARMS INC	1.8%	N207962	001	Feb 28, 2018	Feb NEWA

LIDOCAINE HYDROCHLORIDEINJECTABLE; INJECTION
LIDOCAINE HYDROCHLORIDE

>A>	AP	SPECTRA MDCL DEVICES	1%	A208017	001	Apr 18, 2018	Apr NEWA
-----	----	----------------------	----	---------	-----	--------------	----------

LINACLOTIDECAPSULE; ORAL
LINZESS

	+	ALLERGAN SALES LLC	72MCG	N202811	003	Jan 25, 2017	Jan CAHN
	+		145MCG	N202811	001	Aug 30, 2012	Jan CAHN
	+		290MCG	N202811	002	Aug 30, 2012	Jan CAHN

LIOTRIX (T4;T3)

TABLET; ORAL

THYROLAR-0.25

>A>	+	ALLERGAN SALES LLC	0.0125MG;0.0031MG	N016807	001		Apr CAHN
>D>	+	FOREST LABS	0.0125MG;0.0031MG	N016807	001		Apr CAHN

THYROLAR-0.5

>A>	+	ALLERGAN SALES LLC	0.025MG;0.0063MG	N016807	005		Apr CAHN
>D>	+	FOREST LABS	0.025MG;0.0063MG	N016807	005		Apr CAHN

THYROLAR-1

>A>	+	ALLERGAN SALES LLC	0.05MG;0.0125MG	N016807	004		Apr CAHN
>D>	+	FOREST LABS	0.05MG;0.0125MG	N016807	004		Apr CAHN

THYROLAR-2

>A>	+	ALLERGAN SALES LLC	0.1MG;0.025MG	N016807	002		Apr CAHN
>D>	+	FOREST LABS	0.1MG;0.025MG	N016807	002		Apr CAHN

THYROLAR-3

>A>	+	ALLERGAN SALES LLC	0.15MG;0.0375MG	N016807	003		Apr CAHN
>D>	+	FOREST LABS	0.15MG;0.0375MG	N016807	003		Apr CAHN

THYROLAR-5

>A>	@	ALLERGAN SALES LLC	0.25MG;0.0625MG	N016807	006		Apr CAHN
>D>	@	FOREST LABS	0.25MG;0.0625MG	N016807	006		Apr CAHN

LISINAPRIL

TABLET; ORAL

LISINAPRIL

AB	CASI PHARMS INC	2.5MG	A075994	001	Jul 01, 2002	Mar CAHN
AB		5MG	A075994	002	Jul 01, 2002	Mar CAHN
AB		10MG	A075994	003	Jul 01, 2002	Mar CAHN
AB		20MG	A075994	004	Jul 01, 2002	Mar CAHN
AB		30MG	A075994	005	Jul 01, 2002	Mar CAHN
AB		40MG	A075994	006	Jul 01, 2002	Mar CAHN

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

@ YAOPHARMA CO LTD

2MG

A072993	001	Aug 28, 1992	Jan CAHN
---------	-----	--------------	----------

LORAZEPAM

TABLET; ORAL

LORAZEPAM

@ MYLAN

0.5MG

A071591	002	Oct 13, 1987	Jan CMS1
---------	-----	--------------	----------

@

1MG

A071591	003	Oct 13, 1987	Jan CMS1
---------	-----	--------------	----------

LOSARTAN POTASSIUMTABLET; ORAL
COZAAR

>D>	AB	+	MERCK SHARP DOHME	25MG	N020386	001	Apr 14, 1995	Apr	DISC
>A>		+	@	25MG	N020386	001	Apr 14, 1995	Apr	DISC
>D>	AB	+		50MG	N020386	002	Apr 14, 1995	Apr	DISC
>A>		+	@	50MG	N020386	002	Apr 14, 1995	Apr	DISC
			LOSARTAN POTASSIUM						
		@	APOTEX CORP	25MG	A090790	001	Oct 06, 2010	Mar	DISC
		@		50MG	A090790	002	Oct 06, 2010	Mar	DISC
		@		100MG	A090790	003	Oct 06, 2010	Mar	DISC

LUTETIUM DOTATATE LU-177SOLUTION; IV (INFUSION)
LUTATHERA

+	!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018	Jan	NEWA
---	---	-------------	----------	---------	-----	--------------	-----	------

MACIMORELIN ACETATEFOR SOLUTION; ORAL
MACILEN

+	!	STRONGBRIDGE IRELAND	EQ 60MG BASE/POUCH	N205598	001	Dec 21, 2017	Jan	CAHN
---	---	----------------------	--------------------	---------	-----	--------------	-----	------

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

>D>	AP		BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	001		Apr	CRLD
>A>		+	!	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	001		Apr	CRLD
			PLASMA-LYTE A IN PLASTIC CONTAINER						
>D>	AP		BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	002	Nov 22, 1982	Apr	CRLD
>A>		+	!	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	002	Nov 22, 1982	Apr	CRLD

MANGANESE CHLORIDE

INJECTABLE; INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

+	!	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962	001	Jun 26, 1986	Mar	CRLD
---	---	---------	-----------------------	---------	-----	--------------	-----	------

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

+	!	ICU MEDICAL INC	540MG/100ML; 2.7GM/100ML	N018316	001		Mar	CRLD
---	---	-----------------	--------------------------	---------	-----	--	-----	------

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

VERMOX

+	@	JANSSEN PHARMS	500MG	N208398	001	Oct 19, 2016	Feb	DISC
---	---	----------------	-------	---------	-----	--------------	-----	------

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

@		FOSUN PHARMA	EQ 50MG BASE	A072262	001	Nov 29, 1988	Jan	CAHN
@			EQ 100MG BASE	A072263	001	Nov 29, 1988	Jan	CAHN

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB		MICRO LABS	250MG	A090562	001	Nov 19, 2010	Feb	CAHN
----	--	------------	-------	---------	-----	--------------	-----	------

MEMANTINE HYDROCHLORIDE

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

AA		APOTEX INC	2MG/ML	A209955	001	Feb 09, 2018	Jan	NEWA	
>D>	AA		BIO-PHARM INC	2MG/ML	A205446	001	Dec 07, 2015	Apr	CHRS
>A>	AA	!		2MG/ML	A205446	001	Dec 07, 2015	Apr	CHRS
>D>			NAMENDA						
>D>	AA	+	!	ALLERGAN SALES LLC	N021627	001	Apr 18, 2005	Apr	DISC
>A>		+	@		N021627	001	Apr 18, 2005	Apr	DISC
AA		+	!		N021627	001	Apr 18, 2005	Jan	CAHN

TABLET;ORAL							
MEMANTINE HYDROCHLORIDE							
>A>	AB	CSPC OUYI PHARM CO	5MG	A209527	001	May 07, 2018	Apr NEWA
>A>	AB		10MG	A209527	002	May 07, 2018	Apr NEWA
NAMENDA							
	AB	+ ALLERGAN SALES LLC	5MG	N021487	001	Oct 16, 2003	Jan CAHN
	AB	+	10MG	N021487	002	Oct 16, 2003	Jan CAHN
<u>MEROPENEM</u>							
INJECTABLE;INJECTION							
MEROPEM							
>A>	AP	ACS DOBFAR SPA	500MG/VIAL	A204139	001	Jun 09, 2016	Apr CAHN
>A>	AP		1GM/VIAL	A204139	002	Jun 09, 2016	Apr CAHN
>D>	AP	PAR STERILE PRODUCTS	500MG/VIAL	A204139	001	Jun 09, 2016	Apr CAHN
>D>	AP		1GM/VIAL	A204139	002	Jun 09, 2016	Apr CAHN
<u>MEROPENEM; VABORBACTAM</u>							
POWDER; IV (INFUSION)							
VABOMERE							
	+	REMPEX PHARMS	1GM/VIAL;1GM/VIAL	N209776	001	Aug 29, 2017	Jan CAHN
<u>MESALAMINE</u>							
ENEMA;RECTAL							
MESALAMINE							
		@ G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004	Jan DISC
SUPPOSITORY;RECTAL							
CANASA							
		@ ALLERGAN SALES LLC	500MG	N021252	001	Jan 05, 2001	Jan CAHN
AB	+	!	1GM	N021252	002	Nov 05, 2004	Jan CAHN
TABLET, DELAYED RELEASE;ORAL							
MESALAMINE							
AB		ACTAVIS LABS FL	1.2GM	A203817	001	Mar 23, 2018	Mar NEWA
<u>MESNA</u>							
INJECTABLE;INTRAVENOUS							
MESNA							
		@ MYLAN INSTITUTIONAL	100MG/ML	A076488	001	Mar 08, 2012	Jan DISC
<u>METARAMINOL BITARTRATE</u>							
INJECTABLE;INJECTION							
METARAMINOL BITARTRATE							
		@ FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001		Feb DISC
<u>METAXALONE</u>							
TABLET;ORAL							
METAXALONE							
		MOUNTAIN	400MG	A040486	001	Feb 27, 2015	Jan CAHN
		@ PRIMUS PHARMS	640MG	N022503	001	Jun 01, 2015	Jan CAHN
<u>METFORMIN HYDROCHLORIDE</u>							
TABLET;ORAL							
METFORMIN HYDROCHLORIDE							
		@ SANDOZ	500MG	A075985	001	Jan 25, 2002	Mar DISC
		@	850MG	A075985	002	Jan 25, 2002	Mar DISC
		@	1GM	A075985	003	Jan 25, 2002	Mar DISC
TABLET, EXTENDED RELEASE;ORAL							
METFORMIN HYDROCHLORIDE							
AB1		ALIGNSCIENCE PHARMA	500MG	A209303	001	Mar 19, 2018	Mar NEWA
AB1		GRANULES INDIA LTD	500MG	A209313	001	Mar 16, 2018	Mar NEWA
AB			750MG	A209313	002	Mar 16, 2018	Mar NEWA
<u>METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE</u>							
TABLET;ORAL							
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE							
>D>		TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014	Apr DISC
>A>		@	500MG;EQ 2MG BASE	A077337	001	May 07, 2014	Apr DISC
>D>			500MG;EQ 1MG BASE	A077337	005	May 19, 2017	Apr DISC
>A>		@	500MG;EQ 1MG BASE	A077337	005	May 19, 2017	Apr DISC
>D>			500MG;EQ 4MG BASE	A077337	002	May 07, 2014	Apr DISC
>A>		@	500MG;EQ 4MG BASE	A077337	002	May 07, 2014	Apr DISC
>D>		!	1GM;EQ 4MG BASE	A077337	004	May 07, 2014	Apr DISC
>A>		@	1GM;EQ 4MG BASE	A077337	004	May 07, 2014	Apr DISC

TABLET;ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

>D>		1GM;EQ 2MG BASE	A077337	003	May 07, 2014	Apr	DISC
>A>	@	1GM;EQ 2MG BASE	A077337	003	May 07, 2014	Apr	DISC

METHADONE HYDROCHLORIDE

TABLET;ORAL

METHADONE HYDROCHLORIDE

AA	SUN PHARM INDUSTRIES	5MG	A208305	001	Mar 30, 2018	Mar	NEWA
AA		10MG	A208305	002	Mar 30, 2018	Mar	NEWA

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB	CASI PHARMS INC	5MG	A040411	001	Mar 27, 2001	Mar	CAHN
AB		10MG	A040411	002	Mar 27, 2001	Mar	CAHN

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

>A>	AP	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	A209331	001	Apr 17, 2018	Apr	NEWA
-----	----	--------------------	---------------------	---------	-----	--------------	-----	------

TABLET;ORAL

METHOCARBAMOL

AA	ALLIED PHARMA INC	500MG	A203550	001	Feb 08, 2017	Feb	CAHN	
AA		750MG	A203550	002	Feb 08, 2017	Feb	CAHN	
	@	FOSUN PHARMA	500MG	A084616	001		Jan	CAHN
	@		750MG	A084615	001		Jan	CAHN
>A>	AA	GRANULES INDIA LTD	500MG	A209312	001	May 07, 2018	Apr	NEWA
>A>	AA		750MG	A209312	002	May 07, 2018	Apr	NEWA

METHOTREXATE

SOLUTION;SUBCUTANEOUS

RASUVO

>D>	+	MEDAC PHARMA INC	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Apr	CHRS
>A>	+	!	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Apr	CHRS
>D>	+		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Apr	CHRS
>A>	+	!	10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Apr	CHRS
>D>	+		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Apr	CHRS
>A>	+	!	12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Apr	CHRS
>D>	+		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Apr	CHRS
>A>	+	!	15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Apr	CHRS
>D>	+		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Apr	CHRS
>A>	+	!	17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Apr	CHRS
>D>	+		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Apr	CHRS
>A>	+	!	20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Apr	CHRS
>D>	+		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr	CHRS
>A>	+	!	22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Apr	CHRS
>D>	+		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr	CHRS
>A>	+	!	25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Apr	CHRS
>D>	+		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr	CHRS
>A>	+	!	30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Apr	CHRS

METHYLCLOTHIAZIDE

TABLET;ORAL

METHYLCLOTHIAZIDE

	@	YAOPHARMA CO LTD	2.5MG	A089835	001	Aug 18, 1988	Jan	CAHN
	@		5MG	A089837	001	Aug 18, 1988	Jan	CAHN

METHYLDOPA

TABLET;ORAL

METHYLDOPA

	@	YAOPHARMA CO LTD	125MG	A071700	001	Mar 02, 1988	Jan	CAHN
	@		250MG	N018934	001	Jun 29, 1984	Jan	CAHN
	@		500MG	N018934	002	Jun 29, 1984	Jan	CAHN

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

>A>	AB	GRANULES PHARMS	0.2MG	A210424	001	May 15, 2018	Apr	NEWA
>D>	!	NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Apr	CTEC
>A>	AB	!	0.2MG	A091577	001	May 02, 2011	Apr	CTEC

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
METADATE CD

AB2	+	LANNETT CO INC	10MG	N021259	003	May 27, 2003	Mar	CAHN
AB2	+		20MG	N021259	001	Apr 03, 2001	Mar	CAHN
AB2	+		30MG	N021259	002	Jun 19, 2003	Mar	CAHN
AB2	+		40MG	N021259	004	Feb 19, 2006	Mar	CAHN
AB2	+		50MG	N021259	005	Feb 19, 2006	Mar	CAHN
AB2	+		60MG	N021259	006	Feb 19, 2006	Mar	CAHN

METHYLPHENIDATE HYDROCHLORIDE

AB1		MAYNE PHARMA	10MG	A200886	001	Feb 26, 2018	Feb	NEWA
-----	--	--------------	------	---------	-----	--------------	-----	------

FOR SUSPENSION, EXTENDED RELEASE;ORAL

>A> METHYLPHENIDATE HYDROCHLORIDE

>A>	AB	ACTAVIS LABS FL INC	5MG/ML	A206049	001	May 17, 2018	Apr	NEWA
-----	----	---------------------	--------	---------	-----	--------------	-----	------

QUILLIVANT XR

>D>	+	NEXTWAVE PHARMS	5MG/ML	N202100	001	Sep 27, 2012	Apr	CFTG
-----	---	-----------------	--------	---------	-----	--------------	-----	------

>A>	AB	+	5MG/ML	N202100	001	Sep 27, 2012	Apr	CFTG
-----	----	---	--------	---------	-----	--------------	-----	------

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		BIONPHARMA INC	5MG	A209753	001	Mar 02, 2018	Feb	NEWA
AB			10MG	A209753	002	Mar 02, 2018	Feb	NEWA
AB			20MG	A209753	003	Mar 02, 2018	Feb	NEWA
AB		LANNETT CO INC	5MG	A086429	001		Mar	CAHN
AB			10MG	A085799	001		Mar	CAHN
AB			20MG	A086428	001		Mar	CAHN
AB		MOUNTAIN	5MG	A091159	001	Mar 12, 2014	Jan	CAHN
AB			10MG	A091159	002	Mar 12, 2014	Jan	CAHN
AB			20MG	A091159	003	Mar 12, 2014	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

		@ LANNETT CO INC	10MG	A040306	001	Oct 20, 1999	Mar	CAHN
AB	!		20MG	A089601	001	Jun 01, 1988	Mar	CAHN

METHYLPHENIDATE HYDROCHLORIDE

AB		ACTAVIS LABS FL	54MG	A076655	001	Mar 21, 2018	Mar	NEWA
AB		AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018	Jan	NEWA
AB			27MG	A207515	002	Feb 01, 2018	Jan	NEWA
AB			36MG	A207515	003	Feb 01, 2018	Jan	NEWA
AB			54MG	A207515	004	Feb 01, 2018	Jan	NEWA
AB	!	OSMOTICA	72MG	A205327	005	Jul 28, 2017	Jan	CHRS

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

>A>	AB	TIANJIN TIANYAO	4MG	A204072	001	May 14, 2018	Apr	NEWA
>A>	AB	ZYDUS PHARMS USA INC	4MG	A206751	001	Apr 23, 2018	Apr	NEWA
>A>	AB		8MG	A206751	002	Apr 23, 2018	Apr	NEWA
>A>	AB		16MG	A206751	003	Apr 23, 2018	Apr	NEWA
>A>	AB		32MG	A206751	004	Apr 23, 2018	Apr	NEWA

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

METOCLOPRAMIDE HYDROCHLORIDE

		@ YAOPHARMA CO LTD	EQ 5MG BASE	A074478	001	Oct 05, 1995	Jan	CAHN
		@	EQ 10MG BASE	A072215	001	Jan 30, 1990	Jan	CAHN
		@	EQ 10MG BASE	A074478	002	Oct 05, 1995	Jan	CAHN

METOLAZONE

TABLET;ORAL

MYKROX

>A>		@ LANNETT CO INC	0.5MG	N019532	001	Oct 30, 1987	Apr	CAHN
>D>		@ UCB INC	0.5MG	N019532	001	Oct 30, 1987	Apr	CAHN
		ZAROXOLYN						
AB	+	LANNETT CO INC	2.5MG	N017386	001		Mar	CAHN
AB	+		5MG	N017386	002		Mar	CAHN
AB	+		10MG	N017386	003		Mar	CAHN

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018	Jan	NEWA
+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018	Jan	NEWA
+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018	Jan	NEWA
+	!	EQ 200MG TARTRATE	N210428	004	Jan 26, 2018	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL

METOPROLOL SUCCINATE

AB	ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862	002	Aug 03, 2009	Mar	CMS1
AB	NOVAST LABS LTD	EQ 25MG TARTRATE	A204106	001	Feb 06, 2018	Jan	NEWA
AB		EQ 50MG TARTRATE	A204106	002	Feb 06, 2018	Jan	NEWA
AB		EQ 100MG TARTRATE	A204106	003	Feb 06, 2018	Jan	NEWA
AB		EQ 200MG TARTRATE	A204106	004	Feb 06, 2018	Jan	NEWA
AB	ZYDUS PHARMS USA INC	EQ 25MG TARTRATE	A203894	001	Mar 23, 2018	Mar	NEWA
AB		EQ 50MG TARTRATE	A203894	002	Mar 23, 2018	Mar	NEWA
AB		EQ 100MG TARTRATE	A203894	003	Mar 23, 2018	Mar	NEWA
AB		EQ 200MG TARTRATE	A203894	004	Mar 23, 2018	Mar	NEWA

METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE

@	RENATA	50MG	A074453	001	Apr 27, 1995	Jan	CAHN
@		100MG	A074453	002	Apr 27, 1995	Jan	CAHN
@	YAOPHARMA CO LTD	50MG	A073288	001	Mar 25, 1994	Jan	CAHN
@		100MG	A073289	001	Mar 25, 1994	Jan	CAHN

METRONIDAZOLE

TABLET;ORAL

METRONIDAZOLE

@	FOSUN PHARMA	250MG	N018620	001	Mar 04, 1982	Jan	CAHN
@		250MG	N018740	001	Oct 22, 1982	Jan	CAHN
@		500MG	N018620	002	Jun 02, 1983	Jan	CAHN
@		500MG	N018740	002	Oct 22, 1982	Jan	CAHN

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

MIDODRINE HYDROCHLORIDE

AB	APOTEX INC	2.5MG	A077746	001	Sep 12, 2006	Feb	CTEC
AB		5MG	A077746	002	Sep 12, 2006	Feb	CTEC
AB		10MG	A077746	003	Sep 12, 2006	Feb	CTEC
AB	CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	Mar	CAHN
AB		5MG	A076514	002	Sep 11, 2003	Mar	CAHN
AB		10MG	A076514	003	Jul 02, 2004	Mar	CAHN

MIGLUSTAT

CAPSULE;ORAL

MIGLUSTAT

>A>	AB	AMERIGEN PHARMS LTD	100MG	A208342	001	Apr 17, 2018	Apr	NEWA	
		ZAVESCA							
>D>		!	ACTELION PHARMS LTD	100MG	N021348	001	Jul 31, 2003	Apr	CFTG
>A>	AB	!		100MG	N021348	001	Jul 31, 2003	Apr	CFTG

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

MILNACIPRAN HYDROCHLORIDE

@	USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016	Mar	CAHN
@		25MG	A205071	002	Jan 27, 2016	Mar	CAHN
@		50MG	A205071	003	Jan 27, 2016	Mar	CAHN
@		100MG	A205071	004	Jan 27, 2016	Mar	CAHN

MINOCYCLINE HYDROCHLORIDE

INJECTABLE;INJECTION

MINOCIN

+	!	REMPLEX PHARMS	EQ 100MG BASE/VIAL	N050444	001		Jan	CAHN
---	---	----------------	--------------------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 65MG BASE	A204453	006	Mar 16, 2018	Mar	NEWA
AB		EQ 115MG BASE	A204453	007	Mar 16, 2018	Mar	NEWA
AB	BARR LABS INC	EQ 65MG BASE	A065485	004	May 18, 2012	Jan	CMFD
AB		EQ 115MG BASE	A065485	005	May 18, 2012	Jan	CMFD

TABLET, EXTENDED RELEASE;ORAL
SOLODYN

AB	+	MEDICIS	EQ 65MG BASE	N050808	004	Jul 23, 2009	Mar	CTEC
AB	+	!	EQ 115MG BASE	N050808	005	Jul 23, 2009	Mar	CTEC

MONTELUKAST SODIUM

TABLET;ORAL

MONTELUKAST SODIUM

@ APOTEX CORP

EQ 10MG BASE

A201294 001 Aug 03, 2012 Mar DISC

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

@ APOTEX INC

EQ 4MG BASE

A201508 001 Aug 03, 2012 Mar DISC

@

EQ 5MG BASE

A201508 002 Aug 03, 2012 Mar DISC

MORPHINE SULFATE

SOLUTION;ORAL

MORPHINE SULFATE

>A>	AA		ANI PHARMS INC	10MG/5ML	A205509	001	Apr 17, 2018	Apr	NEWA
>A>	AA			20MG/5ML	A205509	002	Apr 17, 2018	Apr	NEWA
>A>	AA			100MG/5ML	A205509	003	Apr 17, 2018	Apr	NEWA

MUPIROCIN CALCIUM

CREAM;TOPICAL

BACTROBAN

>D>	AB	+	GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Apr	DISC
>A>		+	@	EQ 2% BASE	N050746	001	Dec 11, 1997	Apr	DISC

MUPIROCIN

>D>	AB		GLENMARK PHARMS INC	EQ 2% BASE	A201587	001	Jan 24, 2013	Apr	CHRS
>A>		!		EQ 2% BASE	A201587	001	Jan 24, 2013	Apr	CHRS

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

@ APOTEX CORP

250MG

A090419 001 Apr 22, 2009 Mar DISC

TABLET;ORAL

MYCOPHENOLATE MOFETIL

@ APOTEX

500MG

A090499 001 Apr 22, 2009 Mar DISC

NABUMETONE

TABLET;ORAL

NABUMETONE

AB			CASI PHARMS INC	500MG	A075280	001	Feb 25, 2002	Mar	CAHN
AB				750MG	A075280	002	Feb 25, 2002	Mar	CAHN

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

NAFTIFINE HYDROCHLORIDE

>D>	AB		TARO	1%	A205975	001	Sep 08, 2016	Apr	CHRS
>A>		!		1%	A205975	001	Sep 08, 2016	Apr	CHRS

NAFTIN

>D>	AB	+	SEBELA IRELAND LTD	1%	N019599	001	Feb 29, 1988	Apr	DISC
>A>		+	@	1%	N019599	001	Feb 29, 1988	Apr	DISC

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NARCAN

>D>		+	ADAPT	2MG/SPRAY	N208411	002	Jan 24, 2017	Apr	DISC
>A>		+	@	2MG/SPRAY	N208411	002	Jan 24, 2017	Apr	DISC

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

@ FOSUN PHARMA

50MG

A075434 001 Mar 08, 2000 Jan CAHN

NAPROXEN

TABLET;ORAL

NAPROXEN

@ FOSUN PHARMA

250MG

A074140 001 Dec 21, 1993 Jan CAHN

@

375MG

A074140 002 Dec 21, 1993 Jan CAHN

@

500MG

A074140 003 Dec 21, 1993 Jan CAHN

TABLET, DELAYED RELEASE;ORAL
NAPROXEN

@ FOSUN PHARMA	375MG	A075061	001	Feb 18, 1998	Jan CAHN
@	500MG	A075061	002	Feb 18, 1998	Jan CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

AB	AUROBINDO PHARMA LTD	500MG;EQ 85MG BASE	A207457	001	Feb 15, 2018	Feb NEWA
AB	+! PERNIX IRELAND LTD	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	Feb CFTG

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

@ APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Mar DISC	
@	EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Mar DISC	
AB	CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010	Mar CAHN
AB		EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Mar CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

BYSTOLIC

AB	+ ALLERGAN SALES LLC	EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Feb CFTG
		EQ 2.5MG BASE	N021742	002	Dec 17, 2007	Jan CAHN
AB	+ ALLERGAN SALES LLC	EQ 5MG BASE	N021742	003	Dec 17, 2007	Feb CFTG
		EQ 5MG BASE	N021742	003	Dec 17, 2007	Jan CAHN
AB	+ ALLERGAN SALES LLC	EQ 10MG BASE	N021742	004	Dec 17, 2007	Feb CFTG
		EQ 10MG BASE	N021742	004	Dec 17, 2007	Jan CAHN
AB	+! ALLERGAN SALES LLC	EQ 20MG BASE	N021742	005	Oct 08, 2008	Feb CFTG
		EQ 20MG BASE	N021742	005	Oct 08, 2008	Jan CAHN

NEBIVOLOL HYDROCHLORIDE

@ TORRENT PHARMS LTD	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Mar DISC	
AB		EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Feb NEWA
@	EQ 5MG BASE	A203966	002	Mar 02, 2018	Mar DISC	
AB		EQ 5MG BASE	A203966	002	Mar 02, 2018	Feb NEWA
@	EQ 10MG BASE	A203966	003	Mar 02, 2018	Mar DISC	
AB		EQ 10MG BASE	A203966	003	Mar 02, 2018	Feb NEWA
@	EQ 20MG BASE	A203966	004	Mar 02, 2018	Mar DISC	
AB		EQ 20MG BASE	A203966	004	Mar 02, 2018	Feb NEWA

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

BYVALSON

+! ALLERGAN SALES LLC	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	Jan CAHN
-----------------------	------------------	---------	-----	--------------	----------

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

@ FOSUN PHARMA	50MG	A076302	001	Sep 16, 2003	Jan CAHN
@	100MG	A076302	002	Sep 16, 2003	Jan CAHN
@	150MG	A076302	003	Sep 16, 2003	Jan CAHN
@	200MG	A076302	004	Sep 16, 2003	Jan CAHN
@	250MG	A076302	005	Sep 16, 2003	Jan CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

AP	+! AVADEL LEGACY	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Feb CAHN
AP	+! AVADEL LEGACY	10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Feb CAHN

NEOSTIGMINE METHYLSULFATE

>A>	AP	LUITPOLD PHARMS INC	5MG/10ML (0.5MG/ML)	A209182	001	May 04, 2018	Apr NEWA
>A>	AP		10MG/10ML (1MG/ML)	A209182	002	May 04, 2018	Apr NEWA

NEVIRAPINE

TABLET;ORAL

NEVIRAPINE

@ APOTEX INC	200MG	A203021	001	May 22, 2012	Mar DISC
--------------	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

@ APOTEX INC	400MG	A205258	001	Apr 03, 2014	Jan DISC
@ TECH ORGANIZED	100MG	A207467	001	Jul 31, 2017	Mar DISC

TABLET, EXTENDED RELEASE;ORAL
NEVIRAPINE

@ 400MG A207467 002 Jul 31, 2017 Mar DISC

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB	AUROBINDO PHARMA LTD	500MG	A209236	001	Feb 01, 2018	Jan	NEWA
AB		750MG	A209236	002	Feb 01, 2018	Jan	NEWA
AB		1GM	A209236	003	Feb 01, 2018	Jan	NEWA
>A>	JUBILANT GENERICS	500MG	A209156	001	May 14, 2018	Apr	NEWA
>A>		750MG	A209156	002	May 14, 2018	Apr	NEWA
>A>		1GM	A209156	003	May 14, 2018	Apr	NEWA

NICARDIPINE HYDROCHLORIDE

INJECTABLE;INTRAVENOUS
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER
+ @ CHIESI USA INC 40MG/200ML (0.2MG/ML)

N019734 005 Nov 07, 2008 Mar DISC

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE;ORAL
TASIGNA

+ NOVARTIS EQ 50MG BASE

N022068 003 Mar 22, 2018 Mar NEWA

NITROGLYCERIN

OINTMENT;INTRA-ANAL
RECTIV

+! ALLERGAN SALES LLC 0.4%

N021359 001 Jun 21, 2011 Jan CAHN

TABLET;SUBLINGUAL
NITROGLYCERIN

AB	GLENMARK PHARMS SA	0.3MG	A206391	001	Sep 19, 2017	Jan	CAHN
AB		0.4MG	A206391	002	Sep 19, 2017	Jan	CAHN
AB		0.6MG	A206391	003	Sep 19, 2017	Jan	CAHN
>A>	SIGMAPHARM LABS LLC	0.3MG	A207745	001	May 07, 2018	Apr	NEWA
>A>		0.4MG	A207745	002	May 07, 2018	Apr	NEWA
>A>		0.6MG	A207745	003	May 07, 2018	Apr	NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB	MAYNE PHARMA	EQ 10MG BASE	A073556	002	Mar 30, 1992	Mar	CMS1
AB		EQ 25MG BASE	A073556	003	Mar 30, 1992	Mar	CMS1
AB		EQ 50MG BASE	A073556	004	Mar 30, 1992	Mar	CMS1

NYSTATIN

OINTMENT;TOPICAL
NYSTATIN

@ G AND W LABS INC 100,000 UNITS/GM

A209114 001 Oct 06, 2017 Jan DISC

POWDER;TOPICAL
NYSTATIN

>A>	AT	EPIC PHARMA LLC	100,000 UNITS/GM	A210532	001	Apr 30, 2018	Apr	NEWA
-----	----	-----------------	------------------	---------	-----	--------------	-----	------

SUSPENSION;ORAL
NYSTATIN

@ G AND W LABS INC 100,000 UNITS/ML

A062349 001 Jul 14, 1982 Jan DISC

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	AMNEAL PHARMS LLC	100,000 UNITS/GM;0.1%	A209990	001	Feb 15, 2018	Feb	NEWA
----	-------------------	-----------------------	---------	-----	--------------	-----	------

OINTMENT;TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	STRIDES PHARMA	100,000 UNITS/GM;0.1%	A210077	001	Jan 29, 2018	Jan	NEWA
----	----------------	-----------------------	---------	-----	--------------	-----	------

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

@	AJANTA PHARMA LTD	5MG	A204320	001	May 30, 2017	Mar	DISC
@		10MG	A204320	002	May 30, 2017	Mar	DISC
@		15MG	A204320	003	May 30, 2017	Mar	DISC
@		20MG	A204320	004	May 30, 2017	Mar	DISC

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	MICRO LABS LTD INDIA	EQ 0.1% BASE	A204392	001	Mar 21, 2018	Mar	NEWA
	@ ZAMBON SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015	Mar	DISC

ONDANSETRONTABLET, ORALLY DISINTEGRATING;ORAL
ONDANSETRON

	@ CHARTWELL MOLECULES	4MG	A077406	003	Dec 26, 2006	Mar	CMS1
	@	8MG	A077406	004	Dec 26, 2006	Mar	CMS1

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

>D>	AP	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A077173	001	Dec 26, 2006	Apr	DISC
>A>		@	EQ 2MG BASE/ML	A077173	001	Dec 26, 2006	Apr	DISC

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

AB	CASI PHARMS INC	EQ 4MG BASE	A077517	001	Jun 25, 2007	Mar	CAHN
AB		EQ 8MG BASE	A077517	002	Jun 25, 2007	Mar	CAHN
AB		EQ 24MG BASE	A077517	003	Jun 25, 2007	Mar	CAHN

ORITAVANCIN DIPHOSPHATEPOWDER;IV (INFUSION)
ORBACTIV

+	!	MELINTA	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Jan	CAHN
+	!	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Mar	CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	HETERO LABS LTD III	EQ 30MG BASE	A209438	001	Feb 23, 2018	Feb	NEWA
AB		EQ 45MG BASE	A209438	002	Feb 23, 2018	Feb	NEWA
AB		EQ 75MG BASE	A209438	003	Feb 23, 2018	Feb	NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	LUPIN ATLANTIS	EQ 6MG BASE/ML	A208347	001	Feb 20, 2018	Feb	NEWA
----	----------------	----------------	---------	-----	--------------	-----	------

OXALIPLATININJECTABLE;IV (INFUSION)
OXALIPLATIN

AP	ACTAVIS LLC	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Feb	NEWA	
AP		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb	NEWA	
>A>	AP	EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Apr	CAHN
>A>	AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Apr	CAHN
>D>	AP	SANJA PHARMS CO	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Apr	CAHN
>D>	AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Apr	CAHN

OXYBUTYNIN CHLORIDETABLET, EXTENDED RELEASE;ORAL
DITROPAN XL

+	@	JANSSEN PHARMS	5MG	N020897	001	Dec 16, 1998	Feb	DISC
+	@		10MG	N020897	002	Dec 16, 1998	Feb	DISC
+	@		15MG	N020897	003	Jun 22, 1999	Feb	DISC

OXYBUTYNIN CHLORIDE

AB	!	MYLAN PHARMS INC	15MG	A076644	002	May 10, 2007	Feb	CHRS
----	---	------------------	------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

>A>	AB	+	!	GENUS LIFESCIENCES	5MG	N200534	001	Oct 20, 2010	Apr	CAHN
>D>	AB	+	!	LEHIGH VALLEY	5MG	N200534	001	Oct 20, 2010	Apr	CAHN

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

>A>	AA	+		GENUS LIFESCIENCES	5MG/5ML	N200535	002	Aug 22, 2013	Apr	CAHN
>A>	AA	+	!		100MG/5ML	N200535	001	Oct 20, 2010	Apr	CAHN
>D>	AA	+		LEHIGH VALLEY	5MG/5ML	N200535	002	Aug 22, 2013	Apr	CAHN
>D>	AA	+	!		100MG/5ML	N200535	001	Oct 20, 2010	Apr	CAHN
>A>	AA			SPECGX LLC	5MG/5ML	A210758	001	Apr 30, 2018	Apr	NEWA
>A>	AA				100MG/5ML	A210758	002	Apr 30, 2018	Apr	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	ASCENT PHARMS INC	5MG	A210175	001	Feb 02, 2018	Jan	NEWA
AB		10MG	A210175	002	Feb 02, 2018	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

	@ SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Mar	DISC
	@	7.5MG	A203506	002	Apr 24, 2015	Mar	DISC
	@	10MG	A203506	003	Apr 24, 2015	Mar	DISC
	@	15MG	A203506	004	Apr 24, 2015	Mar	DISC
	@	20MG	A203506	005	Apr 24, 2015	Mar	DISC
	@	30MG	A203506	006	Apr 24, 2015	Mar	DISC
	@	40MG	A203506	007	Apr 24, 2015	Mar	DISC

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

!	CASPER PHARMA LLC	EQ 5MG BASE/GM; 10,000 UNITS/GM	N061015	001		Feb	CMS2
---	-------------------	---------------------------------	---------	-----	--	-----	------

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

PALIPERIDONE

AB	SUN PHARMA GLOBAL	1.5mg	A205618	001	Apr 06, 2018	Mar	NEWA
AB		3MG	A205618	002	Apr 06, 2018	Mar	NEWA
AB		6MG	A205618	003	Apr 06, 2018	Mar	NEWA
AB		9MG	A205618	004	Apr 06, 2018	Mar	NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP	TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Mar	NEWA
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A090713	001	Mar 23, 2018	Mar	NEWA

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

+	JANSSEN PHARMS	24,600USP UNITS; 4,200USP UNITS; 14,200USP UNITS	N022523	001	Apr 12, 2010	Mar	CPOT
+		61,500USP UNITS; 10,500USP UNITS; 35,500USP UNITS	N022523	002	Apr 12, 2010	Mar	CPOT
+		83,900USP UNITS; 21,000USP UNITS; 54,700USP UNITS	N022523	004	Apr 12, 2010	Mar	CPOT
+	!	98,400USP UNITS; 16,800USP UNITS; 56,800USP UNITS	N022523	003	Apr 12, 2010	Mar	CPOT

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

PANTOPRAZOLE SODIUM

>A>	AP	MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Apr	NEWA
-----	----	----------------	-------------------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

>D>	AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr	DISC
>A>		@	EQ 20MG BASE	A200794	001	May 02, 2012	Apr	DISC
>D>	AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr	DISC
>A>		@	EQ 40MG BASE	A200794	002	May 02, 2012	Apr	DISC

PEMOLINE

TABLET; ORAL

PEMOLINE

	@ FOSUN PHARMA	18.75MG	A075286	001	Dec 27, 1999	Jan	CAHN
	@	37.5MG	A075286	002	Jun 30, 1999	Jan	CAHN
	@	75MG	A075286	003	Jun 30, 1999	Jan	CAHN

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

PERMAPEN

BC	CASPER PHARMA LLC	600,000 UNITS/ML	N060014	001		Feb	CMS2
----	-------------------	------------------	---------	-----	--	-----	------

PERINDOPRIL ERBUMINE

	TABLET;ORAL								
	PERINDOPRIL ERBUMINE								
	@ APOTEX	2MG	A090463	001	Aug 30, 2010	Jan	DISC		
	@	4MG	A090463	002	Aug 30, 2010	Jan	DISC		
	@	8MG	A090463	003	Aug 30, 2010	Jan	DISC		
AB	AUROBINDO PHARMA	2MG	A079070	001	Nov 10, 2009	Mar	CHRS		
AB		4MG	A079070	002	Nov 10, 2009	Mar	CHRS		

PHENDIMETRAZINE TARTRATE

	CAPSULE, EXTENDED RELEASE;ORAL								
	PHENDIMETRAZINE TARTRATE								
	+! VIRTUS PHARMS	105MG	N018074	001		Mar	CAHN		
	TABLET;ORAL								
	PHENDIMETRAZINE TARTRATE								
AA	VIRTUS PHARMS	35MG	A085588	001		Mar	CAHN		

PHENTERMINE HYDROCHLORIDE

	CAPSULE;ORAL								
	PHENTERMINE HYDROCHLORIDE								
	@ ELITE LABS INC	15MG	A040460	001	Jan 14, 2003	Jan	CAHN		

PHENYLBUAZONE

	CAPSULE;ORAL								
	PHENYLBUAZONE								
	@ FOSUN PHARMA	100MG	A087774	001	Jun 16, 1982	Jan	CAHN		
	TABLET;ORAL								
	PHENYLBUAZONE								
	@ FOSUN PHARMA	100MG	A084339	001		Jan	CAHN		

PHENYLEPHRINE HYDROCHLORIDE

	SOLUTION;IV (INFUSION)								
	PHENYLEPHRINE HYDROCHLORIDE								
>A>	AP	CIPLA LTD	10MG/ML (10MG/ML)	A210334	001	Apr 27, 2018	Apr	NEWA	
>A>	AP		100MG/10ML (10MG/ML)	A210333	002	Apr 27, 2018	Apr	NEWA	
>D>		+! WEST WARD PHARM CORP	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Apr	CFTG	
>A>	AP	+!	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Apr	CFTG	
	PHENYLEPHRINE HYDROCHLORIDE								
>A>	AP	CIPLA LTD	50MG/5ML (10MG/ML)	A210333	001	Apr 27, 2018	Apr	NEWA	
	VAZCULEP								
>D>		+ AVADEL LEGACY	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Apr	CFTG	
>A>	AP	+	50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Apr	CFTG	
>D>		+!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Apr	CFTG	
>A>	AP	+!	100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Apr	CFTG	

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

	SYRUP;ORAL								
	PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE								
AA	!	VINTAGE	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Jan	CHRS	
	PROMETH VC PLAIN								
	@ G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jan	DISC		

PHENYTOIN

	SUSPENSION;ORAL								
	PHENYTOIN								
AB		WOCKHARDT BIO AG	125MG/5ML	A040420	001	Apr 19, 2002	Jan	CAHN	

PHYTONADIONE

	TABLET;ORAL								
	MEPHYTON								
>D>		+! VALEANT PHARMS	5MG	N010104	003		Apr	CFTG	
>A>	AB	+!	5MG	N010104	003		Apr	CFTG	
>A>		PHYTONADIONE							
>A>	AB	AMNEAL PHARMS CO	5MG	A209373	001	May 11, 2018	Apr	NEWA	

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

>A>	AB	PRINSTON INC	EQ 15MG BASE	A207806	001	Apr 17, 2018	Apr	NEWA
>A>	AB		EQ 30MG BASE	A207806	002	Apr 17, 2018	Apr	NEWA
>A>	AB		EQ 45MG BASE	A207806	003	Apr 17, 2018	Apr	NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

>A>	AP	FRESENIUS KABI	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A203720	001	May 11, 2018	Apr	NEWA
>A>	AP	FRESENIUS KABI USA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A206204	001	May 11, 2018	Apr	NEWA
>A>	AP	SANDOZ INC	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A203557	001	Oct 29, 2014	Apr	CDFR
	AP	WOCKHARDT BIO AG	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan	CPOT
>D>		INJECTABLE; IV (INFUSION)						
>D>		PIPERACILLIN AND TAZOBACTAM						
>D>		SANDOZ INC	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A203557	001	Oct 29, 2014	Apr	CDFR

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB		LABORATORIOS CINFA	10MG	A208991	001	Feb 21, 2018	Feb	NEWA
AB			20MG	A208991	002	Feb 21, 2018	Feb	NEWA
AB		MICRO LABS	10MG	A206152	001	Dec 29, 2017	Feb	CRLD
AB			20MG	A206152	002	Dec 29, 2017	Feb	CRLD
AB		STRIDES PHARMA	10MG	A210347	001	Jan 26, 2018	Jan	NEWA
AB			20MG	A210347	002	Jan 26, 2018	Jan	NEWA

POLIDOCANOL

SOLUTION; INTRAVENOUS

VARITHENA

+	!	PROVENSIS	77.5MG/7.75ML (10MG/ML)	N205098	002	Dec 21, 2017	Jan	CDFR
---	---	-----------	-------------------------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MICRO-K

>D>	AB	+	NESHER PHARMS	8MEQ	N018238	001		Apr	DISC
>A>		+	@	8MEQ	N018238	001		Apr	DISC
>D>			MICRO-K 10						
>D>	AB	+	NESHER PHARMS	10MEQ	N018238	002	May 14, 1984	Apr	DISC
>A>		+	@	10MEQ	N018238	002	May 14, 1984	Apr	DISC

TABLET, EXTENDED RELEASE; ORAL

K-TAB

AB3	+	ABBVIE	10MEQ	N018279	001			Jan	CTEC
AB2	+	!	20MEQ	N018279	003	Nov 25, 2013		Jan	CTEC
		POTASSIUM CHLORIDE							
AB3		PADDOCK LLC	10MEQ	A209688	001	Jan 12, 2018		Jan	NEWA
AB2			20MEQ	A209688	002	Jan 12, 2018		Jan	NEWA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

AB		MOUNTAIN	5MEQ	A077440	001	Jun 09, 2006	Jan	CAHN
AB			10MEQ	A077440	002	Jun 09, 2006	Jan	CAHN
AB		TEVA PHARMS USA INC	5MEQ	A209758	001	Mar 05, 2018	Feb	NEWA
AB			10MEQ	A209758	002	Mar 05, 2018	Feb	NEWA
AB			15MEQ	A209758	003	Mar 05, 2018	Feb	NEWA

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

PRASUGREL

AB		ACCORD HLTHCARE	EQ 5MG BASE	A205987	001	Feb 02, 2018	Jan	NEWA
AB			EQ 10MG BASE	A205987	002	Feb 02, 2018	Jan	NEWA
AB		USPHARMA WINDLAS	EQ 5MG BASE	A205790	001	Oct 16, 2017	Jan	CAHN
AB			EQ 10MG BASE	A205790	002	Oct 16, 2017	Jan	CAHN

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVASTATIN SODIUM

>A>	AB	APPCO PHARMA LLC	10MG	A209869	001	Apr 13, 2018	Apr	NEWA
>A>	AB		20MG	A209869	002	Apr 13, 2018	Apr	NEWA
>A>	AB		40MG	A209869	003	Apr 13, 2018	Apr	NEWA
>A>	AB		80MG	A209869	004	Apr 13, 2018	Apr	NEWA

PREDNISOLONE

TABLET;ORAL

PREDNISOLONE

	@	FOSUN PHARMA	5MG	A080339	001		Jan	CAHN
--	---	--------------	-----	---------	-----	--	-----	------

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL

PREDNISOLONE SODIUM PHOSPHATE

AA	!	WOCKHARDT BIO AG	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Jan	CAHN
----	---	------------------	------------------	---------	-----	--------------	-----	------

SOLUTION/DROPS;OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

>D>		@ BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065	001	Jul 29, 1994	Apr	CAHN
>A>		@	EQ 0.11% PHOSPHATE	A040065	001	Jul 29, 1994	Apr	CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

PROPRANOLOL HYDROCHLORIDE

	@	FOSUN PHARMA	1MG/ML	A076400	001	Feb 26, 2003	Jan	CAHN
--	---	--------------	--------	---------	-----	--------------	-----	------

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

	@	YAOPHARMA CO LTD	10MG	A070663	001	Jun 13, 1986	Jan	CAHN
	@		20MG	A070664	001	Jun 13, 1986	Jan	CAHN
	@		40MG	A070665	001	Jun 13, 1986	Jan	CAHN
	@		60MG	A070666	001	Oct 10, 1986	Jan	CAHN
	@		80MG	A070667	001	Jun 13, 1986	Jan	CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET;ORAL

CORPHED

	@	FOSUN PHARMA	60MG;2.5MG	A088602	001	Apr 11, 1985	Jan	CAHN
--	---	--------------	------------	---------	-----	--------------	-----	------

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

+!		VYERA PHARMS LLC	25MG	N008578	001		Jan	CAHN
----	--	------------------	------	---------	-----	--	-----	------

QUAZEPAM

TABLET;ORAL

DORAL

	@	GALT PHARMS	7.5MG	N018708	003	Feb 26, 1987	Feb	CAHN
+!			15MG	N018708	001	Dec 27, 1985	Feb	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

>D>	AB	SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr	DISC
>A>		@	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr	DISC
>D>	AB		EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr	DISC
>A>		@	EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr	DISC
>D>	AB		EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr	DISC
>A>		@	EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr	DISC
>D>	AB		EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr	DISC
>A>		@	EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr	DISC
		@ YAOPHARMA CO LTD	EQ 5MG BASE	A076803	001	Mar 02, 2005	Jan	CAHN
		@	EQ 10MG BASE	A076803	002	Mar 02, 2005	Jan	CAHN
		@	EQ 20MG BASE	A076803	003	Mar 02, 2005	Jan	CAHN
		@	EQ 40MG BASE	A076803	004	Mar 02, 2005	Jan	CAHN

QUINIDINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
QUINIDINE SULFATE

@ G AND W LABS INC 300MG A040045 001 Jun 30, 1994 Jan DISC

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE;ORAL
ACIPHEX SPRINKLE

+ CERECOR INC 5MG N204736 001 Mar 26, 2013 Feb CAHN

+! 10MG N204736 002 Mar 26, 2013 Feb CAHN

TABLET, DELAYED RELEASE;ORAL
RABEPRAZOLE SODIUM

>A> AB ALKEM LABS LTD 20MG A208644 001 Apr 24, 2018 Apr NEWA

RAMELTEON

TABLET;ORAL
RAMELTEON

AB DR REDDYS LABS SA 8MG A091693 001 Jul 26, 2013 Mar CAHN

RAMIPRIL

CAPSULE;ORAL
RAMIPRIL

@ WATSON LABS 5MG A076549 003 Oct 24, 2005 Mar DISC

@ YAOPHARMA CO LTD 1.25MG A077514 001 Jun 18, 2008 Jan CAHN

@ 2.5MG A077514 002 Jun 18, 2008 Jan CAHN

@ 5MG A077514 003 Jun 18, 2008 Jan CAHN

@ 10MG A077514 004 Jun 18, 2008 Jan CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL
ZANTAC 150

>D> AB + GLAXO GRP LTD EQ 150MG BASE N018703 001 Jun 09, 1983 Apr DISC

>A> + @ EQ 150MG BASE N018703 001 Jun 09, 1983 Apr DISC

RASAGILINE MESYLATE

TABLET;ORAL
RASAGILINE MESYLATE

@ APOTEX INC EQ 0.5MG BASE A201950 001 Sep 12, 2013 Mar DISC

@ EQ 1MG BASE A201950 002 Sep 12, 2013 Mar DISC

REMIFENTANIL HYDROCHLORIDE

INJECTABLE;INJECTION
REMIFENTANIL HYDROCHLORIDE

AP FRESENIUS KABI USA EQ 1MG BASE/VIAL A206223 001 Jan 16, 2018 Jan NEWA

AP EQ 2MG BASE/VIAL A206223 002 Jan 16, 2018 Jan NEWA

AP EQ 5MG BASE/VIAL A206223 003 Jan 16, 2018 Jan NEWA

ULTIVA

AP + MYLAN INSTITUTIONAL EQ 1MG BASE/VIAL N020630 001 Jul 12, 1996 Jan CFTG

AP + EQ 2MG BASE/VIAL N020630 002 Jul 12, 1996 Jan CFTG

AP +! EQ 5MG BASE/VIAL N020630 003 Jul 12, 1996 Jan CFTG

REPAGLINIDE

TABLET;ORAL
REPAGLINIDE

AB CASI PHARMS INC 0.5MG A078555 001 Nov 22, 2013 Mar CAHN

AB 1MG A078555 002 Jan 22, 2014 Mar CAHN

AB 2MG A078555 003 Jan 22, 2014 Mar CAHN

RIBAVIRIN

CAPSULE;ORAL
RIBAVIRIN

AB CASI PHARMS INC 200MG A076192 001 Apr 06, 2004 Mar CAHN

TABLET;ORAL

>D> COPEGUS

>D> AB ROCHE 200MG N021511 001 Dec 03, 2002 Apr DISC

>A> @ 200MG N021511 001 Dec 03, 2002 Apr DISC

ROPIVACAINE HYDROCHLORIDESOLUTION; INJECTION
NAROPIN

AP	+	FRESENIUS KABI USA	400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar	CTEC
AP		ROPIVACAINE HYDROCHLORIDE		A204636	001	Mar 16, 2018	Mar	NEWA
AP		AKORN	200MG/100ML (2MG/ML)	A204636	002	Mar 16, 2018	Mar	NEWA

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

	@	CHARTWELL MOLECULAR	EQ 25MG BASE	A077162	001	Feb 06, 2007	Mar	CAHN
	@		EQ 50MG BASE	A077162	002	Feb 06, 2007	Mar	CAHN
	@		EQ 100MG BASE	A077162	003	Feb 06, 2007	Mar	CAHN
	@	FOSUN PHARMA	EQ 25MG BASE	A077713	001	Feb 06, 2007	Jan	CAHN
	@		EQ 50MG BASE	A077713	002	Feb 06, 2007	Jan	CAHN
	@		EQ 100MG BASE	A077713	003	Feb 06, 2007	Jan	CAHN

SEVELAMER CARBONATE

TABLET; ORAL

SEVELAMER CARBONATE

AB		SANDOZ INC	800MG	A200959	001	Mar 20, 2018	Mar	NEWA
----	--	------------	-------	---------	-----	--------------	-----	------

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

>A>	AB	AJANTA PHARMA LTD	EQ 20MG BASE	A210394	001	May 04, 2018	Apr	NEWA
		@ APOTEX CORP	EQ 20MG BASE	A091379	001	Nov 06, 2012	Mar	DISC

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

	@	YAOPHARMA CO LTD	5MG	A077766	001	Dec 20, 2006	Jan	CAHN
	@		10MG	A077766	002	Dec 20, 2006	Jan	CAHN
	@		20MG	A077766	003	Dec 20, 2006	Jan	CAHN
	@		40MG	A077766	004	Dec 20, 2006	Jan	CAHN
	@		80MG	A077766	005	Dec 20, 2006	Jan	CAHN

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

	+	FOUGERA PHARMS INC	15%	N021902	001	Oct 31, 2006	Jan	CAHN
--	---	--------------------	-----	---------	-----	--------------	-----	------

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

	@	HOSPIRA INC	0.5MEQ/ML	A202679	001	Mar 07, 2017	Mar	DISC
	@		0.5MEQ/ML	A202981	001	Mar 04, 2016	Mar	DISC

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP	+	ICU MEDICAL INC	9MG/ML	N019217	001	Jul 13, 1984	Apr	DISC
>A>		+	@	9MG/ML	N019217	001	Jul 13, 1984	Apr	DISC
	AP	+		9MG/ML	N019217	001	Jul 13, 1984	Feb	CAHN

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AT	+	B BRAUN	900MG/100ML	N016733	001		Mar	CRLD
----	---	---------	-------------	---------	-----	--	-----	------

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

AP		SOFIE	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb	CAHN
----	--	-------	--------------	---------	-----	--------------	-----	------

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE

>A>	AP		MYLAN LABS LTD	25MG/ML	A210763	001	Apr 17, 2018	Apr	NEWA
-----	----	--	----------------	---------	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
AA APNAR PHARMA LP 454GM/BOT A206815 001 Feb 18, 2016 Mar CAHN

SOMATROPIN

INJECTABLE; INJECTION
BIO-TROPIN
@ FERRING 4.8MG/VIAL N019774 001 May 25, 1995 Feb CAIN
ZOMACTON
BX +! FERRING 5MG/VIAL N019774 002 Jan 04, 2002 Feb CAIN
+ 10MG/VIAL N019774 003 Mar 07, 2012 Feb CAIN

SPIRONOLACTONE

TABLET;ORAL
SPIRONOLACTONE
AB CASI PHARMS INC 25MG A086809 001 Mar CAHN

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION
STERILE WATER IN PLASTIC CONTAINER
AT + B BRAUN 100% N016734 001 Mar CRLD

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION
>A> SUCCINYLCHOLINE CHLORIDE
>A> AP ZYDUS PHARMS USA INC 20MG/ML A209467 001 May 04, 2018 Apr NEWA

SUCRALFATE

SUSPENSION;ORAL
CARAFATE
+! ALLERGAN SALES LLC 1GM/10ML N019183 001 Dec 16, 1993 Jan CAHN
TABLET;ORAL
CARAFATE
AB +! ALLERGAN SALES LLC 1GM N018333 001 Jan CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL
SULFAMETHOXAZOLE AND TRIMETHOPRIM
@ FOSUN PHARMA 400MG;80MG A070889 001 Nov 13, 1986 Jan CAHN
@ 400MG;80MG N018598 003 May 19, 1982 Jan CAHN
@ 800MG;160MG A070890 001 Nov 13, 1986 Jan CAHN
>D> SUN PHARM INDUSTRIES 400MG;80MG A071017 002 Aug 25, 1986 Apr CMS1
>A> @ 400MG;80MG A071017 002 Aug 25, 1986 Apr CMS1
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH
@ FOSUN PHARMA 800MG;160MG N018598 004 May 19, 1982 Jan CAHN

SULINDAC

TABLET;ORAL
SULINDAC
@ FOSUN PHARMA 150MG A072712 001 Aug 30, 1991 Jan CAHN
@ 200MG A072713 001 Aug 30, 1991 Jan CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS
SUMAVEL DOSEPRO
+ @ ENDO VENTURES LTD EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) N022239 002 Nov 26, 2013 Mar DISC
+ @ EQ 6MG BASE/0.5ML (EQ 12MG N022239 001 Jul 15, 2009 Mar DISC
BASE/ML)
TABLET;ORAL
SUMATRIPTAN SUCCINATE
@ FOSUN PHARMA EQ 25MG BASE A076976 001 Aug 10, 2009 Jan CAHN
@ EQ 50MG BASE A076976 002 Aug 10, 2009 Jan CAHN
@ EQ 100MG BASE A076976 003 Aug 10, 2009 Jan CAHN

TACROLIMUS

	OINTMENT; TOPICAL						
	TACROLIMUS						
>A>	AB	GLENMARK PHARMS LTD	0.1%	A210393	001	Apr 16, 2018	Apr NEWA

TALC

AEROSOL; INTRAPLEURAL
SCLEROSOL

+!	LYMOL MEDCL	4GM/SPRAY	N020587	001	Dec 24, 1997	Mar CPOT
----	-------------	-----------	---------	-----	--------------	----------

TAMOXIFEN CITRATE

SOLUTION; ORAL
SOLTAMOX

	MIDATECH PHARMA US	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Mar CPOT
--	--------------------	-------------------	---------	-----	--------------	----------

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
PULMOLITE

+ @	JUBILANT DRAXIMAGE	N/A	N017776	001		Feb DISC
-----	--------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
CIS-MDP

	PHARMALUCENCE	N/A	N018124	001		Jan CTEC
--	---------------	-----	---------	-----	--	----------

MDP-BRACCO

@	CARDINAL HEALTH 414	N/A	N018107	001		Jan DISC
---	---------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
DTPA

+!	JUBILANT DRAXIMAGE	N/A	N018511	001	Dec 29, 1989	Jan CAHN
----	--------------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC
RADIOGENIX SYSTEM

+	NORTHSTAR MEDICAL	30-1153mCi/GENERATOR	N202158	001	Feb 08, 2018	Feb NEWA
---	-------------------	----------------------	---------	-----	--------------	----------

TEMOZOLOMIDE

CAPSULE; ORAL
TEMOZOLOMIDE

>D>	AB	MYLAN PHARMS INC	5MG	A205227	001	Jun 29, 2016	Apr DISC
>A>		@	5MG	A205227	001	Jun 29, 2016	Apr DISC
>D>	AB		20MG	A205227	002	Jun 29, 2016	Apr DISC
>A>		@	20MG	A205227	002	Jun 29, 2016	Apr DISC
		@	100MG	A205227	003	Jun 29, 2016	Mar DISC
		@	140MG	A205227	004	Jun 29, 2016	Mar DISC
		@	180MG	A205227	005	Jun 29, 2016	Mar DISC
		@	250MG	A205227	006	Jun 29, 2016	Mar DISC

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

AB	AUROBINDO PHARMA LTD	150MG	A090647	001	Jan 26, 2018	Jan NEWA	
AB		200MG	A090647	002	Jan 26, 2018	Jan NEWA	
AB		250MG	A090647	003	Jan 26, 2018	Jan NEWA	
AB		300MG	A090647	004	Jan 26, 2018	Jan NEWA	
AB	CIPLA LTD	300MG	A078800	001	Jan 26, 2018	Jan NEWA	
AB	HETERO LABS LTD III	300MG	A090636	001	Jan 26, 2018	Jan NEWA	
AB	LAURUS LABS PVT	300MG	A209550	001	Feb 26, 2018	Feb NEWA	
AB	MACLEODS PHARMS LTD	300MG	A203232	001	Jan 26, 2018	Jan NEWA	
AB	STRIDES PHARMA	300MG	A090742	001	Jan 26, 2018	Jan NEWA	
AB	TEVA PHARMS USA	150MG	A091612	002	Jan 26, 2018	Jan NEWA	
AB		200MG	A091612	003	Jan 26, 2018	Jan NEWA	
AB		250MG	A091612	004	Jan 26, 2018	Jan NEWA	
	VIREAD						
AB	+	GILEAD SCIENCES INC	150MG	N021356	002	Jan 18, 2012	Jan CFTG
AB	+		200MG	N021356	003	Jan 18, 2012	Jan CFTG
AB	+		250MG	N021356	004	Jan 18, 2012	Jan CFTG

TERCONAZOLE

		CREAM;VAGINAL							
		TERAZOL 7							
		+ @ JANSSEN PHARMS	0.4%		N019579	001	Dec 31, 1987	Feb	DISC
		TERCONAZOLE							
AB	!	TARO	0.4%		A076043	001	Jan 19, 2005	Feb	CHRS
		SUPPOSITORY;VAGINAL							
		TERAZOL 3							
		+ @ JANSSEN PHARMS	80MG		N019641	001	May 24, 1988	Feb	DISC
		TERCONAZOLE							
AB	!	PERRIGO NEW YORK	80MG		A077149	001	Mar 17, 2006	Feb	CHRS

TESTOSTERONE

		GEL;TRANSDERMAL							
		TESTOSTERONE							
		@ ANI PHARMS INC	25MG/2.5GM PACKET		N202763	001	Feb 14, 2012	Jan	DISC
		@	50MG/5GM PACKET		N202763	002	Feb 14, 2012	Jan	DISC
		SOLUTION, METERED;TRANSDERMAL							
		TESTOSTERONE							
AT		CIPLA LTD	30MG/1.5ML ACTUATION		A209533	001	Jan 29, 2018	Jan	NEWA

TETRABENAZINE

		TABLET;ORAL							
		TETRABENAZINE							
>A>	AB	LUPIN LTD	12.5MG		A210544	001	Apr 20, 2018	Apr	NEWA
>A>	AB		25MG		A210544	002	Apr 20, 2018	Apr	NEWA

TETRACAINE HYDROCHLORIDE

		SOLUTION;OPHTHALMIC							
		TETRACAINE HYDROCHLORIDE							
		+! ALCON LABS	0.5%		N208135	001	Feb 29, 2016	Mar	CAHN

THEOPHYLLINE

		TABLET, EXTENDED RELEASE;ORAL							
		THEOCHRON							
AB		NOSTRUM PHARMS LLC	100MG		A087400	003	Feb 21, 1985	Jan	CTEC
AB			200MG		A087400	004	Feb 21, 1985	Jan	CTEC

THIORIDAZINE HYDROCHLORIDE

		TABLET;ORAL							
		THIORIDAZINE HYDROCHLORIDE							
		@ FOSUN PHARMA	10MG		A088131	001	Aug 30, 1983	Jan	CAHN
		@	15MG		A088132	001	Aug 30, 1983	Jan	CAHN
		@	25MG		A088133	001	Aug 30, 1983	Jan	CAHN
		@	50MG		A088134	001	Aug 30, 1983	Jan	CAHN
		@	100MG		A088135	001	Nov 20, 1984	Jan	CAHN
		@	150MG		A088136	001	Sep 17, 1986	Jan	CAHN
		@	200MG		A088137	001	Sep 17, 1986	Jan	CAHN

THIOTEPA

		INJECTABLE;INJECTION							
		THIOTEPA							
>A>	AP	DR REDDYS LABS LTD	15MG/VIAL		A210337	001	May 04, 2018	Apr	NEWA
>A>	AP	JIANGSU HENGRUI MED	15MG/VIAL		A209150	001	May 04, 2018	Apr	NEWA
>D>	!	WEST-WARD PHARMS INT	15MG/VIAL		A075547	001	Apr 02, 2001	Apr	CTEC
>A>	AP	!	15MG/VIAL		A075547	001	Apr 02, 2001	Apr	CTEC

THIOTHIXENE

		CAPSULE;ORAL							
		NAVANE							
		+ @ PFIZER	1MG		N016584	001		Jan	CRLD
		+ @	2MG		N016584	002		Jan	CRLD
		+ @	5MG		N016584	003		Jan	CRLD
		+ @	10MG		N016584	004		Jan	CRLD
		+ @	20MG		N016584	005		Jan	CRLD

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

@ YAOPHARMA CO LTD	250MG	A075318	001	Aug 20, 1999	Jan CAHN
@	250MG	A075326	001	Aug 20, 1999	Jan CAHN

TIGECYCLINE

POWDER; IV (INFUSION)

TIGECYCLINE

ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	Jan NEWA
---------------------	-----------	---------	-----	--------------	----------

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOPTIC

AT + ATON	EQ 0.25% BASE	N018086	001		Jan CMFD
AT1 +	EQ 0.5% BASE	N018086	002		Jan CMFD

TABLET; ORAL

TIMOLOL MALEATE

@ YAOPHARMA CO LTD	5MG	A072550	001	Apr 13, 1989	Jan CAHN
@	10MG	A072551	001	Apr 13, 1989	Jan CAHN
@	20MG	A072552	001	Apr 13, 1989	Jan CAHN

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB CASI PHARMS INC	EQ 2MG BASE	A076280	001	Nov 26, 2002	Mar CAHN
AB	EQ 4MG BASE	A076280	002	Jun 27, 2002	Mar CAHN
AB ZYDUS PHARMS USA INC	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb NEWA
AB	EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb NEWA

TOLAZAMIDE

TABLET; ORAL

TOLAZAMIDE

@ YAOPHARMA CO LTD	100MG	A071633	001	Dec 09, 1987	Jan CAHN
@	250MG	A070289	001	Mar 13, 1986	Jan CAHN
@	500MG	A070290	001	Mar 13, 1986	Jan CAHN

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

@ YAOPHARMA CO LTD	500MG	A086574	001		Jan CAHN
--------------------	-------	---------	-----	--	----------

TOLMETIN SODIUM

CAPSULE; ORAL

TOLMETIN SODIUM

@ FOSUN PHARMA	EQ 400MG BASE	A073462	001	Apr 30, 1992	Jan CAHN
----------------	---------------	---------	-----	--------------	----------

TABLET; ORAL

TOLMETIN SODIUM

@ FOSUN PHARMA	EQ 200MG BASE	A073588	001	Jul 31, 1992	Jan CAHN
@	EQ 600MG BASE	A074002	001	Sep 27, 1993	Jan CAHN

TOLTERODINE TARTRATE

TABLET; ORAL

TOLTERODINE TARTRATE

@ APOTEX CORP	1MG	A200164	001	Sep 25, 2012	Mar DISC
@	2MG	A200164	002	Sep 25, 2012	Mar DISC

TOLVAPTAN

TABLET; ORAL

JYNARQUE

>A>					
>A>	+ OTSUKA PHARM CO LTD	15MG	N204441	001	Apr 23, 2018 Apr NEWA
>A>	+	30MG	N204441	002	Apr 23, 2018 Apr NEWA
>A>	+	45MG	N204441	003	Apr 23, 2018 Apr NEWA
>A>	+	60MG	N204441	004	Apr 23, 2018 Apr NEWA
>A>	+!	90MG	N204441	005	Apr 23, 2018 Apr NEWA

TOPIRAMATE

CAPSULE;ORAL

TOPIRAMATE

@ FOSUN PHARMA	15MG	A079206	001	Oct 14, 2009	Jan CAHN
@	25MG	A079206	002	Oct 14, 2009	Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

@ FOSUN PHARMA	50MG	A075968	001	Jun 25, 2002	Jan CAHN
----------------	------	---------	-----	--------------	----------

TRANDOLAPRIL

TABLET;ORAL

MAVIK

+ @ ABBVIE	1MG	N020528	001	Apr 26, 1996	Mar DISC
+ @	2MG	N020528	002	Apr 26, 1996	Mar DISC
+ @	4MG	N020528	003	Apr 26, 1996	Mar DISC

AB	!	LUPIN	4MG	A077522	003	Jun 12, 2007	Mar CHRS
----	---	-------	-----	---------	-----	--------------	----------

TRANLYCYPROMINE SULFATE

TABLET;ORAL

TRANLYCYPROMINE SULFATE

>A> AB		KINEDEXE UK	EQ 10MG BASE	A206856	001	Apr 17, 2018	Apr NEWA
--------	--	-------------	--------------	---------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

@ FOSUN PHARMA	100MG	A072483	001	Apr 30, 1990	Jan CAHN
----------------	-------	---------	-----	--------------	----------

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		PERRIGO NEW YORK	0.025%	A086413	002		Mar CMS1
AT			0.1%	A086413	003		Mar CMS1

SPRAY;TOPICAL

KENALOG

AT	+	!	SUN PHARM INDS INC	0.147MG/GM	N012104	001	Feb CAHN
----	---	---	--------------------	------------	---------	-----	----------

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL

SYPRINE

AB	+	!	ATON	250MG	N019194	001	Nov 08, 1985	Jan CFTG
----	---	---	------	-------	---------	-----	--------------	----------

TRIENTINE HYDROCHLORIDE

AB			WATSON LABS TEVA	250MG	A207567	001	Feb 07, 2018	Jan NEWA
----	--	--	------------------	-------	---------	-----	--------------	----------

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

@ FOSUN PHARMA	EQ 10MG BASE/ML	A085787	001	Apr 15, 1982	Jan CAHN
----------------	-----------------	---------	-----	--------------	----------

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

TROPICAMIDE

>D> AT			BAUSCH AND LOMB	0.5%	A040067	001	Jul 27, 1994	Apr CAHN
>A> AT				0.5%	A040067	001	Jul 27, 1994	Apr CAHN

URSODIOL

TABLET;ORAL

URSO 250

>A> AB	+		ALLERGAN SALES LLC	250MG	N020675	001	Dec 10, 1997	Apr CAHN
--------	---	--	--------------------	-------	---------	-----	--------------	----------

>D> AB	+		FOREST LABS INC	250MG	N020675	001	Dec 10, 1997	Apr CAHN
--------	---	--	-----------------	-------	---------	-----	--------------	----------

URSO FORTE

>A> AB	+	!	ALLERGAN SALES LLC	500MG	N020675	002	Jul 21, 2004	Apr CAHN
--------	---	---	--------------------	-------	---------	-----	--------------	----------

>D> AB	+	!	FOREST LABS INC	500MG	N020675	002	Jul 21, 2004	Apr CAHN
--------	---	---	-----------------	-------	---------	-----	--------------	----------

VALSARTAN

TABLET; ORAL

VALSARTAN

AB	SQUARE PHARMS LTD	40MG	A205347	001	Apr 09, 2018	Mar	NEWA
AB		80MG	A205347	002	Apr 09, 2018	Mar	NEWA
AB		160MG	A205347	003	Apr 09, 2018	Mar	NEWA
AB		320MG	A205347	004	Apr 09, 2018	Mar	NEWA
>A>	UNICHEM LABS LTD	40MG	A209261	001	May 04, 2018	Apr	NEWA
>A>		80MG	A209261	002	May 04, 2018	Apr	NEWA
>A>		160MG	A209261	003	May 04, 2018	Apr	NEWA
>A>		320MG	A209261	004	May 04, 2018	Apr	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOMYCIN HYDROCHLORIDE

@ FRESENIUS KABI USA EQ 125MG BASE

A065453 001 Jun 18, 2012 Feb DISC

@ EQ 250MG BASE

A065453 002 Jun 18, 2012 Feb DISC

FOR SOLUTION; ORAL

FIRVANQ KIT

+! RXMTM THERAPS LLC EQ 25MG BASE/ML

N208910 001 Jan 26, 2018 Jan NEWA

+! EQ 50MG BASE/ML

N208910 002 Jan 26, 2018 Jan NEWA

INJECTABLE; INJECTION

VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER

>A> +! BAXTER HLTHCARE EQ 1GM BASE/200ML

N050671 003 Mar 01, 1999 Apr NEWA

VANCOMYCIN HYDROCHLORIDE

@ MYLAN LABS LTD EQ 10GM BASE/VIAL

A091469 001 Jul 01, 2011 Mar DISC

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

>D> + BAYER HLTHCARE 2.5MG

N021400 003 Aug 19, 2003 Apr DISC

>A> + @ 2.5MG

N021400 003 Aug 19, 2003 Apr DISC

>D> TABLET, ORALLY DISINTEGRATING; ORAL

>D> STAXYN

>D> +! BAYER HLTHCARE 10MG

N200179 001 Jun 17, 2010 Apr DISC

>A> + @ 10MG

N200179 001 Jun 17, 2010 Apr DISC

VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

+ PF PRISM CV EQ 0.5MG BASE

N021928 001 May 10, 2006 Feb CAHN

+! EQ 1MG BASE

N021928 002 May 10, 2006 Feb CAHN

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

@ FOSUN PHARMA EQ 25MG BASE

A077515 001 Jun 13, 2008 Jan CAHN

@ EQ 37.5MG BASE

A077515 002 Jun 13, 2008 Jan CAHN

@ EQ 50MG BASE

A077515 003 Jun 13, 2008 Jan CAHN

@ EQ 75MG BASE

A077515 004 Jun 13, 2008 Jan CAHN

@ EQ 100MG BASE

A077515 005 Jun 13, 2008 Jan CAHN

VERAPAMIL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP ! HOSPIRA 5MG/2ML (2.5MG/ML)

A070738 001 May 06, 1987 Jan CPOT

TABLET; ORAL

ISOPTIN

>D> @ FSC 40MG

N018593 003 Nov 23, 1987 Apr CRLD

>D> @ 80MG

N018593 001 Mar 08, 1982 Apr CRLD

>D> @ 120MG

N018593 002 Mar 08, 1982 Apr CRLD

>A> + @ MT ADAMS 40MG

N018593 003 Nov 23, 1987 Apr CRLD

>A> + @ 80MG

N018593 001 Mar 08, 1982 Apr CRLD

>A> + @ 120MG

N018593 002 Mar 08, 1982 Apr CRLD

VERAPAMIL HYDROCHLORIDE

@ YAOPHARMA CO LTD 40MG

A073168 001 Jul 31, 1992 Jan CAHN

@ 80MG

A071423 001 May 24, 1988 Jan CAHN

@ 120MG

A071424 001 May 25, 1988 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL
VERAPAMIL HYDROCHLORIDE

@	APOTEX CORP	120MG	A200878	001	Apr 20, 2012	Mar	DISC
@		180MG	A200878	002	Apr 20, 2012	Mar	DISC
@		240MG	A200878	003	Apr 20, 2012	Mar	DISC

VIGABATRIN

FOR SOLUTION;ORAL
VIGABATRIN

AA	AMNEAL PHARMS	500MG/PACKET	A210155	001	Mar 13, 2018	Feb	NEWA
>A>	AA	TEVA PHARMS USA	A209824	001	Apr 23, 2018	Apr	NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL
VIIBRYD

+	!	ALLERGAN SALES LLC	10MG	N022567	001	Jan 21, 2011	Jan	CAHN
+			20MG	N022567	002	Jan 21, 2011	Jan	CAHN
+			40MG	N022567	003	Jan 21, 2011	Jan	CAHN

VINBLASTINE SULFATE

INJECTABLE;INJECTION
VELBAN

>D>	@	LILLY	10MG/VIAL	N012665	001		Apr	CRLD
>A>	+	@	10MG/VIAL	N012665	001		Apr	CRLD

WARFARIN SODIUM

TABLET;ORAL
WARFARIN SODIUM

@	YAOPHARMA CO LTD	1MG	A040196	001	Sep 30, 1997	Jan	CAHN
@		2MG	A040196	002	Sep 30, 1997	Jan	CAHN
@		2.5MG	A040196	003	Sep 30, 1997	Jan	CAHN
@		3MG	A040196	008	Jul 26, 2000	Jan	CAHN
@		4MG	A040196	004	Sep 30, 1997	Jan	CAHN
@		5MG	A040196	005	Sep 30, 1997	Jan	CAHN
@		6MG	A040196	009	Jul 26, 2000	Jan	CAHN
@		7.5MG	A040196	006	Sep 30, 1997	Jan	CAHN
@		10MG	A040196	007	Sep 30, 1997	Jan	CAHN

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL
ZIPRASIDONE HYDROCHLORIDE

@	MYLAN PHARMS INC	EQ 20MG BASE	A202395	001	Oct 10, 2013	Mar	DISC
@		EQ 40MG BASE	A202395	002	Oct 10, 2013	Mar	DISC
@		EQ 60MG BASE	A202395	003	Oct 10, 2013	Mar	DISC

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)
ZOLEDRONIC ACID

AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Jan	CAHN
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Jan	CAHN

ZOLMITRIPTAN

TABLET;ORAL
ZOLMITRIPTAN

@	APOTEX INC	2.5MG	A202078	001	May 14, 2013	Mar	DISC
@		5MG	A202078	002	May 14, 2013	Mar	DISC

TABLET, ORALLY DISINTEGRATING;ORAL
ZOLMITRIPTAN

@	APOTEX INC	2.5MG	A202476	001	May 14, 2013	Mar	DISC
@		5MG	A202476	002	May 14, 2013	Mar	DISC

ZOLPIDEM TARTRATE

TABLET;ORAL
ZOLPIDEM TARTRATE

>D>	AB	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr	DISC
>A>		@	5MG	A078055	001	Apr 23, 2007	Apr	DISC
>D>	AB		10MG	A078055	002	Apr 23, 2007	Apr	DISC
>A>		@	10MG	A078055	002	Apr 23, 2007	Apr	DISC

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

@ AUROBINDO PHARMA LTD	25MG	A 077645	002	Sep 29, 2006	Feb CAHN
@	50MG	A 077645	003	Sep 29, 2006	Feb CAHN
@	100MG	A 077645	001	Dec 22, 2005	Feb CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ G AND W LABS

325MG

N018060 003 Dec 18, 1986

Jan DISC

@

650MG

N018060 002

Jan DISC

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

PLD ACQUISITIONS

5MG

A077946 001 Dec 27, 2007

Feb CAHN

10MG

A077946 002 Dec 27, 2007

Feb CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

PLD ACQUISITIONS

5MG;120MG

A077991 001 Mar 05, 2008

Feb CAHN

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+! BECTON DICKINSON CO

2%;70% (1ML)

N020832 008 Oct 23, 2008

Feb NEWA

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

PLD ACQUISITIONS LLC

1.34MG

A073458 001 Oct 31, 1993

Jan CAHN

CLOTTRIMAZOLE

CREAM;VAGINAL

MYCELEX-7

@ BAYER HEALTHCARE LLC

1%

N018230 002 Dec 26, 1991

Mar DISC

CREAM, TABLET;TOPICAL, VAGINAL

MYCELEX-7 COMBINATION PACK

@ BAYER HEALTHCARE LLC

1%,100MG

N020389 002 Jun 23, 1994

Feb DISC

TABLET;VAGINAL

MYCELEX-7

@ BAYER HEALTHCARE LLC

100MG

N018182 002 Dec 26, 1991

Mar DISC

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

>A> PERRIGO R AND D

30MG;600MG

A207602 002 Mar 05, 2018

Apr NEWA

>A> 60MG;1.2GM

A207602 001 Mar 05, 2018

Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

>A> DR REDDYS LABS LTD

EQ 20MG BASE

A207673 001 May 15, 2018

Apr NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

STRIDES PHARMA

EQ 200MG FREE ACID AND POTASSIUM
SALT

A204469 001 Mar 28, 2018

Mar NEWA

SUSPENSION;ORAL

IBUPROFEN

>A> AUROBINDO PHARMA LTD

100MG/5ML

A209179 001 Apr 17, 2018

Apr NEWA

TABLET;ORAL

IBUPROFEN

@ P AND L DEV LLC

200MG

A070733 001 Sep 19, 1986

Jan CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

DR REDDYS LABS LTD

5MG

A210375 001 Jan 19, 2018

Jan NEWA

LORATADINE

	TABLET;ORAL							
	LORATADINE							
>A>	AUROBINDO PHARMA LTD	10MG		A208314	001	Apr 16, 2018	Apr	NEWA
	PLD ACQUISITIONS LLC	10MG		A075209	001	Jan 21, 2003	Jan	CAHN
	TABLET, CHEWABLE;ORAL							
	LORATADINE							
>A>	SUN PHARMA GLOBAL	5MG		A210088	001	Apr 16, 2018	Apr	NEWA
	TABLET, ORALLY DISINTEGRATING;ORAL							
	LORATADINE							
	AUROBINDO PHARMA LTD	10MG		A208477	001	Apr 11, 2018	Mar	NEWA

MICONAZOLE NITRATE

	CREAM, SUPPOSITORY;TOPICAL, VAGINAL							
	MICONAZOLE 7 COMBINATION PACK							
	@ G AND W LABS	2%,100MG		A076585	001	Mar 26, 2004	Jan	DISC

NAPROXEN SODIUM

	TABLET;ORAL							
	NAPROXEN SODIUM							
	@ PLD ACQUISITIONS LLC	EQ 200MG BASE		A074646	001	Jan 13, 1997	Jan	CAHN

NICOTINE POLACRILEX

	GUM, CHEWING;BUCCAL							
	THRIVE							
	@ GLAXOSMITHKLINE CONS	EQ 2MG BASE		A077658	001	Jun 19, 2007	Mar	DISC
		EQ 2MG BASE		A077658	001	Jun 19, 2007	Feb	CAHN
		EQ 4MG BASE		A077656	001	Jun 19, 2007	Feb	CAHN
	TROCHE/LOZENGE;ORAL							
	NICORETTE							
+	GLAXOSMITHKLINE CONS	EQ 2MG BASE		N021330	001	Oct 31, 2002	Feb	CTNA
+	GLAXOSMITHKLINE CONS	EQ 4MG BASE		N021330	002	Oct 31, 2002	Feb	CTNA

OMEPRAZOLE; SODIUM BICARBONATE

	CAPSULE;ORAL							
	OMEPRAZOLE AND SODIUM BICARBONATE							
	ZYDUS PHARMS USA INC	20MG;1.1GM		A203345	001	Mar 16, 2018	Mar	NEWA

POLYETHYLENE GLYCOL 3350

	FOR SOLUTION;ORAL							
	POLYETHYLENE GLYCOL 3350							
	APNAR PHARMA LP	17GM/SCOOPFUL		A202071	001	Dec 28, 2012	Mar	CAHN
	AUROBINDO PHARMA LTD	17GM/SCOOPFUL		A209017	001	Apr 09, 2018	Mar	NEWA

RANITIDINE HYDROCHLORIDE

	TABLET;ORAL							
	RANITIDINE HYDROCHLORIDE							
	VIVIMED GLOBAL	EQ 75MG BASE		A209160	001	Mar 05, 2018	Feb	NEWA
		EQ 150MG BASE		A209161	001	Feb 22, 2018	Feb	NEWA

TERBINAFINE

	GEL;TOPICAL							
	LAMISIL AT							
+	GLAXOSMITHKLINE CONS	1%		N021958	001	Jul 24, 2006	Feb	CAHN

TERBINAFINE HYDROCHLORIDE

	SOLUTION;TOPICAL							
	LAMISIL AT							
+	GLAXOSMITHKLINE CONS	1%		N021124	001	Mar 17, 2000	Feb	CAHN
	SPRAY;TOPICAL							
	LAMISIL AT							
+	GLAXOSMITHKLINE CONS	1%		N021124	002	Mar 17, 2000	Feb	CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 4 APRIL 2018

NO APRIL 2018 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2018 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Dec 15, 2029	DS DP U-1981		I-768	Feb 26, 2021
	7855211	Dec 15, 2029	DS DP U-2132			
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	8822438	Aug 24, 2027		U-1579	I-765	Feb 07, 2021
	8822438	Aug 24, 2027		U-1580		
	8822438	Aug 24, 2027		U-2235		
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027		U-1579	I-765	Feb 07, 2021
	8822438	Aug 24, 2027		U-1580		
	8822438	Aug 24, 2027		U-2235		
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	>A> 7459554	Nov 24, 2026	DS			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	>A> 9399012	Sep 11, 2031		U-2261		
	>A> 9399012	Sep 11, 2031		U-2262		
	>A> 9399012*PED	Mar 11, 2032				
	>A> 9610265	Nov 13, 2028		U-2263		
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 001	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP	U-2249		
	9549923	Jul 01, 2030	DS DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	>A> RE46417	Feb 10, 2025	DS DP	U-1263		
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001					I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002					I-763	Jan 12, 2021
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003					I-763	Jan 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	9861771	Oct 11, 2020	DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	9867791	Dec 02, 2030	U-2106		I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	9867791	Dec 02, 2030	U-2106		I-769	Aug 24, 2020
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8252331	Mar 13, 2030	DP			
	8574626	Nov 28, 2025	DP U-20			
	RE39069	May 29, 2018	DP			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001					I-766	Mar 09, 2021
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	9220745	Dec 18, 2034	U-2217		NCE	Dec 21, 2022
	9220745	Dec 18, 2034	U-2218			
	9572856	Sep 20, 2030	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	9220745	Dec 18, 2034	U-2217		NCE	Dec 21, 2022
	9220745	Dec 18, 2034	U-2218			
	9572856	Sep 20, 2030	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	8445507	Sep 15, 2030	DS DP U-2237		NCE	Feb 14, 2023
	8802689	Mar 27, 2027	U-2237			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS DP U-2237			
	9884054	Sep 23, 2033	U-2237			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	7427638	Feb 16, 2028	DS DP			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	7427638	Feb 16, 2028	DS DP			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 003	7427638	Feb 16, 2028	DS DP			
	9872854	May 29, 2034		U-2232		
	9872854	May 29, 2034		U-2233		
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001 >A>	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002 >A>	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003 >A>	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004 >A>	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005 >A>	9941931	Nov 04, 2030	DP			
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006 >A>	9941931	Nov 04, 2030	DP			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001	6723351	Nov 10, 2018	U-2204		>A> ODE-167	Jan 12, 2025
	6723351	Nov 10, 2018	U-2229			
	6723351	Nov 10, 2018	U-573			
	6855339	Nov 10, 2018	U-2204			
	6855339	Nov 10, 2018	U-2229			
	6855339	Nov 10, 2018	U-617			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-617			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-651			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-651			
	8273379	Nov 10, 2018	U-1291			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002	6723351	Nov 10, 2018	U-2204		>A> ODE-167	Jan 12, 2025
	6723351	Nov 10, 2018	U-2229			
	6855339	Nov 10, 2018	U-2204			
	6855339	Nov 10, 2018	U-2229			
	6861076	Nov 10, 2018	U-2204			
	6861076	Nov 10, 2018	U-2229			
	6884439	Nov 10, 2018	U-2204			
	6884439	Nov 10, 2018	U-2229			
	6982096	Nov 10, 2018	U-2204			
	6982096	Nov 10, 2018	U-2229			
	8273379	Nov 10, 2018	U-2204			
	8273379	Nov 10, 2018	U-2229			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001					M-158	Mar 12, 2018
					NPP	Mar 12, 2018
					PED	Sep 12, 2018
					PED	Sep 12, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117	002				M-158	Mar 12, 2018
					NPP	Mar 12, 2018
					PED	Sep 12, 2018
					PED	Sep 12, 2018
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494	001	7112592	Feb 24, 2022	DS DP	U-2244	
		7112592	Feb 24, 2022	DS DP	U-282	
		8178554	Jul 24, 2021	DS DP	U-2245	
		8178554	Jul 24, 2021	DS DP	U-282	
<u>AZELAIC ACID - FINACEA</u>						
N 207071	001	>A> 9211259	Feb 28, 2029		U-1796	
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203	002	9919050	Nov 22, 2025		DP	
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236	001	9901585	Jun 13, 2023		DP	
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247	001	5998402	Apr 04, 2019	DS DP	U-594	
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194	001	8791270	Jan 12, 2026		DP U-1790	
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079	001	9877974	Aug 31, 2030		DP U-1858	
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251	001	6642245	Nov 04, 2020		U-257	NCE
		6703396	Mar 09, 2021	DS DP		
		7390791	May 07, 2022	DS DP		
		7803788	Feb 02, 2022		U-257	
		8754065	Aug 15, 2032	DS DP	U-257	
		9216996	Dec 19, 2033	DS DP		
		9296769	Aug 15, 2032	DS DP	U-257	
		9708342	Jun 19, 2035	DS DP		
		9732092	Dec 19, 2033	DS DP		
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	001				ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	002				ODE-163	Dec 19, 2024
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341	003				ODE-163	Dec 19, 2024
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708	001	9861631	Mar 25, 2031		U-1428	
		9861632	Mar 25, 2031		U-1428	
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144	001	8293742	Jul 14, 2030		U-2222	
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398	001	9907801	Apr 19, 2022		DP U-2239	
		9907802	Apr 19, 2022		DP U-2240	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	>A> 9895422	Jun 07, 2030	U-2114			
	>A> 9895422	Jun 07, 2030	U-2116			
	>A> 9895422	Jun 07, 2030	U-2281			
	>A> 9895422	Jun 07, 2030	U-2282			
	>A> 9895422	Jun 07, 2030	U-2283			
	>A> 9895422	Jun 07, 2030	U-2284			
	>A> 9895422	Jun 07, 2030	U-2285			
	>A> 9895422	Jun 07, 2030	U-2286			
	>A> 9895422	Jun 07, 2030	U-2287			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001				>A> I-771		Apr 06, 2021
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002				>A> I-771		Apr 06, 2021
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001					NP	Nov 30, 2020
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002					NP	Nov 30, 2020
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	9931305	Feb 14, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	9931305	Feb 14, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	9931305	Feb 14, 2022	DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	9861644	Mar 14, 2034	DP			
	>A> 9943530	Feb 02, 2027	U-2274			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	>A> 6114313	Dec 11, 2018	DP U-1715			
	>A> 6130208	Jun 29, 2019	DP U-1715			
	>A> 9925265	May 13, 2029	U-2260			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645	Y		
	9901640	Dec 26, 2028	DP U-219			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9872906	Mar 14, 2034	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWAB</u>						
N 021524 001					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS SWABSTICK</u>						
N 021524 002					M-221	Feb 14, 2021
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - PREVANTICS MAXI SWABSTICK</u>						
N 021524 003					M-221	Feb 14, 2021
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9603796	Apr 21, 2029	DS DP U-2252		I-770	Mar 02, 2021
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	9889115	Jun 23, 2019	U-1660			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	9891239	Sep 03, 2029	DP U-257			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	9891239	Sep 03, 2029	DP U-257			
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	9867815	Feb 07, 2037	U-2225		NCE	Dec 14, 2022
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	>A> 9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	>A> 9925157	Jan 26, 2027	DS DP U-1399			
	>A> 9925158	Jan 26, 2027	DS DP U-1399			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	>A> 9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	>A> 9925157	Jan 26, 2027	DS DP U-1399			
	>A> 9925158	Jan 26, 2027	DS DP U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	>A> 9925156	Jan 26, 2027	DS DP U-1399		ODE-162	Dec 22, 2024
	>A> 9925157	Jan 26, 2027	DS DP U-1399			
	>A> 9925158	Jan 26, 2027	DS DP U-1399			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	>A> 9925174	Jun 14, 2023	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	>A> 9925174	Jun 14, 2023	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	>A> 9925174	Jun 14, 2023	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					>A> I-778	Apr 30, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					>A> I-778	Apr 30, 2021
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	>A> 9918973	Dec 13, 2024	U-1030			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	9884044	Jun 13, 2022	DP U-1546			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	>A> 8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	7456254	Jun 30, 2025	DP U-2139			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	>A> 8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	9889115	Jun 23, 2019	U-1305			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	9889115	Jun 23, 2019	U-1305			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 202895 001	9889115	Jun 23, 2019	U-1305			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					ODE-164	Nov 09, 2024
<u>DASATINIB - SPRYCEL</u>						
N 021986 006					ODE-164	Nov 09, 2024
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001					M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002					M-222	Feb 06, 2021
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003					M-222	Feb 06, 2021
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	6960346	Jul 03, 2023	DP		NP	Feb 09, 2021
	7560120	Sep 05, 2022	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	6509376	Apr 01, 2019	DP			
	7320999	Oct 20, 2019		U-1384		
	7619001	Apr 01, 2019		U-1384		
	7803840	Apr 01, 2019		U-1385		
	8399514	Feb 07, 2028		U-1384		
	8759393	Jul 04, 2018	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	6509376	Apr 01, 2019	DP			
	7320999	Oct 20, 2019		U-1384		
	7619001	Apr 01, 2019		U-1384		
	7803840	Apr 01, 2019		U-1385		
	8399514	Feb 07, 2028		U-1384		
	8759393	Jul 04, 2018	DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9861607	May 18, 2027	U-620			
	>A> 9907780	Apr 11, 2028	DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9861607	May 18, 2027	U-620			
	>A> 9907780	Apr 11, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661 001	>A> 9937132	Feb 18, 2033	DP U-1382			
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 001					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 002					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 078064 003					PC	Jun 19, 2018
<u>EFAVIRENZ - EFAVIRENZ</u>						
A 091471 001					PC	Feb 14, 2018
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9877955	Jan 03, 2028	U-1969			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	>A> 6916802	Apr 29, 2022	DS U-1571			
	>A> 7253185	Apr 29, 2022	DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	>A> 9949997	May 17, 2034	U-2292			
	>A> 9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	>A> 9949997	May 17, 2034	U-2292			
	>A> 9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	>A> 9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	>A> 9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	>A> 9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	>A> 9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	>A> 9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	>A> 9949998	Jun 11, 2034	U-2290			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002	8080580	Jul 13, 2030	DS DP U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 001	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 003	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUOMET</u>						
N 209806 004	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	6699871	Jul 26, 2022	DS DP U-2214			
	6890898	Feb 02, 2019	U-2215			
	7078381	Feb 02, 2019	U-2216			
	7326708	Nov 24, 2026	DS DP U-2214			
	7459428	Feb 02, 2019	U-2215			
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920 001	>A> 7411070	May 25, 2018	DS			
	>A> 7411070*PED	Nov 25, 2018				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	>A> 8778962	Feb 18, 2022	U-1541		>A> I-773	Apr 10, 2021
	>A> 8778962	Feb 18, 2022	U-2280		>A> ODE-169	Apr 10, 2025
	>A> 8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	>A> 8778962	Feb 18, 2022	U-1541		>A> I-773	Apr 10, 2021
	>A> 8778962	Feb 18, 2022	U-2280		>A> ODE-169	Apr 10, 2025
	>A> 8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	>A> 8778962	Feb 18, 2022	U-1541		>A> I-773	Apr 10, 2021
	>A> 8778962	Feb 18, 2022	U-2280		>A> ODE-169	Apr 10, 2025
	>A> 8778962*PED	Aug 18, 2022				
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	>A> 6872700	Jan 14, 2020	U-2288		>A> M-224	Apr 02, 2021
	>A> 6872700	Jan 14, 2020	U-654			
	9884092	Aug 18, 2026	U-1313			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	>A> 6872700	Jan 14, 2020	U-2288		>A> M-224	Apr 02, 2021
	>A> 6872700	Jan 14, 2020	U-654			
	9884092	Aug 18, 2026	U-1313			
	9884092	Aug 18, 2026	U-2154			
	9884092	Aug 18, 2026	U-2155			
	9884092	Aug 18, 2026	U-2156			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9814705	Jan 08, 2024	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001					I-767	Feb 02, 2021
<u>FINGOLIMOD - GILENYA</u>						
N 022527 001	>A> 5604229	Feb 18, 2019	DS U-1086			
	>A> 5604229*PED	Aug 18, 2019				
	>A> 8324283	Mar 29, 2026	DP			
	>A> 8324283*PED	Sep 29, 2026				
	>A> 9187405	Jun 25, 2027	U-1086			
	>A> 9187405*PED	Dec 25, 2027				
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	>A> 8534281	Mar 08, 2030	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	>A> 8534281	Mar 08, 2030	DP			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	8534281	Mar 08, 2030	DP		>A> I-775	Apr 24, 2021
	9750726	Nov 29, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	8534281	Mar 08, 2030	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	9861771	Oct 11, 2020	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	9861771	Oct 11, 2020	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	9861771	Oct 11, 2020	DP			
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	9730890	Jun 22, 2021	DP			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001	>A> 5691336	Mar 04, 2019	DS DP		>A> NPP	Apr 03, 2021
	>A> 5691336*PED	Sep 04, 2019			>A> PED	Oct 03, 2021
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002	>A> 5691336	Mar 04, 2019	DS DP U-2265		>A> NPP	Apr 03, 2021
	>A> 5691336*PED	Sep 04, 2019			>A> PED	Oct 03, 2021
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001					>A> NCE	Apr 17, 2023
					>A> ODE-174	Apr 17, 2025
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002					>A> NCE	Apr 17, 2023
					>A> ODE-174	Apr 17, 2025
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 001	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 002	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 003	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 004	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
N 021700 005	7358366	Apr 19, 2020	DS		Y	
	7358366*PED	Oct 19, 2020				
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	>A> 9931304	Jun 27, 2021	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	>A> 9931304	Jun 27, 2021	DP			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	9913910	Sep 28, 2024	U-2253			
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	>A> 7348361	Nov 06, 2020	DP U-1087		M-220	Feb 15, 2021
	>A> 7348361	Nov 06, 2020	DP U-2250			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9872837	Dec 21, 2031	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9872837	Dec 21, 2031	DP			
<u>HYDROCORTISONE BUTYRATE - HYDROCORTISONE BUTYRATE</u>						
A 209556 001					>A> PC	Aug 11, 2018
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 001	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 002	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 003	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 004	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9789257	Feb 11, 2034	DP			
	9844558	May 02, 2036	DP			
	RE44846	Aug 10, 2019	DP		U-2236	
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026			U-1456	
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8476284	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2228			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9713617	Jun 03, 2033	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801883	Jun 03, 2031	U-2159			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	9125889	Jun 03, 2031	U-1650			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-2150			
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9814721	Jun 03, 2031	U-1947			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	7514444	Dec 28, 2026	DS DP		NCE	Nov 13, 2018
	8008309	Dec 28, 2026	DS DP			
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	8497277	Dec 28, 2026				U-2241
	8497277	Dec 28, 2026				U-2242
	8563563	Apr 26, 2027				U-1491
	8563563	Apr 26, 2027				U-1946
	8563563	Apr 26, 2027				U-2241
	8563563	Apr 26, 2027				U-2242
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026				U-1491
	8703780	Dec 28, 2026				U-2242
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031				U-1456
	8754091	Dec 28, 2026	DP			
	8952015	Dec 28, 2026				U-1456
	8952015	Dec 28, 2026				U-1491
	8952015	Dec 28, 2026				U-1650
	8952015	Dec 28, 2026				U-1946
	8952015	Dec 28, 2026				U-1947
	8952015	Dec 28, 2026				U-2241
	8952015	Dec 28, 2026				U-2242
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031				U-1491
	8999999	Jun 03, 2031				U-1946
	8999999	Jun 03, 2031				U-2241
	8999999	Jun 03, 2031				U-2242
	9125889	Jun 03, 2031				U-1650
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9655857	Mar 03, 2036	DP			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034				U-2150
	9801881	Jun 03, 2031				U-1491
	9801881	Jun 03, 2031				U-2242
	9801883	Jun 03, 2031				U-2159
	9801883	Jun 03, 2031				U-2243
	9814721	Jun 03, 2031				U-1947
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	>A> 9072661	Mar 16, 2032				U-2264
	>A> 9072710	Mar 16, 2032				U-2266
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	9861603	Dec 18, 2026				U-1440
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	9861603	Dec 18, 2026				U-1440
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	9884094	May 01, 2033				U-2238
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			U-1832
	9233211	Mar 02, 2024	DP			
	9345750	May 18, 2031	DP			U-1855
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO MAX SOLOSTAR</u>						
N 206538 002	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 02, 2024	DP	U-2146		
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	>A> 9950039	Dec 10, 2035		U-2277		
	>A> 9950039	Dec 10, 2035		U-2278		
	>A> 9950039	Dec 10, 2035		U-2279		
<u>INSULIN LISPRO - ADMELOG SOLOSTAR</u>						
N 209196 002	7918833	Sep 23, 2027	DP			
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP	U-1832		
	9233211	Mar 02, 2024	DP			
	9408979	Mar 02, 2024	DP			
	9526844	Mar 02, 2024	DP			
	9533105	Aug 17, 2024	DP			
	9561331	Aug 28, 2024	DP			
	9604008	Mar 02, 2024	DP			
	9604009	Aug 16, 2024	DP			
	9610409	Mar 02, 2024	DP			
	9623189	Aug 19, 2024	DP			
	9775954	Mar 02, 2024	DP			
	9827379	Mar 04, 2024	DP	U-2146		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	>A> 9943571	Aug 11, 2029		U-1537		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	>A> 9943571	Aug 11, 2029		U-1537		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	>A> 9943571	Aug 11, 2029		U-1537		
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8629162	Jun 24, 2025		U-2234		
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	8629162	Jun 24, 2025		U-2234		
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	8629162	Jun 24, 2025		U-2234		
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	7495103	May 20, 2027	DS DP		NCE	Feb 12, 2023
	7645789	May 01, 2027	DS DP		>A> ODE-173	Feb 12, 2025
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027		U-2246		
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027		U-2246		
	8598181	May 01, 2027		U-2246		
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025		U-2247		
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033		U-2248		
	9670163	Dec 28, 2026	DP	U-2246		
	>A> 9931334	Dec 28, 2026	DP	U-2275		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	>A> 9931334	Dec 28, 2026	DP U-2276		M-218	Jan 25, 2021
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	>A> 9931334	Dec 28, 2026	DP U-2276		M-218	Jan 25, 2021
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	>A> RE38551	Mar 17, 2022	DS DP U-1567			
	>A> RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	>A> RE38551	Mar 17, 2022	DS DP U-1567			
	>A> RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	>A> RE38551	Mar 17, 2022	DS DP U-1567			
	>A> RE38551	Mar 17, 2022	DS DP U-2140			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	>A> RE38551	Mar 17, 2022	DS DP U-1567			
	>A> RE38551	Mar 17, 2022	DS DP U-2140			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 001	>A> 9901546	May 17, 2019	DP			
<u>LANSOPRAZOLE - PREVACID</u>						
N 021428 002	>A> 9901546	May 17, 2019	DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001					ODE-165	Nov 08, 2024
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002					ODE-165	Nov 08, 2024
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9914802	Nov 13, 2020	DS DP U-1666			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7723390	Mar 14, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 013	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	9283174	May 10, 2031	DP		NP	Feb 28, 2021
	>A> 9925264	May 10, 2031	DP U-2267			
	>A> 9931403	May 10, 2031	DP			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073 001	9890141	Oct 21, 2030	DS			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	9440029	Jan 30, 2032	DP			
	9855388	Apr 24, 2029	DP U-1881			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	9440029	Jan 30, 2032	DP			
	9855388	Apr 24, 2029	DP U-1881			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	9861622	Mar 07, 2025	U-1316			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001				>A> M-225		Apr 26, 2021
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002				>A> M-225		Apr 26, 2021
<u>LULICONAZOLE - LUZU</u>						
N 204153 001				NPP		Feb 20, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9174975	Feb 20, 2024	U-1770		NPP	Mar 05, 2021
	9174975*PED	Aug 20, 2024				
	9907794	May 26, 2026	DP			
<u>LUTETIUM DOTATATE LU-177 - LUTATHERA</u>						
N 208700 001					NCE ODE-166	Jan 26, 2023 Jan 26, 2025
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001	6861409	Aug 01, 2022	DS DP U-2220		>A> ODE-170	Dec 20, 2024
	8192719	Oct 12, 2027	U-2220			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	>A> 7094781	Dec 05, 2025	DS DP			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748 002	8323692	Mar 30, 2023	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	9855215	Jan 02, 2033	DP			
<u>METOPROLOL SUCCINATE - METOPROLOL SUCCINATE</u>						
N 210428 001	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - METOPROLOL SUCCINATE</u>						
N 210428 002	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - METOPROLOL SUCCINATE</u>						
N 210428 003	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - METOPROLOL SUCCINATE</u>						
N 210428 004	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	>A> 9943526	Apr 20, 2036	U-1643			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001					>A> I-777	Apr 27, 2021
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002					>A> I-777	Apr 27, 2021
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310 001	>A> 7544192	Nov 29, 2026	U-2272			
	>A> 7662141	Mar 12, 2024	U-2272			
	>A> 7713255	Mar 12, 2024	U-2272			
	>A> 7951130	Mar 12, 2024	U-2272			
	>A> 7951131	Mar 12, 2024	U-2272			
	>A> 7951133	Mar 12, 2024	U-2272			
	>A> 8025635	Jun 12, 2027	DP U-2272			
	>A> 8109918	Mar 12, 2024	U-2272			
	>A> 8763222	Feb 08, 2032	DP			
	>A> 9585681	Apr 04, 2026	U-2272			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 001	9907793	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIO</u>						
N 205777 002	9907793	Apr 04, 2023	DP U-1556			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	>A> 9931336	Mar 14, 2034	DS DP U-1524			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		>A> ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			>A> ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		>A> PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			>A> PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	7169791	Jul 04, 2023	DS DP U-836		D-170	Dec 22, 2020
	7169791*PED	Jan 04, 2024			NPP	Mar 22, 2021
	8163904	Aug 23, 2028	DS DP		>A> ODE-171	Mar 22, 2025
	8163904*PED	Feb 23, 2029			>A> ODE-172	Mar 22, 2025
	8293756	Sep 25, 2027	DP		PED	Jun 22, 2021
	8293756*PED	Mar 25, 2028			PED	Sep 22, 2021
	8389537	Jul 18, 2026	DS DP U-1374		>A> PED	Sep 22, 2025
	8389537*PED	Jan 18, 2027			>A> PED	Sep 22, 2025
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DS DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DP U-1374			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 003	>A> 7169791	Jul 04, 2023	DS DP U-836		NPP	Mar 22, 2021
	>A> 8163904	Aug 23, 2028	DS DP		>A> ODE-171	Mar 22, 2025
	>A> 8293756	Sep 25, 2027	DP		>A> ODE-172	Mar 22, 2025
	>A> 8389537	Jul 18, 2026	DS DP U-1374		PED	Sep 22, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 003	>A> 8415363	Jul 18, 2026	DS DP U-1407		>A> PED	Sep 22, 2025
	>A> 8501760	Jul 18, 2026	DS DP		>A> PED	Sep 22, 2025
	>A> 9061029	Apr 07, 2032	DS DP U-1374			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	9907756	Jun 07, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	9907756	Jun 07, 2029	DP			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					>A> M-167	Oct 09, 2018
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	>A> 9926559	Jan 09, 2034	U-1943			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001					I-762	Jan 12, 2021
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002					I-762	Jan 12, 2021
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2019	DP			
	5948818	May 13, 2019	DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					>A> I-774	Apr 18, 2021
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					>A> I-774	Apr 18, 2021
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2019	DS			
	9180200	Jan 29, 2032	DP U-805			
	9399014	Dec 15, 2029	U-805			
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 090713 002					PC	Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 001					PC	Sep 19, 2018
<u>PALONOSETRON HYDROCHLORIDE - PALONOSETRON HYDROCHLORIDE</u>						
A 201533 002					PC	Sep 19, 2018
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001	>A> 9925212	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002	>A> 9925212	Oct 08, 2033	U-1766			
<u>PATIROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003	>A> 9925212	Oct 08, 2033	U-1766			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	8420674	Dec 18, 2027	U-2079			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	>A> 7566729	Apr 22, 2029	U-2269			
	>A> 7566729	Apr 22, 2029	U-2270			
	>A> 7635707	Apr 22, 2029	U-2072			
	>A> 7635707	Apr 22, 2029	U-2073			
	>A> 7635707	Apr 22, 2029	U-2074			
	>A> 7635707	Apr 22, 2029	U-2075			
	>A> 7635707	Apr 22, 2029	U-2076			
	>A> 7635707	Apr 22, 2029	U-2083			
	>A> 7767700	Dec 18, 2027	U-2080			
	>A> 7816383	Jan 08, 2030	U-2042			
	>A> 7816383	Jan 08, 2030	U-2050			
	>A> 7910610	Jan 08, 2030	U-2048			
	>A> 7910610	Jan 08, 2030	U-2049			
	>A> 8013002	Jan 08, 2030	U-2047			
	>A> 8013002	Jan 08, 2030	U-2082			
	>A> 8084475	Jan 08, 2030	U-2054			
	>A> 8084475	Jan 08, 2030	U-2268			
	>A> 8318780	Jan 08, 2030	U-2046			
	>A> 8318780	Jan 08, 2030	U-2081			
	>A> 8383150	Sep 22, 2026	DP U-1607			
	>A> 8420674	Dec 18, 2027	U-2079			
	>A> 8592462	Apr 22, 2029	U-2055			
	>A> 8592462	Apr 22, 2029	U-2056			
	>A> 8592462	Apr 22, 2029	U-2057			
	>A> 8592462	Apr 22, 2029	U-2058			
	>A> 8592462	Apr 22, 2029	U-2059			
	>A> 8592462	Apr 22, 2029	U-2060			
	>A> 8592462	Apr 22, 2029	U-2061			
	>A> 8592462	Apr 22, 2029	U-2062			
	>A> 8592462	Apr 22, 2029	U-2063			
	>A> 8609701	Apr 22, 2029	U-2064			
	>A> 8609701	Apr 22, 2029	U-2065			
	>A> 8609701	Apr 22, 2029	U-2066			
	>A> 8609701	Apr 22, 2029	U-2067			
	>A> 8609701	Apr 22, 2029	U-2068			
	>A> 8609701	Apr 22, 2029	U-2069			
	>A> 8609701	Apr 22, 2029	U-2070			
	>A> 8648098	Jan 08, 2030	U-2051			
	>A> 8648098	Jan 08, 2030	U-2052			
	>A> 8754109	Jan 08, 2030	U-2053			
	>A> 8778947	Aug 30, 2033	U-2044			
	>A> 8778947	Aug 30, 2033	U-2045			
	>A> 9561217	Jan 25, 2022	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8420674	Dec 18, 2027	U-2079			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	9610321	Sep 15, 2031	U-1999		I-764	Jan 24, 2021
	9610321	Sep 15, 2031	U-2230			
	9919024	Sep 15, 2031	U-1999			
	9919024	Sep 15, 2031	U-2230			
	9925231	Sep 15, 2031	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8198262	Jun 17, 2025	U-1360	Y		
	8198262	Jun 17, 2025	U-2254	Y		
	8673939	May 15, 2023	U-1360	Y		
	8673939	May 15, 2023	U-2254	Y		
	8735428	May 15, 2023	U-1360	Y		
	8735428	May 15, 2023	U-2254	Y		
<u>RADIUM RA-223 DICHLORIDE - XOFIGO</u>						
N 203971 001 >A>	6635234	Nov 17, 2022	U-2271			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001					M-223	Feb 01, 2021
<u>RITONAVIR - RITONAVIR</u>						
A 202573 001					>A> PC	Sep 16, 2018
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-2142			
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
	9415053	Nov 13, 2024	DP U-1167			
	9415053	Nov 13, 2024	DP U-1200			
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001					NS	Jan 23, 2021
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 002	5712298	Jan 27, 2020	DS DP U-1115		NS	Jan 23, 2021
	8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 002	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
	9468598	Feb 19, 2023	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 002	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 003	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROSIGLITAZONE MALEATE - AVANDIA</u>						
N 021071 004	7358366	Apr 19, 2020	DS	Y		
	7358366*PED	Oct 19, 2020				
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	9925150	Mar 01, 2032	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	>A> 7351701	Jul 23, 2024	U-2012		>A> I-772	Apr 06, 2021
	>A> 7351701	Jul 23, 2024	U-2101		>A> ODE-168	Apr 06, 2025
	>A> 7351701	Jul 23, 2024	U-2273			
	>A> 7531530	Jul 23, 2024	U-2012			
	>A> 7531530	Jul 23, 2024	U-2101			
	>A> 7531530	Jul 23, 2024	U-2273			
	>A> 8071579	Aug 12, 2027	U-2012			
	>A> 8071579	Aug 12, 2027	U-2101			
	>A> 8071579	Aug 12, 2027	U-2273			
	>A> 8143241	Aug 12, 2027	U-2012			
	>A> 8143241	Aug 12, 2027	U-2101			
	>A> 8143241	Aug 12, 2027	U-2273			
	>A> 8859562	Aug 04, 2031	U-2012			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2273			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	>A> 9861638	Feb 10, 2031	U-2012			
	>A> 9861638	Feb 10, 2031	U-2101			
	>A> 9861638	Feb 10, 2031	U-2273			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	>A> 7351701	Jul 23, 2024	U-2012		>A> I-772	Apr 06, 2021
	>A> 7351701	Jul 23, 2024	U-2101		>A> ODE-168	Apr 06, 2025
	>A> 7351701	Jul 23, 2024	U-2273			
	>A> 7531530	Jul 23, 2024	U-2012			
	>A> 7531530	Jul 23, 2024	U-2101			
	>A> 7531530	Jul 23, 2024	U-2273			
	>A> 8071579	Aug 12, 2027	U-2012			
	>A> 8071579	Aug 12, 2027	U-2101			
	>A> 8071579	Aug 12, 2027	U-2273			
	>A> 8143241	Aug 12, 2027	U-2012			
	>A> 8143241	Aug 12, 2027	U-2101			
	>A> 8143241	Aug 12, 2027	U-2273			
	>A> 8859562	Aug 04, 2031	U-2012			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2273			
	>A> 9861638	Feb 10, 2031	U-2012			
	>A> 9861638	Feb 10, 2031	U-2101			
	>A> 9861638	Feb 10, 2031	U-2273			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	>A> 7351701	Jul 23, 2024	U-2012		>A> I-772	Apr 06, 2021
	>A> 7351701	Jul 23, 2024	U-2101		>A> ODE-168	Apr 06, 2025
	>A> 7351701	Jul 23, 2024	U-2273			
	>A> 7531530	Jul 23, 2024	U-2012			
	>A> 7531530	Jul 23, 2024	U-2101			
	>A> 7531530	Jul 23, 2024	U-2273			
	>A> 8071579	Aug 12, 2027	U-2012			
	>A> 8071579	Aug 12, 2027	U-2101			
	>A> 8071579	Aug 12, 2027	U-2273			
	>A> 8143241	Aug 12, 2027	U-2012			
	>A> 8143241	Aug 12, 2027	U-2101			
	>A> 8143241	Aug 12, 2027	U-2273			
	>A> 8859562	Aug 04, 2031	U-2012			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2273			
	>A> 9861638	Feb 10, 2031	U-2012			
	>A> 9861638	Feb 10, 2031	U-2101			
	>A> 9861638	Feb 10, 2031	U-2273			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9856265	Jul 28, 2026	DS DP U-1467			
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	9868745	Nov 16, 2032	DS DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 001					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 002					M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TADALAFIL - CIALIS</u>						
N 021368 003					M-219 PED	Feb 15, 2021 Aug 15, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TADALAFIL - CIALIS</u>						
N 021368	004				M-219 PED	Feb 15, 2021 Aug 15, 2021
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	9855241	Jan 25, 2033	U-2149		
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246	001	>A> 9937181	Mar 14, 2034	DP		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	001	>A> 7378423	May 29, 2027	DS DP	>A> I-778	Apr 30, 2021
		>A> 8835443	Jun 10, 2025	U-1581		
		>A> 8835443	Jun 10, 2025	U-1582		
		>A> 8835443	Jun 10, 2025	U-2020		
		>A> 8835443	Jun 10, 2025	U-2037		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	002	>A> 7378423	May 29, 2027	DS DP	>A> I-778	Apr 30, 2021
		>A> 8835443	Jun 10, 2025	U-1581		
		>A> 8835443	Jun 10, 2025	U-1582		
		>A> 8835443	Jun 10, 2025	U-2020		
		>A> 8835443	Jun 10, 2025	U-2037		
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	003	>A> 7378423	May 29, 2027	DS DP	>A> I-778	Apr 30, 2021
		>A> 8835443	Jun 10, 2025	U-1581		
		>A> 8835443	Jun 10, 2025	U-1582		
		>A> 8835443	Jun 10, 2025	U-2020		
		>A> 8835443	Jun 10, 2025	U-2037		
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382	001	8534281	Mar 08, 2030	DP		
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975	001	8534281	Mar 08, 2030	DP		
<u>VANDETANIB - CAPRELSA</u>						
N 022405	001	7173038	Aug 14, 2021	DS DP		
		8642608	Feb 06, 2022	U-1490		
<u>VANDETANIB - CAPRELSA</u>						
N 022405	002	7173038	Aug 14, 2021	DS DP		
		8642608	Feb 06, 2022	U-1490		
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485	002	9937223	Jan 30, 2035	U-1857		
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886	001	>A> 7713999	May 30, 2024	DS DP	U-2291	
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	001	9861630	Jun 15, 2027	U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	002	9861630	Jun 15, 2027	U-1668		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447	003	9861630	Jun 15, 2027	U-1668		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2018

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9861630	Jun 15, 2027	U-1668			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 38th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm